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Abstract: Background. Pantothenate kinase-associated neurodegeneration 
(PKAN) is a rare genetic disorder characterized by progressive 
generalized dystonia and brain iron accumulation. We assessed whether the 
iron chelator deferiprone (DFP) can reduce brain iron and slow disease 
progression. 
Methods. An 18-month, randomized, double-blind, placebo-controlled trial, 
followed by a pre-planned 18-month open-label extension study in patients 
with PKAN, was conducted in 4 hospitals in Germany, Italy, England and 
the USA. Patients aged ≥4 years with a genetically confirmed diagnosis of 
PKAN, a total score ≥3 on the Barry-Albright Dystonia (BAD) scale, and no 
evidence of iron deficiency, neutropenia, or abnormal liver or renal 
function, were randomly allocated (2:1) to receive DFP oral solution (30 
mg/kg/day) or placebo for 18 months.  Randomization was done using a 
centralized computer random number generator with stratification based on 
age group at onset of symptoms, and patients were allocated to groups by 
a non-blinded randomization team that was independent of the study.  
Patients, caregivers, and investigators were masked to treatment 
allocation. Patients who completed the randomized trial were eligible to 
enroll in a single-arm extension study of another 18 months in which all 
participants received DFP. Co-primary endpoints were the change from 
baseline to Month 18 in the total score on the BAD scale and the score at 
Month 18 on the Patient Global Impression of Improvement (PGI-I). 
Efficacy analyses were done on the modified Intent to Treat (mITT) 
population, which included all patients who received at least one dose of 
study drug and who provided a baseline and at least one post-baseline 
efficacy assessment; safety analyses were done on all patients who 
received at least one dose of study drug. The trial was registered on 
ClinicalTrials.gov (NCT01741532) and EudraCT (2012-000845-11). 
Findings. Between December 2012 and April 2015, 88 patients were randomly 
assigned to DFP (N=58) or placebo (N=30). Of these, 76 patients completed 
the study: 49 in the DFP group and 27 in the placebo group.  After 18 
months, the BAD score worsened by 2.48±0.63 points (DFP), versus 
3.99±0.82 points (placebo; difference -1.51 points, 95% CI [-3.19,0.16], 
p=0.0761). In the predefined subgroup with atypical (disease onset ≥ age 
6) PKAN, the BAD score worsened by 2.33±0.73 points (DFP) versus 
4.52±0.91 points (placebo; difference -2.19 points, 95% CI [ 4.00,-0.38], 
p=0.0187). No subjective change was detected as assessed by the PGI-I: 
mean scores at Month 18 were 4.7±0.4 for placebo and 4.6±0.3 for DFP 
(p=0.7279). In the extension study, patients continuing DFP retained a 
similar rate of disease progression (1.9±0.5 points in the first 18 
months vs 1.4±0.4 points in the second 18 months, p=0.2684), while 
progression in patients switching from placebo to DFP seemed to slow 
(4.4±1.1 points when they were receiving placebo vs 1.4±0.9 points when 
they were receiving DFP, p=0.0206). Patients did not detect a change in 
their condition after the additional 18 months of treatment, with mean 
scores of 4.1±0.2 in the DFP-DFP group and of 4.7±0.3 in the placebo-DFP 
group. DFP was well tolerated and rates of adverse events were similar 
between the treatment groups except for anemia, which was seen in 20.7% 
of DFP-treated patients vs. no placebo patients. No patient discontinued 
therapy due to anemia. There were two deaths, both secondary to 
aspiration. Neither of these events was considered related to DFP use. 
Interpretation.  Deferiprone was well tolerated and seemed to show 
slower, although not statistically significant, disease progression at 18 
months. Patients in neither group perceived an improvement or worsening 
at 18 months based on PGI-I assessments. After an additional 18 months of 
treatment in the extension trial, there was further evidence of slowing 
of disease progression by deferiprone, although patients continued to not 
perceive a change in their condition. This study will help shape the 
design of future trials in this ultraorphan disease. 
Funding. European Commission; FDA; ApoPharma Inc., Canada. 
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Summary  
Background Pantothenate kinase-associated neurodegeneration (PKAN) is a rare genetic disorder 
characterized by progressive generalized dystonia and brain iron accumulation. We assessed 
whether the iron chelator deferiprone (DFP) can reduce brain iron and slow disease progression. 
Methods An 18-month, randomized, double-blind, placebo-controlled trial, followed by a pre-
planned 18-month open-label extension study in patients with PKAN, was conducted in 4 
hospitals in Germany, Italy, England and the USA. Patients aged ≥4 years with a genetically 
confirmed diagnosis of PKAN, a total score ≥3 on the Barry-Albright Dystonia (BAD) scale, and 
no evidence of iron deficiency, neutropenia, or abnormal liver or renal function, were randomly 
allocated (2:1) to receive DFP oral solution (30 mg/kg/day) or placebo for 18 months.  
Randomization was done using a centralized computer random number generator with 
stratification based on age group at onset of symptoms, and patients were allocated to groups by a 
non-blinded randomization team that was independent of the study.  Patients, caregivers, and 
investigators were masked to treatment allocation. Patients who completed the randomized trial 
were eligible to enroll in a single-arm extension study of another 18 months in which all 
participants received DFP. Co-primary endpoints were the change from baseline to Month 18 in 
the total score on the BAD scale and the score at Month 18 on the Patient Global Impression of 
Improvement (PGI-I). Efficacy analyses were done on the modified Intent to Treat (mITT) 
population, which included all patients who received at least one dose of study drug and who 
provided a baseline and at least one post-baseline efficacy assessment; safety analyses were done 
on all patients who received at least one dose of study drug. The trial was registered on 
ClinicalTrials.gov (NCT01741532) and EudraCT (2012-000845-11). 
Findings Between December 2012 and April 2015, 88 patients were randomly assigned to DFP 
(N=58) or placebo (N=30). Of these, 76 patients completed the study: 49 in the DFP group and 
27 in the placebo group.  After 18 months, the BAD score worsened by 2.48±0.63 points (DFP), 
versus 3.99±0.82 points (placebo; difference -1.51 points, 95% CI [-3.19,0.16], p=0.0761). In the 
predefined subgroup with atypical (disease onset ≥ age 6) PKAN, the BAD score worsened by 
2.33±0.73 points (DFP) versus 4.52±0.91 points (placebo; difference -2.19 points, 95% CI 
[-4.00,-0.38], p=0.0187). No subjective change was detected as assessed by the PGI-I: mean 
scores at Month 18 were 4.7±0.4 for placebo and 4.6±0.3 for DFP (p=0.7279). In the extension 
study, patients continuing DFP retained a similar rate of disease progression (1.9±0.5 points in the 
first 18 months vs 1.4±0.4 points in the second 18 months, p=0.2684), while progression in 
patients switching from placebo to DFP seemed to slow (4.4±1.1 points when they were receiving 
placebo vs 1.4±0.9 points when they were receiving DFP, p=0.0206). Patients did not detect a 
change in their condition after the additional 18 months of treatment, with mean scores of 4.1±0.2 
in the DFP-DFP group and of 4.7±0.3 in the placebo-DFP group. DFP was well tolerated and 
rates of adverse events were similar between the treatment groups except for anemia, which was 
seen in 20.7% of DFP-treated patients vs. no placebo patients. No patient discontinued therapy 
due to anemia. There were two deaths, both secondary to aspiration. Neither of these events was 
considered related to DFP use. 
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Interpretation  Deferiprone was well tolerated and seemed to show slower, although not 
statistically significant, disease progression at 18 months. Patients in neither group perceived an 
improvement or worsening at 18 months based on PGI-I assessments. After an additional 18 
months of treatment in the extension trial, there was further evidence of slowing of disease 
progression by deferiprone, although patients continued to not perceive a change in their 
condition. This study will help shape the design of future trials in this ultraorphan disease. 
Funding European Commission; FDA; ApoPharma Inc., Canada. 
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Introduction 
Neurodegeneration with brain iron accumulation (NBIA) is a clinically and genetically 
heterogeneous group of rare hereditary neurodegenerative disorders characterized by high levels 
of brain iron.
1
 Around 50% of cases are due to pantothenate kinase-associated neurodegeneration 
(PKAN), caused by mutations in the pantothenate kinase 2 (PANK2) gene.
2
 The PANK2 enzyme 
localizes to mitochondria and is essential for the biosynthesis of coenzyme A (CoA), which in 
turn is vital for adenosine triphosphate synthesis and fatty acid and neurotransmitter metabolism.  
Absence or abnormal function of PANK2 may contribute to iron accumulation in specific brain 
regions.
3
 Onset of clinical signs ranges from infancy to adulthood; progression ranges from rapid 
to slow; and symptoms may vary greatly. Disease characteristics include progressive dystonia, 
parkinsonism, rigidity and spasticity. The factors that influence disease severity and progression 
rate of PKAN remain unknown. No disease-modifying therapies are yet available in PKAN or 
any form of NBIA.
4,5,6
   
Historically, PKAN has been described as either classic or atypical. In classic PKAN, symptoms 
usually develop before 6 years of age, and most patients require a wheelchair by their mid-teens. 
Atypical PKAN usually becomes evident after 10 years of age, is less severe, and progresses 
more slowly.
3,7
  It is hypothesized that classic PKAN results from complete absence of the 
PANK2 enzyme, whereas atypical disease results from severe deficiency.
3
 
While iron is essential for normal physiological function, an excessive amount or dysregulated 
iron metabolism is potentially toxic. Increased “free” iron in tissues leads to the formation of 
highly reactive oxygen species, causing localized toxicity.
8,9
 Although proof that iron causes 
neurodegeneration in PKAN and most other NBIA is lacking, preferential iron accumulation in 
the basal ganglia likely explains the predominant movement disorder phenotype.
10
  Accordingly, 
iron chelation holds promise to decrease brain iron levels in NBIA, which may retard disease 
progression. 
Deferiprone (DFP, 3-hydroxy-1,2-dimethylpyridin-4-one) is an oral iron chelator approved for 
the treatment of transfusional iron overload in patients with thalassemia. DFP crosses the blood 
brain barrier, chelates excess iron from intracellular organelles, and may transfer it to biologic 
receptors.
11
 Limited safety and efficacy data are available on patients with brain iron 
accumulation. Based on the available data in patients with PKAN or other neurodegenerative 
disorders who received DFP,
6,12-20
 it was hypothesized that DFP could reduce brain iron, which 
might lead to clinical benefit. This article describes the results of the TIRCON2012V1 study - the 
first randomized clinical trial of a putative therapeutic agent in patients with PKAN, and of its 
single-arm extension study, TIRCON2012V1-EXT. 
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Methods 
Key information on study methods is provided here, and further details are available in the 
Supplement. 
Study design 
TIRCON2012V1 was an 18-month randomized, double-blind, placebo-controlled trial that 
evaluated the safety and efficacy of DFP in patients with PKAN.  Patients who completed the 
randomized trial were eligible to enroll in a single-arm extension study of another 18 months, 
TIRCON2012V1-EXT, in which all participants received DFP. 
An independent Data and Safety Monitoring Board regularly reviewed the safety data of both 
trials, and each study was registered on ClinicalTrials.gov prior to enrollment of the first patient 
(trial registration numbers NCT01741532 and NCT02174848, respectively). 
Patients 
Patients were eligible for enrollment in TIRCON2012V1 if they had a diagnosis of PKAN 
confirmed by genetic testing and a total score ≥3 on the Barry-Albright Dystonia (BAD) scale, 
which ranges from 0 (best) to 32 (worst).  Exclusion criteria included treatment with any iron 
chelator in the past 12 months and the presence of medical conditions or other indicators that 
might increase safety concerns. The full list of inclusion/exclusion criteria is provided in the 
Supplement. The use of symptomatic treatments was permitted; however, to reduce confounds, 
individuals were excluded if they had recent (< 2 months) or anticipated changes in any regimen 
being used to treat dystonia, whether medication or a Deep Brain Stimulation (DBS) device. 
Written informed consent was obtained from each participant or the parent/legal guardian before 
any procedures were carried out. 
Randomization and masking 
In TIRCON2012V1, patients were assigned in a 2:1 ratio to receive either DFP at a dose of up to 
30 mg/kg/day divided b.i.d or matching placebo (identical packaging, appearance, and taste), 
using block randomization.  The randomization list was generated using a computer random 
number generator. A centralized randomization was used for all study sites, and patients were 
allocated to groups by a non-blinded randomization team that was independent of the study. 
Allocation concealment was through a centralized randomization process with computer 
generated randomization list. Randomization was stratified based on the patient’s age at 
diagnosis, with one list generated for individuals who had been younger than 6 years at the onset 
of motor symptoms and one for those who had been 6 years or older.  Patients, caregivers, study 
staff, and the neurologists who analyzed videotapes for determination of BAD scores were 
blinded as to treatment assignment, as were the radiologists who analyzed the MRI images for 
determination of iron levels in the globus pallidus. 
In the extension trial, all patients received DFP.  However, since the randomized study was still in 
progress when this study began, both patients and staff remained blinded as to which product had 
been taken for the previous 18 months until both studies had been completed and their data 
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locked. 
 
Procedures 
Participants took the assigned study product twice daily for 18 months.  Compliance was 
evaluated at each post-baseline visit by calculating the volume of medication dispensed and the 
amount of unused drug supply remaining in the bottle.  Efficacy was assessed every 6 months, 
using the following measures: 1) the BAD scale, which measures the severity of dystonia in 8 
body regions (eyes, mouth, neck, trunk, and each upper and lower extremity) and generates 
individual scores and a total score; 2) the Patient Global Impression of Improvement (PGI-I), a 
subjective instrument which consists of a single question asking patients to rate their condition on 
a scale from 1 (very much better) to 7 (very much worse) in comparison to how they had felt at 
baseline; 3) the Unified Parkinson’s Disease Rating Scale (UPDRS) Parts I, II, III, and VI, for 
assessment of motor symptoms that resemble those in Parkinson’s disease as well as quality of 
life aspects; 4) the Functional Independence Measure (FIM) or WeeFIM (pediatric version) for 
assessment of various measures of functional independence; 5) the Pediatric Quality of Life 
(PedsQL) scale for measurement of quality of life; and 6) the Pittsburgh Sleep Quality Index 
(PSQI) for measurement of quality of sleep.  For the BAD scale, the required tests were 
administered and videotaped at the site, and the videotapes were sent to a central site for blinded 
assessment by movement disorders experts.  Iron levels in the globus pallidus were measured by 
MRI-R2* in a subset of patients at baseline and Month 18. Safety assessments were done at each 
visit, and involved collecting adverse events and conducting clinical laboratory tests, physical 
examination, vital signs, and electrocardiogram (screening and Month 18 only). 
In the extension study, patients who had been randomized to DFP continued to receive it and 
those who had been randomized to placebo were switched to DFP.  Again, assessments were 
conducted every 6 months.  Safety evaluations were the same as before, but efficacy measures 
were limited to BAD scale and PGI-I. 
Outcomes 
In the randomized trial, the co-primary efficacy endpoints were change from baseline to Month 
18 in the BAD total score and the score at Month 18 on the PGI-I. The outcome was to be 
considered positive if the group differences in both primary endpoints reached statistical 
significance (p<0.05).  Secondary efficacy endpoints were change from baseline to Month 18 in 
the BAD score for each body region, iron levels in the globus pallidus (as assessed by MRI-R2*), 
and scores on the FIM/ WeeFIM, UPDRS, PedsQL, and PSQI; and the proportions of patients at 
Month 18 with improved or unchanged BAD total scores and PGI-I scores. For the safety 
endpoints, the groups were compared for the frequency of adverse events, frequency of serious 
adverse events, and number of discontinuations due to adverse events. 
In the extension study, the primary endpoint was safety, and the efficacy endpoints were change 
in BAD score and score on the PGI-I. 
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Statistical analysis 
Determination of Sample Size:  At the time of planning the randomized trial, there were no 
published studies with data sufficient to estimate sample size based on either the natural history 
of the disease or the expected impact from an agent that interfered with iron-related 
neurodegeneration. An estimate of the effect size was based on a retrospective study of 23 
patients with NBIA, 22 of whom had most probably PKAN (14 genetically confirmed, the others 
with eye-of-the-tiger sign), and 21 of whom had been assessed for dystonia using the BAD 
scale.
21
 It was assumed that with similar disease progression, after 18 months there could be a 
substantial worsening of the BAD total score in the control group, with a possible difference from 
the DFP group of ≥5 points. Assuming a standard deviation of 6.3 points, 2:1  randomization, 
and 30% drop-out rate, 87 patients would be needed to detect a difference of at least 5 points at a 
two-sided 0.05 level of significance with 80% power. For the extension study, there was no 
formal sample size and power calculation; all patients completingTIRCON2012V1 were invited 
to enroll. 
Analyses:   All statistical analyses were performed using SAS (Windows version 9.3).  Safety 
analyses were based on all randomized patients who received at least one dose of study drug. 
Efficacy analyses were based on the modified Intent-to-Treat (mITT) population, defined as all 
randomized patients who 1) received at least one dose of study drug, and 2) provided a baseline 
and at least one post-baseline efficacy assessment. A Mixed Model for Repeated Measures 
(MMRM) model was used as the primary analysis method to assess the primary and secondary 
endpoints of changes from baseline to the specified time points (Months 6, 12, and 18), with 
baseline value and age of onset of motor symptoms (before 6 years versus at or after 6 years) as 
covariates, and treatment group as the main factor in the model. The marginal mean change (least 
squares estimate) at Month 18 was used to determine the treatment effect in the primary analysis.  
Over the 18-month course of the trial, some participants required changes in their DBS settings or 
in the use or frequency of rescue or as-needed medications, and these variables were also 
included in the MMRM model as visit-dependent covariates. 
A similar MMRM model was used for the analysis of the PGI-I. As the PGI-I score is a 
measurement of change from baseline, it was treated directly as the outcome variable. A logistic 
regression model with similar covariates was used for analysis of the proportion of responders.  
Finally, a subgroup analysis using a similar MMRM model was performed on the co-primary 
efficacy endpoints based on age at onset of motor symptoms (≥6 years vs. <6 years).  The safety 
data for continuous variables were summarized using descriptive statistics, and the safety data for 
discrete variables were tabulated with frequency tables. 
In the extension study, changes in the BAD scale and PGI-I scores were summarized using 
descriptive statistics. Last Observation Carried Forward (LOCF) was used for the scores of 
patients who did not complete treatment.  A paired t-test was used to compare the change in BAD 
total score and PGI-I score between the randomized and the extension studies, while a student t-
test was used for within-study comparison of treatment groups. 
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Role of the funding source 
Funding for the study was provided by the European Commission, the US FDA, and ApoPharma 
Inc., Canada.  The US FDA had input into the design and selection of endpoints. ApoPharma 
participated in study design, data collection, data analysis, data interpretation, and writing of the 
report. The corresponding author had full access to all data in the study and had final 
responsibility for the decision to submit for publication.  
 
 
Results 
Randomized trial 
Following screening of 100 prospective subjects, 89 of a planned 90 patients were enrolled 
between December 13, 2012 and April 21, 2015, with 59 randomized to receive DFP and 30 to 
receive placebo (Figure 1). One patient assigned to the DFP group withdrew prior to receiving 
the first dose, and two assigned to placebo withdrew after receiving study drug but before 
providing any post-baseline efficacy data; accordingly, there were 58 DFP patients and 30 
placebo patients evaluable for safety, and 58 and 28, respectively, for efficacy. 76 patients 
(85.4%) completed the trial, and 12 (in addition to the one patient who was never dosed) 
withdrew:  3 (10.0%) in the placebo group and 9 (15.3%) in the DFP group. Reasons for 
withdrawal in the placebo group were 1 case each of worsening of the disease, protocol violation, 
and voluntary withdrawal, while those in the DFP group were 4 cases of an adverse event, 3 of 
worsening of the disease, and 1 each of investigator’s decision and voluntary withdrawal. Of 
the withdrawals due to adverse events, 3 were for neutropenia (for which withdrawal was 
mandated by the study protocol), and 1 was for fever and pneumonia. 
At baseline, there were no major differences between the treatment groups with respect to age at 
enrolment, duration of disease, sex, and race (Table 1), baseline BAD score, or amount of iron in 
the relevant brain areas. Stratification was used to ensure that each treatment group had 
approximately equal percentages of patients with classic or atypical PKAN, as determined by age 
at onset of motor symptoms: among the 86 patients who were evaluable for efficacy, there were 
12 classic and 16 atypical patients in the placebo arm, and 29 of each type in the DFP arm. Mean 
age at randomization differed considerably between the subgroups (13.7 and 26.5 years for 
patients with classic and atypical PKAN, respectively), but disease duration was similar for both, 
approximately 13 years. As expected, the disease had progressed further in those with classic 
PKAN, as indicated by baseline BAD scores (20.3 vs. 17.0), but the difference did not reach 
statistical significance (p=0.0753). 
Concomitant treatments for dystonia symptoms were an important consideration because of their 
possible confounding effect on the BAD score. Most participants, 18 placebo patients (60.0%) 
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and 42 DFP patients (72.4%), were taking at least one dystonia medication at baseline; 25 
patients, 6 (20%) and 19 (32%), respectively, had a DBS system in place; and 3 patients (1 and 2 
respectively), had a baclofen pump in place. There were no statistically significant differences 
between treatment groups regarding the use of any medication or device for the treatment of 
dystonia at baseline. During the study, additional dystonia medications administered on an as-
needed basis were taken by a higher percentage of placebo patients (21.4%) than DFP patients 
(10.9%), with the difference reaching significance (p=0.0345) for botulinum toxin type A. 
Compliance was very high at all time points, ranging from 95.1% to 99.4% in the placebo group 
and from 96.6% to 99.5% in the DFP group. 
BAD scores at baseline are shown in Table 1. One patient in the placebo group had a score of 31 
and one in the DFP group had the maximum score of 32, meaning that little or no further worsening 
could be detected in those individuals through this instrument. Further analyses showed that results 
were not confounded by a ceiling effect (cf. Discussion, Supplementary material and Suppl. Tables 
1a and 1b). Patients in both treatment groups showed a worsening over time (Figures 2a, 2b, 
and 2c). In the main analysis using the marginal means from the MMRM model, there was a 
mean ±SE worsening of 2.48±0.63 points in the DFP group vs. 3.99±0.82 points in the placebo 
group: i.e., the DFP group overall worsened by 1.51 points less, a difference that approached the 
protocol-defined criterion of p=0.05 for statistical significance (95% CI [-3.19, 0.16], p=0.0761) 
(Table 2). A predefined subgroup analysis that looked separately at patients with classic or 
atypical PKAN showed that DFP use was associated with slower progression in clinical 
symptoms (2.33±0.73 points) than patients on placebo (4.52±0.91 points) in atypical PKAN, a 
difference of 2.19 points, that reached statistical significance (95% CI [-4.00,-0.38], p=0.0187).  
Within the classic subgroup, the difference of 0.81 points in favor of DFP did not reach 
significance (p=0.5701). In the responder analysis, 36% of DFP-treated patients responded to 
therapy compared to 14% of placebo-treated patients (p=0.0893).  
In contrast to the objective signs of disease progression, as assessed by the BAD score, no 
subjective change was detected as assessed by the PGI-I. At Month 18, mean PGI-I scores were 
4.7±0.4 for placebo and 4.6±0.3 for DFP (p=0.7279), indicating that patients in both groups did 
not perceive either improvement or worsening since baseline. There was only a weak correlation 
(r = 0.29) between the PGI-I and the change in BAD score at month 18 (cf. Supplementary 
material and Suppl. Figure 1). 
MRI-R2* imaging for the measurement of iron levels in the globus pallidus was conducted in a 
subset of patients at the start (16 placebo, 24 DFP) and end of the study (13 placebo, 19 DFP). In 
the placebo group, there was virtually no change (an R2* decrease of 0.5±4.0 Hz), while in the DFP 
group there was a decrease of 36.1±3.1 Hz, for a significant treatment group difference of -35.6 
Hz (95%CI, [-44.8,-26.3], p <0.0001) (Figure 3). 
Figure 4 presents a summary of all secondary efficacy endpoints as a Forest plot. Each point 
represents the marginal mean difference between DFP and placebo. The line indicates the 95% 
confidence interval for the difference, both standardized by the standard error of the marginal 
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mean difference. For each endpoint, this graph indicates whether the results were in favor of DFP 
(point to the left of 0.00) or placebo (point to the right of 0.00). Of the 21 measures examined, 13 
were in favor of DFP, 4 showed no treatment difference and 4 were in favor of placebo. 
Differences between the treatment groups that reached statistical significance in favor of DFP 
were seen for the WeeFIM, and for certain BAD body region scores (neck: -0.43; p=0.0465; 
left lower extremity: -0.28; p=0.0391; and right lower extremity: -0.25; p=0.0435).  No 
significant differences were seen in other endpoints. More detailed results on the WeeFIM 
assessments are provided in the Supplement, including Suppl. Figure 2. 
Overall, DFP was well tolerated, and rates of adverse events (AEs) seen in >10% of patients is 
provided in Table 3. Rates were similar between the treatment groups except for AEs related to 
study treatment such as anemia, which was seen in 20.7% of DFP-treated patients vs. no placebo 
patients; however, the hemoglobin value was <10 g/dL in  only three patients with anemia. Non-
significant differences were seen between the DFP and placebo groups in rates of decreased 
serum ferritin (32.8% vs. 16.7%; p=0.1341) and iron deficiency (15.5% vs. 10.0%; p=0.7442).  
Iron supplementation was permitted, based on the investigator’s assessment of need, and was 
taken by 39% of patients in the DFP group and by 27% of patients in the placebo group. There 
were no deaths or episodes of agranulocytosis or severe neutropenia, and there was no significant 
difference between the study groups in the rates of less severe neutropenia (8.6% in DFP vs. 
6.7% in placebo). 
Extension study 
Of the 76 patients who completed the randomized trial, 68 enrolled in the extension study. Those 
who had received DFP continued to receive it (DFP-DFP group, N=44), while those who had 
received placebo were switched to DFP (placebo-DFP group, N=24). All 68 patients were 
evaluable for safety, and 62 (43 DFP-DFP, 19 placebo-DFP) were evaluable for efficacy. 
BAD scores at the start of the extension study are shown in Table 1 (at this time point, one 
placebo-DFP patient had a score of 30 and one DFP-DFP patient had the maximum score of 32).  
Figure 2d displays the change in BAD total score for the 62 patients who provided evaluable 
efficacy data in both studies. In both groups, scores continued to increase (worsen) over time, but  
the DFP-DFP patients showed a similar rate of progression in both studies, while the placebo-
DFP patients progressed more rapidly in the first study and slowed when they were switched to 
DFP. Over the 18 months of the extension study, there was no significant difference in the change 
in BAD score for patients who had been on DFP from the start (1.9±0.5 points in the first 18 
months vs 1.4±0.4 points in the second 18 months, p=0.2684) while there was significantly less 
worsening in the placebo-DFP group (4.4±1.1 points when they were receiving placebo vs 
1.4±0.9 points when they were receiving DFP, p=0.0206) (Suppl. Table 2). 
With respect to the PGI-I, as in the randomized study, patients did not detect a change in their 
condition after the additional 18 months of treatment, with mean scores of 4.1±0.2 in the DFP-
DFP group and of 4.7±0.3 in the placebo-DFP group. 
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For evaluation of safety, data were combined for all 68 patients.  Overall, DFP continued to be 
well tolerated for the 36-month period. There were two deaths, both secondary to aspiration (one 
pneumonia and multi-organ failure, the other to aspiration following the patient vomiting in his 
sleep).  Neither of these patients had experienced neutropenia while in the study. The most 
common adverse event was dystonia, reported in 40 (58.8%) patients, followed by pyrexia in 23 
(33.8%), headache in 20 (29.4%), and condition aggravated and decreased serum ferritin in 18 
each (26.5%). 
 
Discussion 
 
The present study is the largest randomized trial to date and provides the longest prospective 
follow-up of any NBIA population. It yields valuable information on the impact of iron chelation 
but also on the natural history of PKAN through the detailed assessment of placebo recipients, 
indicating that the rate of disease progression is slower than previously estimated.
21
  In the 
current trial, the power calculation for the divergence in the change in BAD total score between 
the treatment groups had assumed that a clinically relevant difference of 5 points could be 
achieved; however, over  18 months, the placebo group worsened by less than anticipated.  
Accordingly, the only way a significant group difference could have been achieved would have 
been for DFP to reverse rather than slow the progression of the disease. It is noteworthy that even 
the difference of 1.51 points approached the protocol-defined criterion for statistical significance 
(p=0.0761), and it is possible that a study duration longer than 18 months with the same number 
of patients would have allowed the detection of a difference large enough to establish statistical 
significance. 
For patient enrollment, there was no exclusion of patients with high BAD scores. This may lead 
to a ceiling effect where patients with high BAD scores (close to the maximum score of 32) at 
baseline cannot worsen as much as patients with lower BAD scores. Randomization resulted in 
proportionally more patients with high baseline BAD scores being assigned to the deferiprone 
treatment group. To investigate whether a ceiling effect confounds the results of our study, we 
repeated the MMRM analysis excluding all patients with a baseline BAD score > 27 who would 
potentially be subject to a ceiling effect. In this analysis, deferiprone-treated patients still 
exhibited a numerically lesser progression in BAD score than placebo-treated patients, with the 
marginal mean difference being very similar to that from the analysis of the mITT population 
(Suppl. Table 1a). The p value worsened from 0.0761 to 0.1114 as a function of the lower 
number of subjects. Additional analysis was conducted to compare response according to the 
tertiles of baseline BAD (Suppl. Table 1b), demonstrating a benefit of DFP versus placebo, 
although p values were not significant due to the low number of subjects. In conclusion, these 
analyses showed that PKAN progression as measured by the BAD score is slower with higher 
baseline values and that this results in a ceiling effect at very high baseline scores. While this is 
important information for the design of future trials, it did not affect the principal outcome of our 
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current study.The potential benefit of DFP is also supported by the lower use of dystonia 
medications during the trial by patients on DFP than patients on placebo, and by the results of the 
extension study.  Among patients who received DFP in both studies, disease progression 
continued at the same rate, while among those who switched from placebo to DFP, it slowed to 
match the rate seen in those who had received DFP in the first study.  The fact that the rate of 
deterioration in the placebo-DFP group was less (p=0.0206) during the 18 months of DFP 
treatment than it was during the 18 months of placebo treatment supports the effect of this drug in 
patients acting as their own controls. 
Another factor for consideration is the stage of the disease, since in any neurodegenerative 
process, the later the intervention with an agent that might have the ability to slow progression, 
the less the expected benefit. Participants in this study had been experiencing PKAN symptoms for 
approximately 13 years at the time of enrollment, and it is likely that for many, the disease 
progression was too advanced for a preventative drug to provide significant benefit.  If brain iron 
contributes to the pathology seen in PKAN,
10
 then early initiation of DFP , where there has been 
less extensive iron-induced neurodegeneration, would be expected to maximize its benefit in 
slowing disease progression. Support for the view of a greater impact of DFP when the disease is 
less advanced was provided by the predefined subgroup analysis looking separately at patients 
with classic vs. atypical PKAN.  In atypical PKAN, in addition to symptoms appearing later,  
the disease progresses more slowly;
2,7 
hence, even though the patients with atypical PKAN had 
the disease for about the same duration as those with classic PKAN, the extent of irreversible 
neurodegeneration would have been less. This difference may explain why patients with atypical 
PKAN had a better response than patients on placebo in the randomized portion of the study 
(p=0.0187).  
The low prevalence of PKAN (1 to 3 cases per million population
21
) was responsible for a 
paucity of patients, and, in light of the slower than predicted rate of disease progression, a larger 
number of patients could have compensated for inadequate power to reach the preset level of 
significance of p<0.05 in the 18-month study. As the conduct of larger studies is improbable, any 
attempt at future clinical trials will likely require patient enrichment for targeted questions. 
With respect to the PGI-I endpoint, most participants reported neither worsening nor 
improvement from baseline despite the indications seen on more objective measures; and the 
same was true in the extension study. The correlation between the PGI-I and the change in BAD 
score at Month-18 is weak (r = 0.29), in which < 10% of the PGI-I variation can be explained by 
the change in BAD (r
2
 < 0.1), indicating that the PGI-I is not an adequate tool for assessment in 
PKAN over an 18-month period. The PGI-I is, by definition, subjective, and was likely 
inappropriate for this study. It may be a good tool for assessing the short-term effect of drugs that 
induce improvement or reversal of disease, but it was likely difficult for patients to judge whether 
their condition had worsened or improved over an 18-month period, explaining why no net 
worsening was detected, even by those on placebo. 
The most notable change observed was the profound reduction of iron in the globus pallidus:  a 
mean decrease of 36.1 Hz in the DFP-treated group compared to 0.50 Hz in the placebo group 
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(p <0.0001). This finding is consistent with reports of DFP-induced reductions in the levels of 
brain iron seen in Friedreich’s ataxia,17 Parkinson’s disease,18 and other NBIA disorders.22 
Importantly, the reduction in brain iron load induced by DFP was not associated with systemic 
iron depletion. 
Freezing phenomenon, an event commonly observed in PKAN patients, was seen in 10% of 
patients on placebo versus in none of those on DFP (p=0.0370), even though there were twice as 
many patients on DFP. Freezing has been linked to pathology in the basal ganglia and brainstem, 
both of which are areas affected in PKAN and in which iron was decreased by treatment with DFP. 
Further exploration of the mechanism is warranted.
24
 
With respect to other secondary efficacy endpoints of the randomized study, although many of 
the group differences did not reach significance, patients who received DFP exhibited less 
worsening over 18 months of treatment than patients on placebo in most outcome measures. 
Responder analysis (the percentage of patients showing either improvement or stabilization on 
the total BAD score) found that the responder rate for patients on DFP was 2.6 times that for 
patients on placebo: 36% vs. 14% (p=0.0893). DFP patients showed less worsening on the 
individual BAD scores for nearly all body regions, with group differences reaching statistical 
significance (albeit marginal, as they would not reach significance if multiplicity were 
considered) for neck (p=0.0465), left lower extremity (p=0.0391), and right lower extremity 
(p=0.0435). 
Next to the reduction of brain iron levels, the most substantial difference between treatments was 
seen on the WeeFIM measure, where actual improvement—not merely less worsening—was seen 
in DFP patients in the domain of cognition, with the treatment group difference reaching 
statistical significance (p=0.0324).  No statistically significant group differences were seen on the 
other secondary measures. However, examination of all the secondary endpoints revealed a 
pattern suggesting a beneficial effect of DFP across a broad range of functions. 
The tolerability of DFP was evidenced by the near-total compliance and low dropout rate in both 
studies. The two deaths were unrelated to study treatment, and rates of adverse events, which 
were mainly of mild intensity, were similar between the treatment groups on most measures 
(Table 3 and Suppl. Table 3). In general, the safety findings were consistent with those of other 
studies of DFP in patients with both brain iron overload
6,12,25,26
 and systemic iron overload.  
There were no occurrences of agranulocytosis, the most serious adverse event associated with 
DFP, and there was no significant group difference in the frequency of patients experiencing 
milder episodes of neutropenia, all of which resolved rapidly. There was a concern that non-iron-
overloaded patients being treated with an iron chelator might experience hematological events 
linked to a lowering of iron body stores, such as decreased serum ferritin, anemia, and iron 
deficiency. However, while these events were seen in a higher percentage of DFP patients in the 
randomized trial, the rates were low, the group difference reached significance only for anemia, 
none of the events were serious, and all could be managed by iron supplementation. 
A major strength of the study related to the ability to actually enroll close to 10% of all estimated 
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PKAN patients in the US and Europe.  The major limitation in the study was the lack of adequate 
pre-existing natural history data in PKAN patients to enable an informed power calculation for the 
primary outcome related to a change in BAD. Consequently, the slower than expected rate of 
worsening in the placebo-treated patients impacted the ability to achieve a significant difference in 
the overall ITT population. 
In summary, this study, together with previous findings, shows that the membrane permeable iron 
chelator deferiprone achieved target engagement (lowering of iron in the basal ganglia) in patients 
with PKAN. While the clinical endpoints were not met for the mITT population in the randomized 
trial, planned subgroup analysis provided some evidence of slowing of disease progression in the 
atypical patients and the results of the extension trial indicate potential slowing of progression by 
deferiprone in the overall population as well. This study will help shape the design of future trials in 
this ultraorphan disease. 
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Summary  
Background Pantothenate kinase-associated neurodegeneration (PKAN) is a rare genetic disorder 
characterized by progressive generalized dystonia and brain iron accumulation. We assessed 
whether the iron chelator deferiprone (DFP) can reduce brain iron and slow disease progression. 
Methods An 18-month, randomized, double-blind, placebo-controlled trial, followed by an a pre-
planned 18-month open-label extension study [A: was the extension study pre-planned? There 
are no details in the protocol provided] in patients with PKAN, was conducted in 4 hospitals in 
Germany, Italy, England and the USA. Key eligibility criteria includedPatients aged ≥4 years 
with, a genetically confirmed diagnosis of PKAN, a total score ≥3 on the Barry-Albright 
Dystonia (BAD) scale, and no evidence of iron deficiency, neutropenia, or abnormal liver or 
renal function, . Eligible patients (N=88) were randomly allocated (2:1) to receive DFP oral 
solution (30 mg/kg/day) or placebo for 18 months.  Randomization was done using a centralized 
computer random number generator with stratification based on age group at onset of symptoms, 
and patients were allocated to groups by a non-blinded randomization team that was independent 
of the study.  Patients, caregivers, and investigators were masked to treatment allocation. Patients 
who completed the randomized trial were eligible to enroll in a single-arm extension study of 
another 18 months in which all participants received DFP. Co-pPrimary endpoints were the change 
from baseline to Month 18 in the total score on the BAD scale and the score at Month 18 on the 
Patient Global Impression of Improvement (PGI-I). Efficacy analyses were done on the modified 
Intent to Treat (mITT) population, which included all patients who received at least one dose of 
study drug and who provided a baseline and at least one post-baseline efficacy assessment; safety 
analyses were done on all patients who received at least one dose of study drug. The trial was 
registered on ClinicalTrials.gov (NCT01741532) and EudraCT (2012-000845-11). 
Findings Between December 2012 and April 2015, 88 patients were randomly assigned to DFP 
(N=58) or placebo (N=30). Of these, 76 patients completed the study: 49 in the DFP group and 
27 in the placebo group.  Participants in both groups had an average disease duration of 13 years 
before enrollment. After 18 months, the BAD score worsened by 2.48±0.63 points (DFP), versus 
3.99±0.82 points (placebo; difference -1.51 points, 95% CI [-3.19,0.16], p=0.0761). [A: 
subgroup analysis has been removed as reporting should not be selective in the abstract.] In 
the predefined subgroup with atypical (disease onset ≥ age 6) PKAN, the BAD score worsened 
by 2.33±0.73 points (DFP) versus 4.52±0.91 points (placebo; difference -2.19 points, 95% CI 
[-4.00,-0.38], p=0.0187). In the extension study, patients continuing on DFP retained the slower rate 
of disease progression while progression in patients switching from placebo to DFP slowed 
significantly. No subjective change was detected as assessed by the PGI-I: mean scores at Month 
18 were 4.7±0.4 for placebo and 4.6±0.3 for DFP (p=0.7279), indicating that patients in both 
groups did not perceive either improvement or worsening since baseline. In the extension study, 
patients continuing oncontinuing DFP retained the slowera similar rate of disease progression 
(1.9±0.5 points in the first 18 months vs 1.4±0.4 points in the second 18 months, p=0.2684), 
while progression in patients switching from placebo to DFP seemed to slowed significantly 
(4.4±1.1 points when they were receiving placebo vs 1.4±0.9 points when they were receiving 
Comment [KTPD2]: If possible, we 
would like to keep this sentence as it 
reflects the results in our predefined 
stratified subgroups, hence we do not 
consider it as selective reporting. 
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DFP, p=0.0206). Patients also did not detect a change in their condition after the additional 18 
months of treatment, with mean scores of 4.1±0.2 in the DFP-DFP group and of 4.7±0.3 in the 
placebo-DFP group. Regarding safety, DFP was well tolerated, and rates of adverse events were 
similar between the treatment groups except for anemia, which was seen in 20.7% of DFP-treated 
patients vs. no placebo patients. No patient discontinued therapy due to anemia. There were two 
deaths, both secondary to aspiration. Neither of these events was considered related to DFP use. 
Interpretation  This trial is the largest randomized trial to date and provides the longest 
prospective follow-up of any NBIA population. Deferiprone was well tolerated but did notand 
seemed to show seem to slower, although not statistically significant,  disease progression at 18 
months. and p Patients in neither group perceived an improvement or worsening at 18 months 
based on PGI-I assessments. After an additional 18 months of treatment in While the primary 
endpoints were not met for the Intent-to-Treat population in the randomized trial, subgroup 
analysis and the results of tthe extension trial, there was somefurther evidence  indicateof slowing 
of disease progression by deferiprone, although patients didcontinued to not perceive a change in 
their condition. This study will help shape the design of future trials in this ultraorphan disease. 
Funding European Commission; FDA; ApoPharma Inc., Canada. 
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Introduction 
Neurodegeneration with brain iron accumulation (NBIA) is a clinically and genetically 
heterogeneous group of rare hereditary neurodegenerative disorders characterized by high levels 
of brain iron.
1
 Around 50% of cases are due to pantothenate kinase-associated neurodegeneration 
(PKAN), caused by mutations in the pantothenate kinase 2 (PANK2) gene.
2
 The PANK2 enzyme 
localizes to mitochondria and is essential for the biosynthesis of coenzyme A (CoA), which in 
turn is vital for adenosine triphosphate synthesis and fatty acid and neurotransmitter metabolism.  
Absence or abnormal function of PANK2 may contribute to iron accumulation in specific brain 
regions.
3
 Onset of clinical signs ranges from infancy to adulthood; progression ranges from rapid 
to slow; and symptoms may vary greatly. Disease characteristics include progressive dystonia, 
parkinsonism, rigidity and spasticity. The factors that influence disease severity and progression 
rate of PKAN remain unknown. No disease-modifying therapies are yet available in PKAN or 
any form of NBIA.
4,5,6
    
The factors that influence disease severity and progression rate of PKAN remain unknown.  
Disability usually increases over time, and no genetic or other specific therapies exist.
4,5,6
 
Historically, PKAN has been described as either classic or atypical. In classic PKAN, symptoms 
usually develop before 6 years of age, and most patients require a wheelchair by their mid-teens. 
Atypical PKAN usually becomes evident after 10 years of age, is less severe, and progresses 
more slowly.
3,7
  It is hypothesized that classic PKAN results from complete absence of the 
PANK2 enzyme, whereas atypical disease results from severe deficiency.
3
 
While iron is essential for normal physiological function, an excessive amount or dysregulated 
iron metabolism is potentially toxic. Increased “free” iron in tissues leads to the formation of 
highly reactive oxygen species, causing localized toxicity.
8,9
 Although proof that iron causes 
neurodegeneration in PKAN and most other NBIA is lacking, preferential iron accumulation in 
the basal ganglia likely explains the predominant movement disorder phenotype.
10
  Accordingly, 
iron chelation holds promise to decrease brain iron levels in NBIA, which may retard disease 
progression. 
Deferiprone (DFP, 3-hydroxy-1,2-dimethylpyridin-4-one) is an oral iron chelator approved for 
the treatment of transfusional iron overload in patients with thalassemia. DFP crosses the blood 
brain barrier, chelates excess iron from intracellular organelles, and may transfer it to biologic 
receptors.
11
 Limited safety and efficacy data are available on patients with brain iron 
accumulation. Based on the available data in patients with PKAN or other neurodegenerative 
disorders who received DFP,
6,12-20
 it was hypothesized that DFP could reduce brain iron, which 
might lead to clinical benefit. This article describes the results of the TIRCON2012V1 study - the 
first randomized clinical trial of a putative therapeutic agent in patients with PKAN, and of its 
single-arm extension study, TIRCON2012V1-EXT. 
 
  
Comment [KTPD4]: Sentence from 
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Methods 
Key information on study methods is provided here, and further details are available in the 
Supplement. 
Study design 
TIRCON2012V1 was an 18-month randomized, double-blind, placebo-controlled trial that 
evaluated the safety and efficacy of DFP in patients with PKAN.  Patients who completed the 
randomized trial were eligible to enroll in a single-arm extension study of another 18 months, 
TIRCON2012V1-EXT, in which all participants received DFP. 
An independent Data and Safety Monitoring Board regularly reviewed the safety data of both 
trials, and each study was registered on ClinicalTrials.gov prior to enrollment of the first patient 
(trial registration numbers NCT01741532 and NCT02174848, respectively). 
Patients 
Patients were eligible for enrollment in TIRCON2012V1 if they had a diagnosis of PKAN 
confirmed by genetic testing and a total score ≥3 on the Barry-Albright Dystonia (BAD) scale, 
which ranges from 0 (best) to 32 (worst).  Exclusion criteria included treatment with any iron 
chelator in the past 12 months and the presence of medical conditions or other indicators that 
might increase safety concerns. The full list of inclusion/exclusion criteria is provided in the 
Supplement. The use of symptomatic treatments was permitted; however, to reduce confounds, 
individuals were excluded if they had recent (< 2 months) or anticipated changes in any regimen 
being used to treat dystonia, whether medication or a Deep Brain Stimulation (DBS) device. 
Written informed consent was obtained from each participant or the parent/legal guardian before 
any procedures were carried out. 
Randomization and masking 
In TIRCON2012V1, patients were assigned in a 2:1 ratio to receive either DFP at a dose of up to 
30 mg/kg/day divided b.i.d or matching placebo (identical packaging, appearance, and taste), 
using block randomization.  The randomization list was generated using a computer random 
number generator. A centralized randomization was used for all study sites, and patients were 
allocated to groups by a non-blinded randomization team that was independent of the study. 
Allocation concealment was through a centralized randomization process with computer 
generated randomization list. Randomization was stratified based on the patient’s age at 
diagnosis, with one list generated for individuals who had been younger than 6 years at the onset 
of motor symptoms and one for those who had been 6 years or older.  Patients, caregivers, study 
staff, and the neurologists who analyzed videotapes for determination of BAD scores were 
blinded as to treatment assignment, as were the radiologists who analyzed the MRI images for 
determination of iron levels in the globus pallidus. 
In the extension trial, all patients received DFP.  However, since the randomized study was still in 
progress when this study began, both patients and staff remained blinded as to which product had 
been taken for the previous 18 months until both studies had been completed and their data 
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locked. 
 
Procedures 
Participants took the assigned study product twice daily for 18 months.  Compliance was 
evaluated at each post-baseline visit by calculating the volume of medication dispensed and the 
amount of unused drug supply remaining in the bottle.  Efficacy was assessed every 6 months, 
using the following measures: 1) the BAD scale, which measures the severity of dystonia in 8 
body regions (eyes, mouth, neck, trunk, and each upper and lower extremity) and generates 
individual scores and a total score; 2) the Patient Global Impression of Improvement (PGI-I), a 
subjective instrument which consists of a single question asking patients to rate their condition on 
a scale from 1 (very much better) to 7 (very much worse) in comparison to how they had felt at 
baseline; 3) the Unified Parkinson’s Disease Rating Scale (UPDRS) Parts I, II, III, and VI, for 
assessment of motor symptoms that resemble those in Parkinson’s disease as well as quality of 
life aspects; 4) the Functional Independence Measure (FIM) or WeeFIM (pediatric version) for 
assessment of various measures of functional independence; 5) the Pediatric Quality of Life 
(PedsQL) scale for measurement of quality of life; and 6) the Pittsburgh Sleep Quality Index 
(PSQI) for measurement of quality of sleep.  For the BAD scale, the required tests were 
administered and videotaped at the site, and the videotapes were sent to a central site for blinded 
assessment by movement disorders experts.  Iron levels in the globus pallidus were measured by 
MRI-R2* in a subset of patients at baseline and Month 18. Safety assessments were done at each 
visit, and involved collecting adverse events and conducting clinical laboratory tests, physical 
examination, vital signs, and electrocardiogram (screening and Month 18 only). 
In the extension study, patients who had been randomized to DFP continued to receive it and 
those who had been randomized to placebo were switched to DFP.  Again, assessments were 
conducted every 6 months.  Safety evaluations were the same as before, but efficacy measures 
were limited to BAD scale and PGI-I. 
Outcomes 
In the randomized trial, the co-primary efficacy endpoints were change from baseline to Month 
18 in the BAD total score and the score at Month 18 on the PGI-I. The outcome was to be 
considered positive if the group differences in both primary endpoints reached statistical 
significance (p<0.05).  Secondary efficacy endpoints were change from baseline to Month 18 in 
the BAD score for each body region, iron levels in the globus pallidus (as assessed by MRI-R2*), 
and scores on the FIM/ WeeFIM, UPDRS, PedsQL, and PSQI; and the proportions of patients at 
Month 18 with improved or unchanged BAD total scores and PGI-I scores. For the safety 
endpoints, the groups were compared for the frequency of adverse events, frequency of serious 
adverse events, and number of discontinuations due to adverse events. 
In the extension study, the primary endpoint was safety, and the efficacy endpoints were change 
in BAD score and score on the PGI-I. 
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Statistical analysis 
Determination of Sample Size:  At the time of planning the randomized trial, there were no 
published studies with data sufficient to estimate sample size based on either the natural history 
of the disease or the expected impact from an agent that interfered with iron-related 
neurodegeneration. An estimate of the effect size was based on a retrospective study of 23 
patients with NBIA, 22 of whom had most probably PKAN (14 genetically confirmed, the others 
with eye-of-the-tiger sign), and 21 of whom had been assessed for dystonia using the BAD 
scale.
21
 It was assumed that with similar disease progression, after 18 months there could be a 
substantial worsening of the BAD total score in the control group, with a possible difference from 
the DFP group of ≥5 points. Assuming a standard deviation of 6.3 points, 2:1  randomization, 
and 30% drop-out rate, 87 patients would be needed to detect a difference of at least 5 points at a 
two-sided 0.05 level of significance with 80% power. For the extension study, there was no 
formal sample size and power calculation; all patients completingTIRCON2012V1 were invited 
to enroll. 
Analyses:   All statistical analyses were performed using SAS (Windows version 9.3).  Safety 
analyses were based on all randomized patients who received at least one dose of study drug. 
Efficacy analyses were based on the modified Intent-to-Treat (mITT) population, defined as all 
randomized patients who 1) received at least one dose of study drug, and 2) provided a baseline 
and at least one post-baseline efficacy assessment. A Mixed Model for Repeated Measures 
(MMRM) model was used as the primary analysis method to assess the primary and secondary 
endpoints of changes from baseline to the specified time points (Months 6, 12, and 18), with 
baseline value and age of onset of motor symptoms (before 6 years versus at or after 6 years) as 
covariates, and treatment group as the main factor in the model. The marginal mean change (least 
squares estimate) at Month 18 was used to determine the treatment effect in the primary analysis.  
Over the 18-month course of the trial, some participants required changes in their DBS settings or 
in the use or frequency of rescue or as-needed medications, and these variables were also 
included in the MMRM model as visit-dependent covariates. 
A similar MMRM model was used for the analysis of the PGI-I. As the PGI-I score is a 
measurement of change from baseline, it was treated directly as the outcome variable. A logistic 
regression model with similar covariates was used for analysis of the proportion of responders.  
Finally, a subgroup analysis using a similar MMRM model was performed on the co-primary 
efficacy endpoints based on age at onset of motor symptoms (≥6 years vs. <6 years).  The safety 
data for continuous variables were summarized using descriptive statistics, and the safety data for 
discrete variables were tabulated with frequency tables. 
In the extension study, changes in the BAD scale and PGI-I scores were summarized using 
descriptive statistics. Last Observation Carried Forward (LOCF) was used for the scores of 
patients who did not complete treatment.  A paired t-test was used to compare the change in BAD 
total score and PGI-I score between the randomized and the extension studies, while a student t-
test was used for within-study comparison of treatment groups. 
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Role of the funding source 
Funding for the study was provided by the European Commission, the US FDA, and ApoPharma 
Inc., Canada.  The US FDA had input into the design and selection of endpoints. ApoPharma 
participated in study design, data collection, data analysis, data interpretation, and writing of the 
report. The corresponding author had full access to all data in the study and had final 
responsibility for the decision to submit for publication.  
 
 
Results 
Randomized trial 
Following screening of 100 prospective subjects, 89 of a planned 90 patients were enrolled 
between December 13, 2012 and April 21, 2015, with 59 randomized to receive DFP and 30 to 
receive placebo (Figure 1). One patient assigned to the DFP group withdrew prior to receiving 
the first dose, and two assigned to placebo withdrew after receiving study drug but before 
providing any post-baseline efficacy data; accordingly, there were 58 DFP patients and 30 
placebo patients evaluable for safety, and 58 and 28, respectively, for efficacy. 76 patients 
(85.4%) completed the trial, and 12 (in addition to the one patient who was never dosed) 
withdrew:  3 (10.0%) in the placebo group and 9 (15.3%) in the DFP group. Reasons for 
withdrawal in the placebo group were 1 case each of worsening of the disease, protocol violation, 
and voluntary withdrawal, while those in the DFP group were 4 cases of an adverse event, 3 of 
worsening of the disease, and 1 each of investigator’s decision and voluntary withdrawal. Of 
the withdrawals due to adverse events, 3 were for neutropenia (for which withdrawal was 
mandated by the study protocol), and 1 was for fever and pneumonia. 
At baseline, there were no major differences between the treatment groups with respect to age at 
enrolment, duration of disease, sex, and race (Table 1), baseline BAD score, or amount of iron in 
the relevant brain areas. Stratification was used to ensure that each treatment group had 
approximately equal percentages of patients with classic or atypical PKAN, as determined by age 
at onset of motor symptoms: among the 86 patients who were evaluable for efficacy, there were 
12 classic and 16 atypical patients in the placebo arm, and 29 of each type in the DFP arm. Mean 
age at randomization differed considerably between the subgroups (13.7 and 26.5 years for 
patients with classic and atypical PKAN, respectively), but disease duration was similar for both, 
approximately 13 years. As expected, the disease had progressed further in those with classic 
PKAN, as indicated by baseline BAD scores (20.3 vs. 17.0), but the difference did not reach 
statistical significance (p=0.0753). 
Concomitant treatments for dystonia symptoms were an important consideration because of their 
possible confounding effect on the BAD score. Most participants, 18 placebo patients (60.0%) 
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and 42 DFP patients (72.4%), were taking at least one dystonia medication at baseline; 25 
patients, 6 (20%) and 19 (32%), respectively, had a DBS system in place; and 3 patients (1 and 2 
respectively), had a baclofen pump in place. There were no statistically significant differences 
between treatment groups regarding the use of any medication or device for the treatment of 
dystonia at baseline. During the study, additional dystonia medications administered on an as-
needed basis were taken by a higher percentage of placebo patients (21.4%) than DFP patients 
(10.9%), with the difference reaching significance (p=0.0345) for botulinum toxin type A. 
Compliance was very high at all time points, ranging from 95.1% to 99.4% in the placebo group 
and from 96.6% to 99.5% in the DFP group. 
BAD scores at baseline are shown in Table 1. One patient in the placebo group had a score of 31 
and one in the DFP group had the maximum score of 32, meaning that little or no further worsening 
could be detected in those individuals through this instrument. Further analyses showed that results 
were not confounded by a ceiling effect (cf. Discussion, Supplementary material and Suppl. Tables 
1a and 1b). Patients in both treatment groups showed a worsening over time (Figures 2a, 2b, 
and 2c). In the main analysis using the marginal means from the MMRM model, there was a 
mean ±SE worsening of 2.48±0.63 points in the DFP group vs. 3.99±0.82 points in the placebo 
group: i.e., the DFP group overall worsened by 1.51 points less, a difference that approached the 
protocol-defined criterion of p=0.05 for statistical significance (95% CI [-3.19, 0.16], p=0.0761) 
(Table 2). A predefined subgroup analysis that looked separately at patients with classic or 
atypical PKAN showed that DFP use was associated with slower progression in clinical 
symptoms (2.33±0.73 points) than patients on placebo (4.52±0.91 points) in atypical PKAN, a 
difference of 2.19 points, that reached statistical significance (95% CI [-4.00,-0.38], p=0.0187).  
Within the classic subgroup, the difference of 0.81 points in favor of DFP did not reach 
significance (p=0.5701). In the responder analysis, 36% of DFP-treated patients responded to 
therapy compared to 14% of placebo-treated patients (p=0.0893).  
In contrast to the objective signs of disease progression, as assessed by the BAD score, no 
subjective change was detected as assessed by the PGI-I. At Month 18, mean PGI-I scores were 
4.7±0.4 for placebo and 4.6±0.3 for DFP (p=0.7279), indicating that patients in both groups did 
not perceive either improvement or worsening since baseline. There was only a weak correlation 
(r = 0.29) between the PGI-I and the change in BAD score at month 18 (cf. Supplementary 
material and Suppl. Figure 1). 
MRI-R2* imaging for the measurement of iron levels in the globus pallidus was conducted in a 
subset of patients at the start (16 placebo, 24 DFP) and end of the study (13 placebo, 19 DFP). In 
the placebo group, there was virtually no change (an R2* decrease of 0.5±4.0 Hz), while in the DFP 
group there was a decrease of 36.1±3.1 Hz, for a significant treatment group difference of -35.6 
Hz (95%CI, [-44.8,-26.3], p <0.0001) (Figure 3). [A: could this figure be moved to the 
appendix] 
Figure 4 presents a summary of all secondary efficacy endpoints as a Forest plot. Each point 
represents the marginal mean difference between DFP and placebo. The line indicates the 95% 
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confidence interval for the difference, both standardized by the standard error of the marginal 
mean difference. For each endpoint, this graph indicates whether the results were in favor of DFP 
(point to the left of 0.00) or placebo (point to the right of 0.00). Of the 21 measures examined, 13 
were in favor of DFP, 4 showed no treatment difference and 4 were in favor of placebo. 
Differences between the treatment groups that reached statistical significance in favor of DFP 
were seen for the WeeFIM, and for certain BAD body region scores (neck: -0.43; p=0.0465; 
left lower extremity: -0.28; p=0.0391; and right lower extremity: -0.25; p=0.0435).  No 
significant differences were seen in other endpoints. More detailed results on the WeeFIM 
assessments are provided in the Supplement, including Suppl. Figure 12. 
An overview of the different categories of safety findings during the randomized phase of the 
studies is shown in Suppl. Table 4, and a listing of individual AEs seen in >10% of patients in 
Suppl. Table 5. [A: ideally a table of AEs should be included in the main manuscript]  
Overall, DFP was well tolerated, and rates of adverse events (AEs) seen in >10% of patients is 
provided in Table 3. Rates were similar between the treatment groups except for AEs related to 
study treatment such as anemia, which was seen in 20.7% of DFP-treated patients vs. no placebo 
patients; however, the hemoglobin value was <10 g/dL in  only three patients with anemia. Non-
significant differences were seen between the DFP and placebo groups in rates of decreased 
serum ferritin (32.8% vs. 16.7%; p=0.1341) and iron deficiency (15.5% vs. 10.0%; p=0.7442).  
Iron supplementation was permitted, based on the investigator’s assessment of need, and was 
taken by 39% of patients in the DFP group and by 27% of patients in the placebo group. There 
were no deaths or episodes of agranulocytosis or severe neutropenia, and there was no significant 
difference between the study groups in the rates of less severe neutropenia (8.6% in DFP vs. 
6.7% in placebo). 
Extension study 
Of the 76 patients who completed the randomized trial, 68 enrolled in the extension study. Those 
who had received DFP continued to receive it (DFP-DFP group, N=44), while those who had 
received placebo were switched to DFP (placebo-DFP group, N=24). All 68 patients were 
evaluable for safety, and 62 (43 DFP-DFP, 19 placebo-DFP) were evaluable for efficacy. 
BAD scores at the start of the extension study are shown in Table 1 (at this time point, one 
placebo-DFP patient had a score of 30 and one DFP-DFP patient had the maximum score of 32).  
Figure 2d displays the change in BAD total score for the 62 patients who provided evaluable 
efficacy data in both studies. In both groups, scores continued to increase (worsen) over time, but  
the DFP-DFP patients showed a similar rate of progression in both studies, while the placebo-
DFP patients progressed more rapidly in the first study and slowed when they were switched to 
DFP. Over the 18 months of the extension study, there was no significant difference in the change 
in BAD score for patients who had been on DFP from the start (1.9±0.5 points in the first 18 
months vs 1.4±0.4 points in the second 18 months, p=0.2684) while there was significantly less 
worsening in the placebo-DFP group (4.4±1.1 points when they were receiving placebo vs 
1.4±0.9 points when they were receiving DFP, p=0.0206) (Suppl. Table 2). 
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With respect to the PGI-I, as in the randomized study, patients did not detect a change in their 
condition after the additional 18 months of treatment, with mean scores of 4.1±0.2 in the DFP-
DFP group and of 4.7±0.3 in the placebo-DFP group. 
For evaluation of safety, data were combined for all 68 patients.  Overall, DFP continued to be 
well tolerated for the 36-month period. There were two deaths, both secondary to aspiration (one 
pneumonia and multi-organ failure, the other to aspiration following the patient vomiting in his 
sleep).  Neither of these patients had experienced neutropenia while in the study. The most 
common adverse event was dystonia, reported in 40 (58.8%) patients, followed by pyrexia in 23 
(33.8%), headache in 20 (29.4%), and condition aggravated and decreased serum ferritin in 18 
each (26.5%). 
 
Discussion 
No disease-modifying therapies are yet available in PKAN or any form of NBIA.
4,5,6
  Excess 
brain iron is seen in various types of neurodegenerative conditions, including PKAN and 
Parkinson’s disease, as well as in normal aging.22  Excess iron is believed to catalyze the 
formation of reactive oxygen species from the by-products of oxygen consumption, which could 
affect neuronal functions either by directly damaging cell components or by chemically affecting 
signal mediators such as dopamine.
18
  Hence, chelators that remove brain iron may serve as 
therapy for those conditions. [A: this section should be incorporated into the introduction or 
deleted if info is duplicated. Please start your discussion with a summary of your findings] 
The present study is the largest randomized trial to date and provides the longest prospective 
follow-up of any NBIA population. It yields valuable information on the impact of iron chelation 
but also on the natural history of PKAN through the detailed assessment of placebo recipients, 
indicating that the rate of disease progression is slower than previously estimated.
21
  In the 
current trial, the power calculation for the divergence in the change in BAD total score between 
the treatment groups had assumed that a clinically relevant difference of 5 points could be 
achieved; however, over  18 months, the placebo group worsened by less than anticipated.  
Accordingly, the only way a significant group difference could have been achieved would have 
been for DFP to reverse rather than slow the progression of the disease. It is noteworthy that even 
the difference of 1.51 points approached the protocol-defined criterion for statistical significance 
(p=0.0761), and it is possible that a study duration longer than 18 months with the same number 
of patients would have allowed the detection of a difference large enough to establish statistical 
significance. 
For patient enrollment, there was no exclusion of patients with high BAD scores. This may lead 
to a ceiling effect where patients with high BAD scores (close to the maximum score of 32) at 
baseline cannot worsen as much as patients with lower BAD scores. Randomization resulted in 
proportionally more patients with high baseline BAD scores being assigned to the deferiprone 
treatment group. To investigate whether a ceiling effect confounds the results of our study, we 
repeated the MMRM analysis excluding all patients with a baseline BAD score > 27 who would 
Comment [KTPD7]: done 
Comment [KTPD8]: paragraph on 
possible confounding by ceiling effect, as 
requested 
 12 
 
potentially be subject to a ceiling effect. In this analysis, deferiprone-treated patients still 
exhibited a numerically lesser progression in BAD score than placebo-treated patients, with the 
marginal mean difference being very similar to that from the analysis of the mITT population 
(Suppl. Table 1a). The p value worsened from 0.0761 to 0.1114 as a function of the lower 
number of subjects. Additional analysis was conducted to compare response according to the 
tertiles of baseline BAD (Suppl. Table 1b), demonstrating a benefit of DFP versus placebo, 
although p values were not significant due to the low number of subjects. In conclusion, these 
analyses showed that PKAN progression as measured by the BAD score is slower with higher 
baseline values and that this results in a ceiling effect at very high baseline scores. While this is 
important information for the design of future trials, it did not affect the principal outcome of our 
current study. 
The potential benefit of DFP is also supported by the lower use of dystonia medications during 
the trial by patients on DFP than patients on placebo, and by the results of the extension study.  
Among patients who received DFP in both studies, disease progression continued at the same 
rate, while among those who switched from placebo to DFP, it slowed to match the rate seen in 
those who had received DFP in the first study.  The fact that the rate of deterioration in the 
placebo-DFP group was significantlyseemed to bewas less (p=0.0206) during the 18 months of 
DFP treatment than it was during the 18 months of placebo treatment supports the effect of this 
drug in patients acting as their own controls. 
Another factor for consideration is the stage of the disease, since in any neurodegenerative 
process, the later the intervention with an agent that might have the ability to slow progression, 
the less the expected benefit. Participants in this study had been experiencing PKAN symptoms for 
approximately 13 years at the time of enrollment, and it is likely that for many, the disease 
progression was too advanced for a preventative drug to provide significant benefit.  If brain iron 
contributes to the pathology seen in PKAN,
10
 then early initiation of DFP , where there has been 
less extensive iron-induced neurodegeneration, would be expected to maximize its benefit in 
slowing disease progression. Support for the view of a greater impact of DFP when the disease is 
less advanced was provided by the predefined subgroup analysis looking separately at patients 
with classic vs. atypical PKAN.  In atypical PKAN, in addition to symptoms appearing later, 
the disease progresses more slowly;
2,7 
hence, even though the patients with atypical PKAN had 
the disease for about the same duration as those with classic PKAN, the extent of irreversible 
neurodegeneration would have been less. This difference may explain why patients with atypical 
PKAN had a significantlyseemed to have had a better response than patients on placebo in the 
randomized portion of the study (p=0.0187). A similar finding of interest came from a post hoc 
subgroup analysis (data not shown) to see if patients who had been diagnosed with PKAN more 
recently would respond better than those with a longer disease duration. Five years was selected 
as the threshold as there were not enough patients to allow for a lower one. Nine patients in the 
placebo group and 6 in the DFP group had a disease duration of less than 5 years.  Among 
patients with a duration greater than 5 years, the treatment group difference on change in BAD 
score was just 0.86 points, while among those in whom it was less than 5 years, it was 3.14 
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points, although there was inadequate power to demonstrate statistical significance 
(p=0.3436).[A: discussion on post-hoc analysis has been removed as these data are not 
presented here] 
The low prevalence of PKAN (1 to 3 cases per million population
21
) was responsible for a 
paucity of patients, and, in light of the slower than predicted rate of disease progression, a larger 
number of patients could have compensated for inadequate power to reach the preset level of 
significance of p<0.05 in the 18-month study. As the conduct of larger studies is improbable, any 
attempt at future clinical trials will likely require patient enrichment for targeted questions. 
With respect to the PGI-I endpoint, most participants reported neither worsening nor 
improvement from baseline despite the indications seen on more objective measures; and the 
same was true in the extension study. The correlation between the PGI-I and the change in BAD 
score at Month-18 is weak (r = 0.29), in which < 10% of the PGI-I variation can be explained by 
the change in BAD (r
2
 < 0.1), indicating that the PGI-I is not an adequate tool for assessment in 
PKAN over an 18-month period. The PGI-I is, by definition, subjective, and was likely 
inappropriate for this study. It may be a good tool for assessing the short-term effect of drugs that 
induce improvement or reversal of disease, but it was likely difficult for patients to judge whether 
their condition had worsened or improved over an 18-month period, explaining why no net 
worsening was detected, even by those on placebo. 
The most notable change observed was the profound reduction of iron in the globus pallidus:  a 
mean decrease of 36.1 Hz in the DFP-treated group compared to 0.50 Hz in the placebo group 
(p <0.0001). This finding is consistent with reports of DFP-induced reductions in the levels of 
brain iron seen in Friedreich’s ataxia,17 Parkinson’s disease,18 and other NBIA disorders.22 
Importantly, the reduction in brain iron load induced by DFP was not associated with systemic 
iron depletion. 
Freezing phenomenon, an event commonly observed in PKAN patients, was seen in 10% of 
patients on placebo versus in none of those on DFP (p=0.0370), even though there were twice as 
many patients on DFP. Freezing has been linked to pathology in the basal ganglia and brainstem, 
both of which are areas affected in PKAN and in which iron was decreased by treatment with DFP. 
Further exploration of the mechanism is warranted.
24
 
With respect to other secondary efficacy endpoints of the randomized study, although many of 
the group differences did not reach significance, patients who received DFP exhibited less 
worsening over 18 months of treatment than patients on placebo in most outcome measures. 
Responder analysis (the percentage of patients showing either improvement or stabilization on 
the total BAD score) found that the responder rate for patients on DFP was 2.6 times that for 
patients on placebo: 36% vs. 14% (p=0.0893). DFP patients showed less worsening on the 
individual BAD scores for nearly all body regions, with group differences reaching statistical 
significance (albeit marginal, as they would not reach significance if multiplicity were 
considered) for neck (p=0.0465), left lower extremity (p=0.0391), and right lower extremity 
(p=0.0435). 
Comment [KTPD9]: ok 
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Next to the reduction of brain iron levels, the most substantial difference between treatments was 
seen on the WeeFIM measure, where actual improvement—not merely less worsening—was seen 
in DFP patients in the domain of cognition, with the treatment group difference reaching 
statistical significance (p=0.0324).  No statistically significant group differences were seen on the 
other secondary measures. However, examination of all the secondary endpoints revealed a 
pattern suggesting a beneficial effect of DFP across a broad range of functions. 
The tolerability of DFP was evidenced by the near-total compliance and low dropout rate in both 
studies. The two deaths were unrelated to study treatment, and rates of adverse events, which 
were mainly of mild intensity, were similar between the treatment groups on most measures 
(Table 3 and Suppl. Table 3). In general, the safety findings were consistent with those of other 
studies of DFP in patients with both brain iron overload
6,12,25,26
 and systemic iron overload.  
There were no occurrences of agranulocytosis, the most serious adverse event associated with 
DFP, and there was no significant group difference in the frequency of patients experiencing 
milder episodes of neutropenia, all of which resolved rapidly. There was a concern that non-iron-
overloaded patients being treated with an iron chelator might experience hematological events 
linked to a lowering of iron body stores, such as decreased serum ferritin, anemia, and iron 
deficiency. However, while these events were seen in a higher percentage of DFP patients in the 
randomized trial, the rates were low, the group difference reached significance only for anemia, 
none of the events were serious, and all could be managed by iron supplementation. 
A major strength of the study related to the ability to actually enroll close to 10% of all estimated 
PKAN patients in the US and Europe.  The major limitation in the study was the lack of adequate 
pre-existing natural history data in PKAN patients to enable an informed power calculation for the 
primary outcome related to a change in BAD. Consequently, the slower than expected rate of 
worsening in the placebo-treated patients impacted the ability to achieve a significant difference in 
the overall ITT population. 
In summary, this study, together with previous findings, shows that the membrane permeable iron 
chelator deferiprone achieved target engagement (lowering of iron in the basal ganglia) in patients 
with PKAN. While the clinical endpoints were not met for the mITT population in the randomized 
trial, planned subgroup analysis revealed a significantprovided some evidence of slowing of disease 
progression in the atypical patients (p=0.0187) and the results of the extension trial indicate 
potential slowing of progression by deferiprone in the overall population as well. This study will 
help shape the design of future trials in this ultraorphan disease. 
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Response to Reviewer #2 with particular focus on assessment of “Ceiling Effect” 
 
Verbatim Comment from Reviewer #2:  
The authors have addressed many of my points, but not fully addressed my main criticism of the study. 
As discussed below, I think the study is limited and possibly confounded by the inclusion of people with 
high baseline scores of BAD. While this is problematic, I don't think it is "fatal" to publishing the study, 
since there were no prior studies for this disease to refer to, and it is a significant challenge to recruit so 
many subjects of this rare disease.  
Looking at the spaghetti diagram, I think quite clearly those with higher baseline BAD values (>27) have 
slower decline than the rest of the group. This is potentially problematic because the DFP group appear 
to have proportionally more subjects above this value at baseline compared to placebo. This difference 
in rates was confirmed with the analysis of slope in subjects stratified by baseline BAD - while this was 
on the cusp of significance, I am sure that significance would be observed if the parameters were 
changed (e.g. one group only had five subjects, so it lacked power). There is a real possibility that the 
apparent trend toward significance on the primary outcome was due to proportionally more 'slow 
decliners' ('slow' because of high baseline BAD) in the DFP group. Accordingly, in Supp Table 1, the trend 
on the primary outcome was further diminished when subjects with higher baseline BAD were removed.  
The authors argue that is appropriate to include subjects with high, even maximum BAD score because 
there is a chance that DFP will lower the score. However, the power analysis was predicated on average 
decline of subjects -which would be impossible (or only limited) in people with high (>27) BAD. While 
only a few subjects were on maximum BAD score at the beginning and conclusion of the study, the slope 
analysis performed by the authors demonstrated that those with high (>27) BAD did not decline over 
the study period (P=0.4738). So a limitation of the study is not just the maximum score of 32 reached, 
but a ceiling effect that begins at ~27. Not all subjects are therefore assessed equally in this study. Many 
subjects can show decline on the BAD instrument, but those with high baseline BAD cannot. It is not 
sufficient to say that the possibility that DFP could improve BAD justified the inclusion of a patient with 
maximum or very high BAD (because they are different to other subjects in the study whose symptoms 
could potentially change in either direction). I highlighted this limitation in my previous review, and I 
think the authors should mention this potential confound in the discussion. They talk about the staging 
of the disease in regard to neurodegeneration, but not the limitation of the instrument, the variable 
rates of decline according to BAD score, and the flaw in the study that allowed inclusion of patients with 
high, especially maximum BAD. This is an important limitation to highlight in order to aid interpretation 
of the result, but also to inform future studies that use the BAD scale (so that they can be aware of the 
limitations of this instrument).  
Related to this last point, can I please request that the authors calculate and state in the manuscript the 
rates of decline in subjects according to strata of baseline BAD (e.g. <8, 9-16, 17-24, 25-32; or whatever 
the authors judge appropriate). The reason for this request is again for planning future studies involving 
this patient group. In the current manuscript, the authors calculate that the rate of decline for the whole 
group is less than they anticipated, but, as discussed above, this may be in part due to the fact that high 
baseline BAD patients do not materially decline over 18 months, therefore their inclusion likely 
attenuated the calculation of the average rate.  
Supplementary table 1 & 3 are not referred to in the text, and supplementary info is presented out of 
order (e.g. Supp Table 4&5 is referred to before Supp Table 
 
*Reply to Reviewers Comments
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Response: 
We want to thank Reviewer #2 for a most thoughtful review of the manuscript and we believe that our 
responses to the matters he raised has enhanced the quality of manuscript.  Most particularly, we 
welcome his/her detailed query pertaining to the possibility that a “ceiling effect” in the BAD score may 
be responsible for the observed differences between placebo and deferiprone-treated patients.  In fact, 
this question was one that we grappled with upon initial review of the data, and it was not until we were 
confident that a ceiling effect did not explain the difference, that we submitted the manuscript.  We did 
not, at the time of submission, present all the analyses that were conducted to provide us with that 
assurance, but since this matter has been emphasized, we will present it now, as well as include the 
further analyses requested by the reviewer. This is in addition to the previous comments we provided. 
We concur with Reviewer #2 that, on paper, a ceiling effect exists in the context that if a patient is 
already at BAD score 29, 30 or higher, there is little room for them to worsen, and if they do not worsen 
in the score, it might be categorized as a slower rate of deterioration in that patient.  In this study, there 
were more patients with a higher score in the group that was randomized to deferiprone, thus raising 
the possibility that the observed results might have been an artefact of the randomization process.   
To address the ceiling effect theory, we conducted a number of analyses, including those suggested by 
the reviewer, all of which led us to our conclusion that the observed reduction in patient worsening was 
a direct result of deferiprone administration and not an artefact due to a ceiling effect.  The following 
analyses support this conclusion, albeit the lower number of subjects led to weaker p values, due to 
segmenting the population. 
Note: In our previous responses, we called the estimated mean from the MMRM analysis as LSmean in 
all the tables. In this document, we changed the term LSmean to Marginal Mean, as requested by 
Reviewer #3, to be consistent with what was used in the manuscript. 
1. Reanalysis using a cut-off of 27 in BAD: 
By excluding all patients that would have had the potential to experience a ceiling effect, and using the 
cut-off of 27, as suggested by the reviewer, it is evident that the difference in response to treatment is 
not lessened whatsoever by the dropping of patients with a cut-off of 27, even though, as would be 
expected, fewer subjects lessens the level of statistical significance, as shown now in Suppl. Table 1a: 
Suppl. Table 1a: Main MMRM analysis excluding baseline BAD > 27 in the TIRCON study 
Subpopulation 
Placebo DFP 
DFP-Placebo 
Marginal 
Mean 
Difference 
(95% CI) 
P-value 
N 
Marginal 
Mean 
Change (SE) 
n 
Marginal 
Mean 
Change 
(SE) 
All patients 28 3.99 (0.82) 58 2.48 (0.63) 
-1.51 
 (-3.19, 0.16) 
0.0761 
Baseline BAD <=27  26 4.62 (0.96) 42 3.07 (0.81) 
-1.55 
(-3.47, 0.37) 
0.1114 
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This analysis demonstrates that removal of patients with a high baseline BAD did not adversely affect 
the outcome, arguing against the supposition that a ceiling effect may have been responsible for the 
observed decreased progression of disease.  
 
2. Reanalysis using different strata of baseline BAD score: 
As requested, the analysis was repeated using different strata of baseline.  To avoid the risk of bias in 
selection of what might constitute suitable cut-off points, we let the data select the points by choosing 
tertiles of baseline BAD.  The MMRM modelling performed for the primary analysis was repeated for 
each subgroup defined by the tertile of the baseline BAD score: ≤13, 13-24, >24.  The results are 
summarized now in Suppl. Table 1b. The analysis reveals that the treatment effect as measured by the 
Marginal mean difference between DFP and placebo was observed for each subgroup, indicating benefit 
of deferiprone over placebo regardless of the baseline BAD level, and, numerically, the largest observed 
difference is in those with no potential for a ceiling effect. 
 
Suppl. Table 1b: Main MMRM analysis by subgroups based on the tertiles of baseline BAD 
Subpopulation 
Placebo DFP 
DFP-Placebo 
Marginal Mean 
Difference 
(95% CI) 
P-value 
n 
Marginal Mean 
Change(SE) 
N 
Marginal 
Mean 
Change 
(SE) 
All patients 28 3.99 (0.82) 58 2.48 (0.63) 
-1.51 
 (-3.19, 0.16) 
0.0761 
Baseline BAD:  <= 13 12 7.65 (1.57) 17 6.06 (1.45) 
-1.59 
(-5.46, 2.27) 
0.4025 
Baseline BAD:  13-24 10 3.60 (1.29) 21 2.32 (1.02) 
-1.27 
(-3.65, 1.10) 
0.2780 
Baseline BAD:  > 24  6 1.55 (0.76) 20 0.77 (0.45) 
-0.78 
(-2.42, 0.87) 
0.3359 
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3. Reanalysis by examination of the slopes for worsening of BAD over time according to strata: 
 
As requested, the slopes of the change in BAD score (per month) in the 2 treatment groups were 
estimated for different strata of baseline. To avoid bias in the selection of strata, each subgroup was 
defined by the tertile of baseline BAD score. Results are given in Table 3 (not included in manuscript nor 
supplement). The analysis shows that as one approaches the upper range of BAD scores, the slopes tend 
to flatten, but in each case the slope for the placebo-treated patients is steeper than the slope for the 
deferiprone-treated patients, in support of the conclusion that the protective effect of deferiprone was 
not a function of the ceiling effect.  
Table 3: Slope of change in BAD by strata based on tertile of baseline BAD and by treatment group 
Subpopulation Treatment Group 
Slope (SE)‡ 
p-value 
DFP vs Placebo  
p-value 
Baseline BAD:  <= 13 
DFP (N=17) 
0.20 (0.05) 
0.0003 
0.4113 
Placebo (N=12) 
0.26 (0.06) 
<0.0001 
Baseline BAD:  13-24 
DFP (N=21) 
0.12 (0.05) 
0.0108 
0.5717 
Placebo (N=10) 
0.17 (0.06) 
0.0099 
Baseline BAD:  > 24 
DFP (N=20) 
0.04 (0.05) 
0.3772 
0.5115 
Placebo (N=6) 
0.11 (0.08) 
0.2041 
‡ Change in BAD score per month 
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4. Reanalysis by examination of the slopes for worsening of BAD in TIRCON + TIRCON EXT: 
Using the suggestion of the reviewer to analyze the slopes for the change in BAD score (per month) in 
the 2 treatment groups for the randomized study, we thought there would be value in a similar analysis 
in which we compared the slopes in the randomized (TIRCON) study vs the open label (EXT) study.  Here 
we examined the slopes for change in BAD over time for both deferiprone and placebo-treated patients 
in each arm for BAD ≤27.  Analysis of the data showed the slope for the placebo patients was steeper in 
the randomized study than the slope for the deferiprone-treated patients, but when they transitioned to 
deferiprone in the EXT study, the rates were comparable (Table 4, not included in manuscript nor 
supplement). 
 
Table 4. Slope of change in BAD (per month) for TIRCON and TIRCON-EXT study for those with baseline 
BAD ≤27 
Study Treatment Group 
Slope (SE)‡ 
p-value 
DFP vs Placebo  
p-value 
TIRCON 
 (N=68) 
DFP (N=42) 
0.14 (0.04) 
0.0002 
0.2971 
Placebo (N=26) 
0.20 (0.04) 
<0.0001 
TIRCON-EXT 
(N=46) 
DFP-DFP (N=32) 
0.09 (0.03) 
0.0122 
0.8785 
Placebo-DFP (N=14) 
0.08 (0.05) 
0.1305 
‡ Change in BAD score per month 
 
In summary, several different statistical approaches were used to assess whether a ceiling effect might 
explain the beneficial effect of deferiprone.  Regardless of the method used, analysis of the data failed 
to support the supposition of a ceiling effect as the determinant of the observed results.  More 
specifically, numerically, the greatest treatment difference was seen in those with less advanced 
disease, even though the analyses, employing the smaller “N” in each case, could not confer statistical 
significance.  This greater response to deferiprone in those with less severe disease is consistent with 
other observations (e.g., atypical versus classical PKAN patients) in the manuscript and supplementary 
information.   
We have inserted a paragraph in the Discussion to succinctly summarize the fact that we have addressed 
the question of a potential ceiling effect, but that analysis indicated that a ceiling effect did not explain 
the favourable response to deferiprone.  Information has been added to the Supplement in support of 
the conclusion, as well. 
We also thank the Reviewer for having noted the omission of the reference to the Supplementary table 
and the need to rearrange the order. 
 
Supplement 
Methods 
Study design 
TIRCON2012V1 was conducted at 4 treatment centers located in Germany, Italy, the United 
Kingdom and United States, and was approved by the respective Ethics Committees (Ludwig 
Maximilians University, Munich; Istituto Neurologico Carlo Besta, Milan; Yorkshire & The 
Humber, Leeds East Research; and Children’s Hospital & Research Center Oakland). The 
sites and Ethics Committees were the same for the single-arm extension study, 
TIRCON2012V1-EXT. An independent Data and Safety Monitoring Board regularly 
reviewed the safety data of both trials, and each study was registered on ClinicalTrials.gov 
prior to enrollment of the first patient (trial registration numbers NCT01741532 and 
NCT02174848, respectively). 
 
Patients 
Recruitment was via the centers’ own patients, referral from other neurologists and by posting 
information on the NBIA Disorders Association website.  
 
Full list of inclusion and exclusion criteria: 
Inclusion Criteria 
1. Males or females 4 years of age and older at screening visit 
2. Have PKAN, confirmed by genetic testing  
3. BAD total score ≥ 3 at the screening visit 
4. Patients who have Deep Brain Stimulation (DBS) systems or baclofen pumps in place will 
be eligible for the study, but they must have had a stable setting for at least two months 
prior to the screening visit; Enrollment of non-DBS patients will be given priority in order 
to ensure the majority can undergo imaging 
5. Informed consent/assent obtained before any study-related activities 
6. Ability and willingness to adhere to the protocol including appointments and evaluation 
schedule 
7. Sexually active female patients of childbearing potential must have a negative pregnancy 
test result at Screening Visit. In addition, if applicable, females of childbearing potential 
must use an effective method of contraception according to local requirements, OR have 
had a tubal ligation, OR have had a hysterectomy, OR participates in a non-heterosexual 
lifestyle, OR have a male sexual partner has been sterilized 
8. If the patient is a heterosexual sexually-active male, patient must confirm, in writing, that 
he and/or his female partner will use an effective method of contraception according to 
local requirements for the length of the trial and for 30 days following completion of the 
study or early termination  
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Exclusion Criteria 
1. Evidence of iron deficiency defined by Fe:TIBC ratio <15%, or serum ferritin <12 ng/mL 
2. Treatment with deferiprone in the past 12 months 
3. Previous failure of treatment with deferiprone, or previous discontinuation of treatment 
with deferiprone due to adverse events 
4. Conditions known to contraindicate the use of deferiprone (history of agranulocytosis or 
recurrent episodes of neutropenia) 
5. A serious, unstable illness during the past 3 months before screening visit including but 
not limited to: hepatic, renal, gastro-enterologic, respiratory, cardiovascular, 
endocrinologic, neurologic or immunologic disease 
6. Evidence of abnormal liver or renal function (serum liver enzyme level(s) > 3 times upper 
limit of normal at screening) or abnormal creatinine levels at screening visit 
7. Disorders associated with neutropenia (ANC < 1.5 x 109/L) or thrombocytopenia (platelet 
count < 50 x 109/L) in the 12 months preceding the initiation of the study medication. 
Exception: for patients whose neutropenia was attributed by the treating physician to 
episodes of infection or to drugs associated with a decline in the neutrophil count and in 
whom the ANC has fully recovered at the screening visit 
8. History of malignancy 
9. QTcF interval > 450 msec 
10. HIV positive 
11. Myocardial infarction, cardiac arrest or cardiac failure within 1 year before screening visit 
12. Bowel disease causing malabsorption 
13. History of alcohol or drug abuse 
14. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is 
longer) preceding the baseline visit 
15. Currently taking iron chelators 
16. Pregnant, nursing females and females of childbearing potential who are heterosexually 
active and unwilling, or unable, to use an acceptable method of contraception according to 
local requirements 
17. Males who are sexually active and unwilling, or unable, to use an acceptable method of 
contraception according to local requirements 
18. History or presence of hypersensitivity or idiosyncratic reaction to deferiprone 
19. Patients (or when applicable parent or patients’ legal representatives) with a mental 
incapacity, unwillingness or language barriers precluding adequate understanding or co-
operation 
20. Any condition that, in investigator’s opinion, would adversely affect the patient’s ability 
to complete the study or its assessments 
21. Baclofen pump placement less than two months prior to the screening visit 
22. Current and ongoing participation in other clinical studies 
 
 
  
Procedures 
In both trials, dosage was based on milligrams of DFP per kilogram of body weight, starting 
at 5 mg/kg b.i.d. and titrated up to 15 mg/kg b.i.d. by Week 12.  In TIRCON2012V1, patients 
in the control group received a matching volume of placebo during the same time periods.   
All efficacy measures were administered at baseline (except for the PGI-I, which is a measure 
of change from baseline), months 6, 12, and 18 or early termination.  Iron levels in the globus 
pallidus were measured by MRI-R2* in a subset of patients (those without a DBS device and 
able to undergo an MRI scan) at baseline and Month 18.  MRI scans were conducted 
according to a standardized imaging protocol, and the images were sent to central reading by 
radiologists who were blinded to treatment. None of the MRI-R2* results were disclosed by 
the radiologist until the last patient completed the trial. 
Information was also collected on the use of concomitant medications, with particular 
attention on any changes in drugs or devices used to relieve symptoms of dystonia. Patients 
had weekly hematology tests to monitor their absolute neutrophil count (ANC). Patients with 
two consecutive samples with ANC < 1.5×10
9
/L were withdrawn from the study. 
To reduce the confounding effects of concomitant therapies on the assessment of treatment, 
patients with recent or expected changes in therapies that have the potential to affect dystonia 
symptoms were excluded from enrolment.  
 
 
 
  
Results 
 
There were proportionally more patients with baseline BAD score close to the maximum 
score of 32 being randomized to the deferiprone treatment group. To investigate whether a 
“ceiling effect” might account for the differences observed in BAD in response to treatment 
with deferiprone, the mITT data were re-analyzed after excluding all patients that would 
have had the potential to experience a ceiling effect. Using the cut-off of 27 for the baseline 
BAD score, it is evident that the difference in response to treatment is not lessened by the 
dropping of patients with a cut-off of 27, even though, as would be expected, fewer subjects 
lessens the level of statistical significance, as shown in Suppl. Table 1a.  
 
Suppl. Table 1a: Main MMRM analysis excluding baseline BAD > 27 in the TIRCON study 
Subpopulation 
Placebo DFP 
DFP-Placebo 
Marginal 
Mean 
Difference 
(95% CI) 
P-value 
N 
Marginal 
Mean 
Change (SE) 
n 
Marginal 
Mean 
Change 
(SE) 
All patients 28 3.99 (0.82) 58 2.48 (0.63) 
-1.51 
 (-3.19, 0.16) 
0.0761 
Baseline BAD <=27  26 4.62 (0.96) 42 3.07 (0.81) 
-1.55 
(-3.47, 0.37) 
0.1114 
 
 
 
To further investigate the impact of ceiling effect, a reanalysis of the data was conducted 
using 3 different strata of baseline values. To avoid the risk of bias in selection of what might 
constitute suitable cut-off points, we let the data select the points by choosing tertiles of 
baseline BAD.  The MMRM modelling performed for the primary analysis was repeated for 
each subgroup defined by the tertiles of the baseline BAD score: ≤13, 13-24, >24.  The results 
are summarized in Suppl. Table 1b below. The analysis reveals that the treatment effect as 
measured by the marginal mean difference between DFP and placebo was observed for each 
subgroup, indicating benefit of deferiprone over placebo regardless of the baseline BAD 
level, and, numerically, the largest observed difference is in those with no potential for a 
ceiling effect. Weaker levels of significance are attributed to smaller numbers of subjects in 
each group, compared to the full cohort. 
 
 
 
 
 
 
 
Suppl. Table 1b: Main MMRM analysis by subgroups based on the tertiles of baseline BAD 
Subpopulation 
Placebo DFP 
DFP-Placebo 
Marginal Mean 
Difference 
(95% CI) 
P-value 
n 
Marginal 
Mean 
Change 
(SE) 
n 
Marginal 
Mean 
Change 
(SE) 
All patients 28 3.99 (0.82) 58 2.48 (0.63) 
-1.51 
 (-3.19, 0.16) 
0.0761 
Baseline BAD:  ≤ 13 12 7.65 (1.57) 17 6.06 (1.45) 
-1.59 
(-5.46, 2.27) 
0.4025 
Baseline BAD:  13-24 10 3.60 (1.29) 21 2.32 (1.02) 
-1.27 
(-3.65, 1.10) 
0.2780 
Baseline BAD:  > 24  6 1.55 (0.76) 20 0.77 (0.45) 
-0.78 
(-2.42, 0.87) 
0.3359 
 
  
Over the 18 months of the extension study, there was no significant difference in the change 
in BAD score for patients who had been on DFP from the start (1.9±0.5 points in the first 18 
months vs 1.4±0.4 points in the second 18 months, p=0.2684) while there was significantly 
less worsening in the placebo-DFP group (4.4±1.1 points when they were receiving placebo 
vs 1.4±0.9 points when they were receiving DFP, p=0.0206) (Suppl. Table 2). Placebo-DFP 
group represents the patients who received placebo during the first 18 months and deferiprone 
during the subsequent 18 months. DFP-DFP group represent the patients who received 
deferiprone during the 36 months of both trials. Classical PKAN are patients with age at onset 
of disease < 6 years. Atypical PKAN are patients with age at onset of disease ≥ 6 years. 
Suppl. Table 2. Changes in BAD score in the TIRCON and TIRCON-Extension studies 
 Placebo-DFP Group 
Age at onset of symptoms N 
TIRCON study T-EXT study TIRCON  
vs. T-EXT 
 p-value§ 
Baseline Score 
Mean (SD) 
Change from 
Baseline 
Baseline Score 
Mean (SD) 
Change from 
Baseline 
Overall 19 15.9 (8.0) 4.4 (4.8) 20.4 (8.1) 1.4 (3.7) 0.0206 
< 6 years 
(classic PKAN) 
8 18.0 (9.3) 5.3 (6.1) 23.3 (6.8) 4.3 (3.8) 0.6614 
≥6 years  
(atypical PKAN) 
 
11 14.5 (6.9) 3.8 (3.9) 18.3 (8.7) -0.6 (1.9) 0.0037 
 DFP-DFP Group 
Age at onset of symptoms N 
TIRCON study T-EXT study TIRCON  
vs. T-EXT 
 p-value§ 
Baseline Score 
Mean (SD) 
Change from 
Baseline 
Baseline Score 
Mean (SD) 
Change from 
Baseline 
Overall 43 19.3 (8.1) 1.9 (3.2) 21.3 (7.6) 1.4 (2.4) 0.2684 
< 6 years 
(classic PKAN) 
20 20.9 (7.9) 2.3 (4.2) 23.2 (7.2) 2.0 (3.0) 0.6973 
≥6 years  
(atypical PKAN) 
 
23 18.0 (8.3) 1.6 (1.9) 19.7 (7.8) 0.9 (1.7) 0.1514 
§ 
P-value from paired t-test 
 
  
Correlation between the BAD scale and the PGI-I 
The change of PGI-I at completion of 18 months of study therapy was included as a co-
primary endpoint based on a request by a regulatory agency.  
At Month 18, the LSmean scores were 4.66 for placebo and 4.55 for DFP, with no significant 
group difference (p=0.7279) indicating that, overall, patients did not detect either an 
improvement or a worsening in their condition from baseline.   
To the best of our knowledge, the PGI-I had not been previously used in a prospective study 
in patients with NBIA and no data are currently available on its value for identifying the 
clinical significance of other study measures. To that extent, the TIRCON study provides 
valuable data for the determination,  if a correlation existed between a measurement of disease 
progression such as the BAD score and the PGI-I.  
Suppl. Figure 1 shows the correlation between the PGI-I and the change in BAD score at 
Month-18.  The analysis reveals a weak correlation (r = 0.29), in which < 10% of the PGI-I 
variation can be explained by the change in BAD (r square < 0.1), indicating the PGI-I is not 
an adequate tool for assessment in PKAN over an 18 month period. 
 
Suppl. Figure 1. Correlation between change from baseline in BAD score and PGI-I score at Month 18. 
 
 
 
  
Wee FIM 
The WeeFIM, which rates 18 activities of daily living in terms of how much assistance is 
needed, scores each item from 1 (total dependence) to 7 (complete independence), and 
generates a global score that ranges from 18 to 126.  Thus, a decrease in score indicates 
worsening. The global score for the placebo group worsened by 2.40 points while that for the 
DFP group improved by 4.91 points, although the difference was not significant (p=0.2026). 
For the subscale scores, a significant difference in favor of DFP (p=0.0324) was seen for 
cognition.  Treatment group differences in the domain of cognition reached significance in 
favor of DFP for problem solving (p=0.0258) and social interaction (p=0.0414), and 
approached significance for memory (p=0.0574). Suppl. Figure 2 displays a polar graph for 
each treatment group of all the elements contributing to the global WeeFIM score. For the 
placebo group, there was either worsening or lack of improvement in all measures; for the 
DFP group, improvement was seen for 4 of the 5 cognitive components (comprehension, 
social interaction, problem solving, and memory) and no change on the fifth (expression) but 
worsening or lack of improvement for the items in the self-care and mobility domains. 
 
  
  
 
 
 
 
Suppl. Figure 2.   Polar graph of WeeFIM scores. The blue lines represent scores at baseline, and the red lines 
represent scores at Month 18.  Values that are closer to the center indicate lower functioning, so a red line that is 
inside the blue line indicates worsening, a red line that overlaps the blue line indicates no change, and a red line 
that is outside the blue line indicates improvement. 
 
 
 
  
SAFETY 
Regarding safety, DFP was well tolerated and rates of adverse events were similar between 
the treatment groups except for anemia, which was seen more frequent in DFP-treated 
patients than in placebo patients. An overview of the different categories of safety findings 
during the randomized phase of the studies is shown in Suppl. Table 3.  
 
Suppl. Table 3.  
Overview of the different categories of safety findings during the randomized phase of the studies 
Number of patients with at least one: 
Placebo 
(N=30) 
% (n) 
DFP 
(N=58) 
% (n) 
P-value 
(Fisher's exact test) 
Adverse event 100.0 (30) 98.3 (57) 1.0000 
Serious adverse event  33.3 (10) 31.0 (18) 0.8146 
Severe adverse event 26.7 (8) 29.3 (17) 1.0000 
Adverse event related to study treatment 43.3 (13) 79.3 (46) 0.0015 
Death 0.0 (0) 0.0 (0) NA 
Adverse event leading to withdrawal 0.0 (0) 6.9 (4) 0.2947 
 
  
List of author names and affiliations 
First, 
middle 
names or 
initials 
surnames affiliations 
Thomas Klopstock Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-
University of Munich, Munich, Germany 
German Center for Neurodegenerative Diseases (DZNE), Munich, 
Germany  
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany 
Fernando Tricta ApoPharma Inc, Toronto, Ontario, Canada 
Lynne Neumayr Department of Hematology/Oncology, UCSF Benioff Children’s Hospital 
and Research Center Oakland, Oakland, California, USA 
Ivan Karin Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-
University of Munich, Munich, Germany 
Giovanna Zorzi Department of Pediatric Neuroscience, Neurological Institute Carlo Besta, 
Milan, Italy 
Caroline Fradette ApoPharma Inc, Toronto, Ontario, Canada 
Tomasz Kmieć Department of Neurology and Epileptology, Children’s Memorial Health 
Institute, Warsaw, Poland 
Boriana Büchner Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-
University of Munich, Munich, Germany 
Hannah E Steele Institute of Genetic Medicine, Newcastle University, Newcastle Upon 
Tyne, UK 
Rita Horvath Institute of Genetic Medicine, Newcastle University, Newcastle Upon 
Tyne, UK 
Department of Clinical Neurosciences, Cambridge University, 
Cambridge, UK 
Patrick F Chinnery Department of Clinical Neurosciences, Cambridge University, 
Cambridge, UK 
Anna Basu Institute of Neuroscience, Newcastle University. Newcastle Upon Tyne, 
UK 
Clemens Küpper Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-
University of Munich, Munich, Germany 
Christiane Neuhofer Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-
University of Munich, Munich, Germany 
Bernadette Kálmán Institute of Laboratory Medicine, Szentagothai Research Center, 
University of Pécs, Pécs, Hungary 
Petr Dušek Charles University, Prague, Czechia 
Zuhal Yapici Department of Child Neurology, Istanbul Faculty of Medicine, Turkey 
Ian Wilson Institute of Cellular Medicine & Newcastle Magnetic Resonance Centre, 
Newcastle University, Newcastle Upon Tyne, UK 
Feng Zhao ApoPharma Inc, Toronto, Ontario, Canada 
Federica Zibordi Department of Pediatric Neuroscience, Neurological Institute Carlo Besta, 
Milan, Italy 
Nardo Nardocci Department of Pediatric Neuroscience, Neurological Institute Carlo Besta, 
Milan, Italy 
Christine Aguilar Pediatric Rehabilitation Department, UCSF Benioff Children’s Hospital 
and Research Center Oakland 
Susan J Hayflick Department of Molecular & Medical Genetics, Oregon Health & Science 
University, Portland, Oregon, USA 
Michael Spino ApoPharma Inc, Toronto, Ontario, Canada 
Andrew M Blamire Institute of Cellular Medicine & Newcastle Magnetic Resonance Centre, 
Newcastle University, Newcastle Upon Tyne, UK 
Penelope Hogarth Department of Molecular & Medical Genetics, Oregon Health & Science 
University, Portland, Oregon, USA 
Elliott Vichinsky Department of Hematology/Oncology, UCSF Benioff Children’s Hospital 
and Research Center Oakland, Oakland, California, USA 
 
 
Supplement 
Methods 
Study design 
TIRCON2012V1 was conducted at 4 treatment centers located in Germany, Italy, the United 
Kingdom and United States, and was approved by the respective Ethics Committees (Ludwig 
Maximilians University, Munich; Istituto Neurologico Carlo Besta, Milan; Yorkshire & The 
Humber, Leeds East Research; and Children’s Hospital & Research Center Oakland). The 
sites and Ethics Committees were the same for the single-arm extension study, 
TIRCON2012V1-EXT. An independent Data and Safety Monitoring Board regularly 
reviewed the safety data of both trials, and each study was registered on ClinicalTrials.gov 
prior to enrollment of the first patient (trial registration numbers NCT01741532 and 
NCT02174848, respectively). 
 
Patients 
Recruitment was via the centers’ own patients, referral from other neurologists and by posting 
information on the NBIA Disorders Association website.  
 
Full list of inclusion and exclusion criteria: 
Inclusion Criteria 
1. Males or females 4 years of age and older at screening visit 
2. Have PKAN, confirmed by genetic testing  
3. BAD total score ≥ 3 at the screening visit 
4. Patients who have Deep Brain Stimulation (DBS) systems or baclofen pumps in place will 
be eligible for the study, but they must have had a stable setting for at least two months 
prior to the screening visit; Enrollment of non-DBS patients will be given priority in order 
to ensure the majority can undergo imaging 
5. Informed consent/assent obtained before any study-related activities 
6. Ability and willingness to adhere to the protocol including appointments and evaluation 
schedule 
7. Sexually active female patients of childbearing potential must have a negative pregnancy 
test result at Screening Visit. In addition, if applicable, females of childbearing potential 
must use an effective method of contraception according to local requirements, OR have 
had a tubal ligation, OR have had a hysterectomy, OR participates in a non-heterosexual 
lifestyle, OR have a male sexual partner has been sterilized 
8. If the patient is a heterosexual sexually-active male, patient must confirm, in writing, that 
he and/or his female partner will use an effective method of contraception according to 
local requirements for the length of the trial and for 30 days following completion of the 
study or early termination  
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Exclusion Criteria 
1. Evidence of iron deficiency defined by Fe:TIBC ratio <15%, or serum ferritin <12 ng/mL 
2. Treatment with deferiprone in the past 12 months 
3. Previous failure of treatment with deferiprone, or previous discontinuation of treatment 
with deferiprone due to adverse events 
4. Conditions known to contraindicate the use of deferiprone (history of agranulocytosis or 
recurrent episodes of neutropenia) 
5. A serious, unstable illness during the past 3 months before screening visit including but 
not limited to: hepatic, renal, gastro-enterologic, respiratory, cardiovascular, 
endocrinologic, neurologic or immunologic disease 
6. Evidence of abnormal liver or renal function (serum liver enzyme level(s) > 3 times upper 
limit of normal at screening) or abnormal creatinine levels at screening visit 
7. Disorders associated with neutropenia (ANC < 1.5 x 109/L) or thrombocytopenia (platelet 
count < 50 x 109/L) in the 12 months preceding the initiation of the study medication. 
Exception: for patients whose neutropenia was attributed by the treating physician to 
episodes of infection or to drugs associated with a decline in the neutrophil count and in 
whom the ANC has fully recovered at the screening visit 
8. History of malignancy 
9. QTcF interval > 450 msec 
10. HIV positive 
11. Myocardial infarction, cardiac arrest or cardiac failure within 1 year before screening visit 
12. Bowel disease causing malabsorption 
13. History of alcohol or drug abuse 
14. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is 
longer) preceding the baseline visit 
15. Currently taking iron chelators 
16. Pregnant, nursing females and females of childbearing potential who are heterosexually 
active and unwilling, or unable, to use an acceptable method of contraception according to 
local requirements 
17. Males who are sexually active and unwilling, or unable, to use an acceptable method of 
contraception according to local requirements 
18. History or presence of hypersensitivity or idiosyncratic reaction to deferiprone 
19. Patients (or when applicable parent or patients’ legal representatives) with a mental 
incapacity, unwillingness or language barriers precluding adequate understanding or co-
operation 
20. Any condition that, in investigator’s opinion, would adversely affect the patient’s ability 
to complete the study or its assessments 
21. Baclofen pump placement less than two months prior to the screening visit 
22. Current and ongoing participation in other clinical studies 
 
 
  
Procedures 
In both trials, dosage was based on milligrams of DFP per kilogram of body weight, starting 
at 5 mg/kg b.i.d. and titrated up to 15 mg/kg b.i.d. by Week 12.  In TIRCON2012V1, patients 
in the control group received a matching volume of placebo during the same time periods.   
All efficacy measures were administered at baseline (except for the PGI-I, which is a measure 
of change from baseline), months 6, 12, and 18 or early termination.  Iron levels in the globus 
pallidus were measured by MRI-R2* in a subset of patients (those without a DBS device and 
able to undergo an MRI scan) at baseline and Month 18.  MRI scans were conducted 
according to a standardized imaging protocol, and the images were sent to central reading by 
radiologists who were blinded to treatment. None of the MRI-R2* results were disclosed by 
the radiologist until the last patient completed the trial. 
Information was also collected on the use of concomitant medications, with particular 
attention on any changes in drugs or devices used to relieve symptoms of dystonia. Patients 
had weekly hematology tests to monitor their absolute neutrophil count (ANC). Patients with 
two consecutive samples with ANC < 1.5×10
9
/L were withdrawn from the study. 
To reduce the confounding effects of concomitant therapies on the assessment of treatment, 
patients with recent or expected changes in therapies that have the potential to affect dystonia 
symptoms were excluded from enrolment.  
 
Role of the funding source 
Funding for the study was provided by the European Commission, the US FDA, and 
ApoPharma Inc., Canada.  The US FDA had input into the design and selection of endpoints. 
The sponsor, ApoPharma, participated in study design, data collection, data analysis, data 
interpretation, and writing of the report. The corresponding author had full access to all data 
in the study and had final responsibility for the decision to submit for publication.  
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Results 
 
There were proportionally more patients with baseline BAD score close to the maximum 
score of 32 being randomized to the deferiprone treatment group. To investigate whether a 
“ceiling effect” might account for the differences observed in BAD in response to treatment 
with deferiprone, the mITT data were re-analyzed after excluding all patients that would 
have had the potential to experience a ceiling effect. Using the cut-off of 27 for the baseline 
BAD score, it is evident that the difference in response to treatment is not lessened by the 
dropping of patients with a cut-off of 27, even though, as would be expected, fewer subjects 
lessens the level of statistical significance, as shown in Suppl. Table 1a.  
 
Suppl. Table 1a: Main MMRM analysis excluding baseline BAD > 27 in the TIRCON study 
Subpopulation 
Placebo DFP 
DFP-Placebo 
Marginal 
Mean 
Difference 
(95% CI) 
P-value 
N 
Marginal 
Mean 
Change (SE) 
n 
Marginal 
Mean 
Change 
(SE) 
All patients 28 3.99 (0.82) 58 2.48 (0.63) 
-1.51 
 (-3.19, 0.16) 
0.0761 
Baseline BAD <=27  26 4.62 (0.96) 42 3.07 (0.81) 
-1.55 
(-3.47, 0.37) 
0.1114 
 
 
 
To further investigate the impact of ceiling effect, a reanalysis of the data was conducted 
using 3 different strata of baseline values. To avoid the risk of bias in selection of what might 
constitute suitable cut-off points, we let the data select the points by choosing tertiles of 
baseline BAD.  The MMRM modelling performed for the primary analysis was repeated for 
each subgroup defined by the tertiles of the baseline BAD score: ≤13, 13-24, >24.  The results 
are summarized in Suppl. Table 1b below. The analysis reveals that the treatment effect as 
measured by the marginal mean difference between DFP and placebo was observed for each 
subgroup, indicating benefit of deferiprone over placebo regardless of the baseline BAD 
level, and, numerically, the largest observed difference is in those with no potential for a 
ceiling effect. Weaker levels of significance are attributed to smaller numbers of subjects in 
each group, compared to the full cohort. 
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Suppl. Table 1b: Main MMRM analysis by subgroups based on the tertiles of baseline BAD 
Subpopulation 
Placebo DFP 
DFP-Placebo 
Marginal Mean 
Difference 
(95% CI) 
P-value 
n 
Marginal 
Mean 
Change 
(SE) 
n 
Marginal 
Mean 
Change 
(SE) 
All patients 28 3.99 (0.82) 58 2.48 (0.63) 
-1.51 
 (-3.19, 0.16) 
0.0761 
Baseline BAD:  ≤ 13 12 7.65 (1.57) 17 6.06 (1.45) 
-1.59 
(-5.46, 2.27) 
0.4025 
Baseline BAD:  13-24 10 3.60 (1.29) 21 2.32 (1.02) 
-1.27 
(-3.65, 1.10) 
0.2780 
Baseline BAD:  > 24  6 1.55 (0.76) 20 0.77 (0.45) 
-0.78 
(-2.42, 0.87) 
0.3359 
 
 
 
 
 
To investigate whether the inclusion of patients with a baseline BAD score close to or at the 
maximum score of 32 (ceiling effects) impacted on the results of the BAD score analysis, we 
performed an unscheduled sensitivity analysis by removing patients from the analysis who  
(i) had already achieved the maximum BAD score of 32 at baseline, or 
(ii) had already achieved a maximum BAD score of >=30 at baseline 
 
As shown in Suppl. Table 1 below, results did not change significantly by removing these 
patients.  
 
 
Suppl. Table 1.  
BAD score analysis based on inclusion or exclusion of patients with high BAD scores at baseline 
Population 
Placebo DFP DFP-Placebo 
Mean Difference 
(95% CI) 
P-value 
n 
Marginal Mean 
Change (SE) 
n 
Marginal Mean 
Change (SE) 
All patients 28 3.99 (0.82) 58 2.48 (0.63) -1.51 (-3.19, 0.16) 0.0761 
Removing max BAD=32 at Month 18 28 4.04 (0.83) 56 2.51 (0.64) -1.52 (-3.23, 0.18) 0.0793 
Removing max BAD >=30 at baseline 27 4.30 (0.91) 50 2.77 (0.73) -1.53 (-3.33, 0.27) 0.0942 
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Comment [KTPD3]: Replaced by 
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Over the 18 months of the extension study, there was no significant difference in the change 
in BAD score for patients who had been on DFP from the start (1.9±0.5 points in the first 18 
months vs 1.4±0.4 points in the second 18 months, p=0.2684) while there was significantly 
less worsening in the placebo-DFP group (4.4±1.1 points when they were receiving placebo 
vs 1.4±0.9 points when they were receiving DFP, p=0.0206) (Suppl. Table 2). Placebo-DFP 
group represents the patients who received placebo during the first 18 months and deferiprone 
during the subsequent 18 months. DFP-DFP group represent the patients who received 
deferiprone during the 36 months of both trials. Classical PKAN are patients with age at onset 
of disease < 6 years. Atypical PKAN are patients with age at onset of disease ≥ 6 years. 
 
Suppl. Table 2. Changes in BAD score in the TIRCON and TIRCON-Extension studies 
 Placebo-DFP Group 
Age at onset of symptoms N 
TIRCON study T-EXT study TIRCON  
vs. T-EXT 
 p-value§ 
Baseline Score 
Mean (SD) 
Change from 
Baseline 
Baseline Score 
Mean (SD) 
Change from 
Baseline 
Overall 19 15.9 (8.0) 4.4 (4.8) 20.4 (8.1) 1.4 (3.7) 0.0206 
< 6 years 
(classic PKAN) 
8 18.0 (9.3) 5.3 (6.1) 23.3 (6.8) 4.3 (3.8) 0.6614 
≥6 years  
(atypical PKAN) 
 
11 14.5 (6.9) 3.8 (3.9) 18.3 (8.7) -0.6 (1.9) 0.0037 
 DFP-DFP Group 
Age at onset of symptoms N 
TIRCON study T-EXT study TIRCON  
vs. T-EXT 
 p-value§ 
Baseline Score 
Mean (SD) 
Change from 
Baseline 
Baseline Score 
Mean (SD) 
Change from 
Baseline 
Overall 43 19.3 (8.1) 1.9 (3.2) 21.3 (7.6) 1.4 (2.4) 0.2684 
< 6 years 
(classic PKAN) 
20 20.9 (7.9) 2.3 (4.2) 23.2 (7.2) 2.0 (3.0) 0.6973 
≥6 years  
(atypical PKAN) 
 
23 18.0 (8.3) 1.6 (1.9) 19.7 (7.8) 0.9 (1.7) 0.1514 
§ 
P-value from paired t-test 
 
  
Suppl. Table 3 provides the results of the randomized study, not using the marginal means 
from the MMRM model for the assessment of treatment difference in mean change of BAD 
score.   
 
Suppl. Table 3.  
Observed change in BAD total score at Month 18 by age at onset of symptoms - mITT population 
Subpopulation 
Placebo DFP P-value 
(T test) n Mean (SD) n Mean (SD) 
All patients 27 3.9 (4.3) 49 2.1 (3.5) 0.0578 
Age at onset of disease:  < 6  12 4.8 (5.0) 23 2.6 (4.7) 0.2195 
Age at onset of disease:  ≥ 6  15 3.1 (3.6) 26 1.7 (1.9) 0.1537 
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Correlation between the BAD scale and the PGI-I 
The change of PGI-I at completion of 18 months of study therapy was included as a co-
primary endpoint based on a request by a regulatory agency.  
At Month 18, the LSmean scores were 4.66 for placebo and 4.55 for DFP, with no significant 
group difference (p=0.7279) indicating that, overall, patients did not detect either an 
improvement or a worsening in their condition from baseline.   
To the best of our knowledge, the PGI-I had not been previously used in a prospective study 
in patients with NBIA and no data are currently available on its value for identifying the 
clinical significance of other study measures. To that extent, the TIRCON study provides 
valuable data for the determination,  if a correlation existed between a measurement of disease 
progression such as the BAD score and the PGI-I.  
Suppl. Figure 21 shows the correlation between the PGI-I and the change in BAD score at 
Month-18.  The analysis reveals a weak correlation (r = 0.29), in which < 10% of the PGI-I 
variation can be explained by the change in BAD (r square < 0.1), indicating the PGI-I is not 
an adequate tool for assessment in PKAN over an 18 month period. 
 
Suppl. Figure 21. Correlation between change from baseline in BAD score and PGI-I score at Month 18. 
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Wee FIM 
The WeeFIM, which rates 18 activities of daily living in terms of how much assistance is 
needed, scores each item from 1 (total dependence) to 7 (complete independence), and 
generates a global score that ranges from 18 to 126.  Thus, a decrease in score indicates 
worsening. The global score for the placebo group worsened by 2.40 points while that for the 
DFP group improved by 4.91 points, although the difference was not significant (p=0.2026). 
For the subscale scores, a significant difference in favor of DFP (p=0.0324) was seen for 
cognition.  Treatment group differences in the domain of cognition reached significance in 
favor of DFP for problem solving (p=0.0258) and social interaction (p=0.0414), and 
approached significance for memory (p=0.0574). Suppl. Figure 1 2 displays a polar graph for 
each treatment group of all the elements contributing to the global WeeFIM score. For the 
placebo group, there was either worsening or lack of improvement in all measures; for the 
DFP group, improvement was seen for 4 of the 5 cognitive components (comprehension, 
social interaction, problem solving, and memory) and no change on the fifth (expression) but 
worsening or lack of improvement for the items in the self-care and mobility domains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Suppl. Figure 12.   Polar graph of WeeFIM scores. The blue lines represent scores at baseline, and the red lines 
represent scores at Month 18.  Values that are closer to the center indicate lower functioning, so a red line that is 
inside the blue line indicates worsening, a red line that overlaps the blue line indicates no change, and a red line 
that is outside the blue line indicates improvement. 
 
 
 
  
Correlation between the BAD scale and the PGI-I 
The change of PGI-I at completion of 18 months of study therapy was included as a co-
primary endpoint based on a request by a regulatory agency.  
At Month 18, the LSmean scores were 4.66 for placebo and 4.55 for DFP, with no significant 
group difference (p=0.7279) indicating that, overall, patients did not detect either an 
improvement or a worsening in their condition from baseline.   
To the best of our knowledge, the PGI-I had not been previously used in a prospective study 
in patients with NBIA and no data are currently available on its value for identifying the 
clinical significance of other study measures. To that extent, the TIRCON study provides 
valuable data for the determination,  if a correlation existed between a measurement of disease 
progression such as the BAD score and the PGI-I.  
Suppl. Figure 2 shows the correlation between the PGI-I and the change in BAD score at 
Month-18.  The analysis reveals a weak correlation (r = 0.29), in which < 10% of the PGI-I 
variation can be explained by the change in BAD (r square < 0.1), indicating the PGI-I is not 
an adequate tool for assessment in PKAN over an 18 month period. 
 
Suppl. Figure 2. Correlation between change from baseline in BAD score and PGI-I score at Month 18. 
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SAFETY 
Regarding safety, DFP was well tolerated and rates of adverse events were similar between 
the treatment groups except for anemia, which was seen more frequent in DFP-treated 
patients than in placebo patients. An overview of the different categories of safety findings 
during the randomized phase of the studies is shown in Suppl. Table 3. 4, and a listing of 
individual AEs seen in >10% of patients in Suppl. Table 5.   
 
Suppl. Table 3.4.  
Overview of the different categories of safety findings during the randomized phase of the studies 
Number of patients with at least one: 
Placebo 
(N=30) 
% (n) 
DFP 
(N=58) 
% (n) 
P-value 
(Fisher's exact test) 
Adverse event 100.0 (30) 98.3 (57) 1.0000 
Serious adverse event  33.3 (10) 31.0 (18) 0.8146 
Severe adverse event 26.7 (8) 29.3 (17) 1.0000 
Adverse event related to study treatment 43.3 (13) 79.3 (46) 0.0015 
Death 0.0 (0) 0.0 (0) NA 
Adverse event leading to withdrawal 0.0 (0) 6.9 (4) 0.2947 
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manuscript. 
  
Suppl. Table 5. Summary of adverse events seen in ≥10% of patients – Safety population 
Adverse Event 
Placebo (N=30) 
% (n) 
DFP (N=58) 
% (n) 
P-value 
(Fisher's exact test) 
Dystonia  46.7 (14)  43.1 (25) 0.8225 
Pyrexia  43.3 (13)  27.6 (16) 0.1567 
Serum ferritin decreased 16.7   (5)  32.8 (19) 0.1341 
Headache 30.0   (9)  22.4 (13) 0.4478 
Nasopharyngitis  20.0   (6)  19.0 (11) 1.0000 
Anaemia 0.0   (0)   20.7 (12) 0.0067 
Condition aggravated 30.0   (9)  17.2 (10) 0.1827 
Neutrophil count decreased 10.0   (3)  17.2 (10) 0.5294 
Pain in extremity 13.3   (4)  17.2 (10) 0.7641 
Cough 16.7   (5)  17.2 (10) 1.0000 
Vomiting  26.7   (8)  15.5   (9) 0.2580 
Iron deficiency 10.0   (3) 15.5   (9) 0.7442 
Oropharyngeal pain 10.0   (3) 15.5   (9) 0.7442 
Upper respiratory tract infection 13.3   (4)  13.8   (8) 1.0000 
Arthralgia 3.3   (1) 13.8   (8) 0.1579 
Bronchitis  6.7   (2)   12.1   (7) 0.7124 
Laceration 10.0   (3)  10.3   (6) 1.0000 
Ear pain 10.0   (3)  1.7   (1) 0.1127 
Abdominal pain upper 16.7   (5)  6.9   (4) 0.2637 
Constipation 13.3   (4)  3.4   (2) 0.1746 
Diarrhoea  10.0   (3)  6.9   (4) 0.6860 
Gastrointestinal infection 10.0   (3)  5.2   (3) 0.4058 
Freezing phenomenon  10.0   (3)  0.0   (0) 0.0370 
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Research in context 
 
Evidence before this study 
While designing this trial and during its conduct and analysis, we undertook several 
systematic reviews of the literature between January 2010 and February 2019. We 
searched PubMed using the search term (“Pantothenate Kinase-Associated 
Neurodegeneration” OR “PKAN” OR “Neurodegeneration with brain iron 
accumulation” OR “NBIA”) AND (“deferiprone” OR “iron chelation” OR “iron chelator” 
OR “Iron Chelating Agents”). Of 33 publications, 4 reported original data on the use 
of deferiprone (DFP) in more than one PKAN patient. An open-label pilot trial in 10 
patients showed significant reduction of globus pallidus iron content but no clinical 
improvement after 6 months of treatment. Another small open-label trial including 4 
PKAN patients showed significant reduction of globus pallidus iron in 3 of 3 patients, 
as well as mild-to-moderate motor improvement in 2 of the 4 patients after 12 months 
of treatment. A follow-up study of these 4 PKAN patients showed a relatively stable 
course over a total period of 48 months. In another small open-label trial, DFP 
treatment for 18 months led to a reduction of iron load in globus pallidus in all, and 
some clinical improvement in 4 of 5 PKAN patients. Taken together, there has been 
some low-quality evidence from case reports and small uncontrolled pilot trials that 
DFP may be beneficial in PKAN.  
 
Added value of this study 
This study is the first randomized controlled trial of DFP in PKAN, and actually the 
first randomized trial of any treatment in any form of NBIA. While all previous reports 
together (single cases and pilot trials) had involved 23 PKAN patients, this study 
randomized 88 PKAN patients, showing the feasibility of randomized trials even in 
ultraorphan diseases like PKAN with an estimated prevalence of 1 in 1 million. 
Moreover, this study had a duration of 18 months in its randomized part plus an 
open-label extension of another 18 months, finally providing safety and efficacy data 
for 36 months of DFP treatment. As a result, the combined analysis of the 
randomized trial and the extension study shows excellent safety and tolerability of 
DFP in PKAN over 36 month, and strong evidence that DFP leads to a marked 
reduction in brain iron. Regarding the primary endpoint on the change in Barry-
Albright dystonia scale), there was only weak evidence to show potential slowing of 
disease progression in DFP-treated as compared to placebo-treated patients. The 
difference seemed to be greater in a predefined subgroup of patients with atypical 
PKAN. The rate of progression seemed to slow down in patients who switched from 
placebo to DFP in the extension trial. There was no evidence of change in the co-
primary endpoint, Patient Global Impression of Improvement (PGI-I). 
 
Implications of all the available evidence 
This study, together with previous findings, shows that iron chelation with deferiprone 
achieves target engagement (lowering of iron in the basal ganglia) in PKAN. While 
the clinical endpoints were not met for the modified Intent-to-Treat population in the 
randomized trial, subgroup analysis and the results of the extension trial indicate 
some slowing of disease progression by deferiprone. This study will help shape the 
design of future trials in this ultraorphan disease. 
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Research in context 
 
Evidence before this study 
While designing this trial and during its conduct and analysis, we undertook several 
systematic reviews of the literature between January 2010 and February 2019. We 
searched PubMed using the search term (“Pantothenate Kinase-Associated 
Neurodegeneration” OR “PKAN” OR “Neurodegeneration with brain iron 
accumulation” OR “NBIA”) AND (“deferiprone” OR “iron chelation” OR “iron chelator” 
OR “Iron Chelating Agents”). Of 33 publications, 4 reported original data on the use 
of deferiprone (DFP) in more than one PKAN patient. An open-label pilot trial in 10 
patients showed significant reduction of globus pallidus iron content but no clinical 
improvement after 6 months of treatment. Another small open-label trial including 4 
PKAN patients showed significant reduction of globus pallidus iron in 3 of 3 patients, 
as well as mild-to-moderate motor improvement in 2 of the 4 patients after 12 months 
of treatment. A follow-up study of these 4 PKAN patients showed a relatively stable 
course over a total period of 48 months. In another small open-label trial, DFP 
treatment for 18 months led to a reduction of iron load in globus pallidus in all, and 
some clinical improvement in 4 of 5 PKAN patients. Taken together, there has been 
some low-quality evidence from case reports and small uncontrolled pilot trials that 
DFP may be beneficial in PKAN.  
 
Added value of this study 
This study is the first randomized controlled trial of DFP in PKAN, and actually the 
first randomized trial of any treatment in any form of NBIA. While all previous reports 
together (single cases and pilot trials) had involved 23 PKAN patients, this study 
randomized 88 PKAN patients, showing the feasibility of randomized trials even in 
ultraorphan diseases like PKAN with an estimated prevalence of 1 in 1 million. 
Moreover, this study had a duration of 18 months in its randomized part plus an 
open-label extension of another 18 months, finally providing safety and efficacy data 
for 36 months of DFP treatment. As a result, the combined analysis of the 
randomized trial and the extension study shows excellent safety and tolerability of 
DFP in PKAN over 36 month, and unequivocal strong evidence that DFP leads to a 
marked reduction in brain iron. Regarding the primary endpoint on the change in 
Barry-Albright dystonia scale), there was only weak evidence to show potential some 
slowing of disease progression in DFP-treated as compared to placebo-treated 
patients. but the difference only reached the protocol-defined criterion for statistical 
significance for theThe difference seemed to be greater in a predefined subgroup of 
patients with atypical PKAN, not for the whole Intent-to-Treat population. Moreover, 
tThe rate of progression seemed to slowed down significantly in patients who 
switched from placebo to DFP in the extension trial. There were no significantwas no 
evidence of changes at all in the co-primary endpoint, Patient Global Impression of 
Improvement (PGI-I). 
 
Implications of all the available evidence 
This study, together with previous findings, shows that iron chelation with deferiprone 
achieves target engagement (lowering of iron in the basal ganglia) in PKAN. While 
the clinical endpoints were not met for the modified Intent-to-Treat population in the 
randomized trial, subgroup analysis and the results of the extension trial indicate 
some slowing of disease progression by deferiprone. This study will help shape the 
design of future trials in this ultraorphan disease. 
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  Randomized Study 
 
Extension Study 
  Placebo Deferiprone 
Placebo-
Deferiprone 
Deferiprone-
Deferiprone 
Age at 
enrollment 
(years) 
N 30 59 19 43 
Mean ± SD 
19.2 ± 
12.5 
20.8 ± 10.7 18.2 ± 10.0 22.7 ± 9.6 
Min - Max 5 - 55 4 - 52 6 - 40 6 - 47 
 
Age at onset 
(years) 
Mean ± SD 7.5 ±   6.2 8.4 ±   7.2 
 
8.0 ±   6.4 8.2 ±   6.2 
Min - Max 1 - 23 1 - 29 1 - 23 1 - 19 
 
Sex 
Female N (%) 17 (56.7) 25 (42.4) 
 
11 (57.9) 16 (37.2) 
Male N (%) 13 (43.3) 34 (57.6) 8 (42.1) 27 (62.8) 
 
Racial Origin 
Asian N (%) 1 (3.3) 6 (10.2) 
 
0 (0.0) 3 (7.0) 
Black N (%) 0 (0.0) 2 (3.4) 0 (0.0) 0 (0.0) 
Unknown N(%) 1 (3.3) 0 (0.0) 1 (5.3) 0 (0.0) 
White N (%) 28 (93.3) 51 (86.4) 18 (94.7) 40 (93.0) 
 
 Basal 
ganglia MRI 
R2* (Hz) 
N 16 24 
 Not Applicable 
Mean ± SD 
93.5 ± 
31.2 
96.6 ± 31.6 
Min, Max 
35.7, 
167.8 
34.0, 152.5 
 
BAD total 
score 
N 28 58 
 
19 43 
Mean ± SD 
16.5 ± 
8.1 
19.6 ± 8.4 20.4 ± 8.1 21.3 ± 7.6 
Min - Max 2 - 31 1 - 32 3 - 30 3 - 30 
Table 1. Patients’ demographics, basal ganglia iron loading as assessed by MRI R2* and Barry-Albright 
Dystonia (BAD) scale at baseline of the randomized and extension studies. All patients in the extension 
study received only deferiprone for up to 18 months and their data are grouped by the therapy they 
received during the 18 preceding months, i.e., deferiprone or placebo, while in the randomized study.  
 BAD scores at baseline of the randomized study are based on the modified intent-to-treat population, 
defined as all randomized patients who 1) received at least one dose of study drug, and 2) provided a 
baseline and at least one post-baseline efficacy assessment. BAD scores at the baseline of the extension 
study are based on that study’s intent-to-treat population, which has the same definition as the 
modified intent-to-treat population of the randomized study. BAD data obtained at the end of study 
(Month 18) visit of the randomized study was used as the baseline value of the extension study. 
 
Tables 1-3
 Randomized Study 
  
Marginal mean change in BAD score  
(95% CI) 
DFP-Placebo 
mean Difference 
(95% CI)* 
P-value 
All Patients 
Placebo N=28 
3.99  
(2.38, 5.60) 
-1.51 
 (-3.19, 0.16) 
0.0761 
Deferiprone N=58 
2.48  
(1.25, 3.71) 
 
Classical PKAN 
Placebo N=12 
3.72  
(1.19, 6.25) 
-0.81  
(-3.68, 2.06) 
0.5701 
Deferiprone N=29 
2.91 
 (1.09, 4.73) 
 
Atypical PKAN 
Placebo N=16 
4.52  
(2.74, 6.30) -2.19 
 (-4.00, -0.38) 
0.0187 
Deferiprone N=29 
2.33  
(0.90, 3.76) 
Table 2. Marginal mean change* and 95% CI in BAD score from baseline to end of study during deferiprone or placebo use up to 18 months in 
the randomized trial. Classical PKAN are patients with age at onset of disease < 6 years. Atypical PKAN are patients with age at onset of disease ≥ 
6 years. 
*
 Based on least squares estimate from the MMRM model 
 P-value from MMRM model 
 
 
 
 
Table 3. Summary of adverse events seen in ≥10% of patients – Safety population 
Adverse Event 
Placebo (N=30) 
% (n) 
DFP (N=58) 
% (n) 
P-value 
(Fisher's exact test) 
Dystonia 46.7 (14) 43.1 (25) 0.8225 
Pyrexia 43.3 (13) 27.6 (16) 0.1567 
Serum ferritin decreased 16.7 (5) 32.8 (19) 0.1341 
Headache 30.0 (9) 22.4 (13) 0.4478 
Nasopharyngitis 20.0 (6) 19.0 (11) 1.0000 
Anaemia 0.0 (0) 20.7 (12) 0.0067 
Condition aggravated 30.0 (9) 17.2 (10) 0.1827 
Neutrophil count decreased 10.0 (3) 17.2 (10) 0.5294 
Pain in extremity 13.3 (4) 17.2 (10) 0.7641 
Cough 16.7 (5) 17.2 (10) 1.0000 
Vomiting 26.7 (8) 15.5 (9) 0.2580 
Iron deficiency 10.0 (3) 15.5 (9) 0.7442 
Oropharyngeal pain 10.0 (3) 15.5 (9) 0.7442 
Upper respiratory tract infection 13.3 (4) 13.8 (8) 1.0000 
Arthralgia 3.3 (1) 13.8 (8) 0.1579 
Bronchitis 6.7 (2) 12.1 (7) 0.7124 
Laceration 10.0 (3) 10.3 (6) 1.0000 
Ear pain 10.0 (3) 1.7 (1) 0.1127 
Abdominal pain upper 16.7 (5) 6.9 (4) 0.2637 
Constipation 13.3 (4) 3.4 (2) 0.1746 
Diarrhoea 10.0 (3) 6.9 (4) 0.6860 
Gastrointestinal infection 10.0 (3) 5.2 (3) 0.4058 
Freezing phenomenon 10.0 (3) 0.0 (0) 0.0370 
 
Table 3. Summary of adverse events seen in ≥10% of patients. Rates are based on all randomized patients 
who received at least one dose of study drug. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Pa!ent flow diagram of the randomized study from !me of screening to !me of 
comple!on a#er 18 months on study therapy or early withdrawal.    
 
Assessed for eligibility (n=100) 
Excluded (n=11) 
Not mee!ng inclusion criteria (n=11) 
 
Analysed for safety (n= 58) 
Analyzed for efficacy (58)
 
Discon!nued interven!on.  Reasons: Adverse 
event (n=4), worsening of the disease (n=3), 
voluntary withdrawal (n=1), sponsor decision 
(n=1) 
Allocated to deferiprone (n=59) 
 
Received allocated interven!on (n=58)
 
 
Did not receive allocated interven!on (n=1; 
withdrawn before dosing began due to a 
medical event)
 
Discon!nued interven!on.  Reasons:  
Worsening of the disease (n=1), protocol 
viola!on (n=1), voluntary withdrawal (n=1) 
Allocated to placebo (n=30) 
 Received allocated interven!on (n=30)  
Analysed for safety (n=30) 
Analyzed for efficacy (n=28)  
Excluded from analysis. Reason: Withdrew 
before providing at least one post-baseline 
efficacy assessment (n=2) 
Alloca!on  
Analysis 
Follow -Up 
Randomized (n=89) 
Enrollment  
Figure 1
Click here to download Figure: Fig1.eps
  
 
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
5
5,5
812160
B
A
D
 T
o
ta
l 
S
co
re
  
M
e
a
n
 C
h
a
n
g
e
 f
ro
m
 B
a
se
li
n
e
 
Month
p = 0.0941 p = 0.1592 p = 0.0761
Placebo
Deferiprone
2.a. All PKAN
Figure 2a
Click here to download Figure: Fig2a.eps
  
 
 
 
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
5
5,5
812160
B
A
D
 T
o
ta
l 
S
co
re
  
M
e
a
n
 C
h
a
n
g
e
 f
ro
m
 B
a
se
li
n
e
 
Month
p = 0.0346 p = 0.0471 p = 0.0187
Placebo
2.b. Atypical PKAN
Deferiprone
Figure 2b
Click here to download Figure: Fig2b.eps
  
 
 
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
5
5,5
812160
B
A
D
 T
o
ta
l 
S
co
re
  
M
e
a
n
 C
h
a
n
g
e
 f
ro
m
 B
a
se
li
n
e
 
Month
p = 0.6632 p = 0.5851 p = 0.5701
Placebo
2.c. Classic PKAN
Deferiprone
Figure 2c
Click here to download Figure: Fig2c.eps
  
-2
-1
0
1
2
3
4
5
6
7
8
1
M
e
a
n
 C
h
a
n
g
e
 i
n
 B
A
D
 
Placebo - Deferiprone 
N=19, 19
Baseline → Month 18
Deferiprone - Deferiprone 
N=43, 43
Baseline → Month 18 Month 18 → Month 36 (LOCF)
TIRCON2012V1 TIRCON2012V1-EXT TIRCON2012V1 TIRCON2012V1-EXT
Month 18 → Month 36 (LOCF)
2.d. Change in BAD over the two 
studies
p = 0.0500 
p = 0.0206 
p = 0.9781 
p = 0.2684 
Figure 2d
Click here to download Figure: Fig2d.eps
Figures 2.a, 2.b, 2.c and 2.d.  Marginal mean change (±SE) in BAD total score over time in patients with dierent classes of PKAN in 
the randomized study: 2a.  All PKAN, 2b. Atypical PKAN and 2c. Classic PKAN. The p-values for each class of PKAN was obtained 
from a MMRM model for the comparison of the DFP and placebo groups. 2.d. Observed change from baseline in BAD total score 
over the two studies. The bars on the left panel show the mean (±95% condence limits) change for the patients who received placebo 
over the 18 months of the randomized study (red bar) and deferiprone over the 18 months of the extension study (blue bar). The bars 
on the right panel show the corresponding changes for the patients who received deferiprone in both studies (both bars blue). The p-
value was obtained from a t-test for any comparison between the two groups of patients or from a paired t-test for any comparison 
within the same group of patients. 
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Figure 3.  Illustra!ve MRI data and response to DFP treatment.  Imaging panels show a slice from the 
conven!onal T2 weighted scan through the basal ganglia (le") with the R2* maps at baseline (center) 
and 18 Months (right).  The expanded anatomical region illustrated for R2* is marked by the box on the 
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R2* values).  The center panel shows the mean globus pallidus R2* across both hemispheres for each 
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reduc!on in GP iron levels on treatment.
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 Suppl. Figure 1. Polar graph of WeeFIM scores. The blue lines represent scores at baseline, and the red lines represent scores at 
Month 18.  Values that are closer to the center indicate lower func!oning, so a red line that is inside the blue line indicates worsening, 
a red line that overlaps the blue line indicates no change, and a red line that is outside the blue line indicates improvement. 
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PROTOCOL SYNOPSIS 
Title of the Study: 
 
A randomized, double-blind, placebo-controlled trial of deferiprone in 
patients with pantothenate kinase-associated neurodegeneration (PKAN) 
Protocol Code: 
 
TIRCON2012V1 
 
Development 
Phase: 
 
Phase III 
Sponsor: 
 
ApoPharma Inc.  
Principal 
Investigators: 
 
Thomas Klopstock, MD – Europe 
Elliott Vichinsky, MD – USA   
 
Study Centre: 
 
Multicentre – 5 centres  
 
Planned Study 
Period: 
 
Duration of treatment for an individual patient will be 18 months. 
Study Objectives: 
 
Co-Primary:  
o To evaluate the change in severity of dystonia (BAD scale) in patients 
with PKAN treated with deferiprone for 18 months compared to 
placebo.  
o To evaluate the patient’s global impression of condition’s 
improvement in patients treated with deferiprone for 18 months 
compared to placebo (PGI-I).  
Secondary:  
o To evaluate the effect of deferiprone compared to placebo on the 
change in globus pallidus iron levels (MRI) (subset of patients). 
o To evaluate the effect of deferiprone compared to placebo on motor 
symptoms (UPDRS); 
o To evaluate the effect of deferiprone compared to placebo on a 
measure of functional independence (WeeFIM or FIM); 
o To evaluate the effect of deferiprone compared to placebo on 
quality of life (PedsQL); 
o To evaluate the effect of deferiprone compared to placebo on the 
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patient’s quality of sleep (PSQI); 
o To evaluate the pharmacokinetics of deferiprone and its 3-O-
glucuronide metabolite (subset of patients); 
o To evaluate the safety and tolerability of deferiprone in patients 
with PKAN. 
 
Study Design: 
 
Multi-center, double-blind, randomized, placebo-controlled study in patients 
with PKAN. Approximately 90 patients will be enrolled and randomized in a 
2:1 (deferiprone:placebo) ratio. Block randomization will be used to ensure 
the same 2:1 ratio will be reached in patients in whom motor symptom onset 
was observed at < 6 yrs and in patients in whom motor symptom onset was 
observed at ≥ 6 yrs.  
 
Investigational 
Products: 
 
Deferiprone oral solution (80 mg/ml). 
 
Treatment 
(duration, 
treatment arms, 
dose, route) 
 
Patients are to be administered deferiprone or placebo at rising doses 
ranging from 5 to 15 mg/kg BID. Patients will be given 5 mg/kg BID for 
the first 6 weeks. If the dose is tolerated and there are no signs of toxicity, 
the dose will be increased to 10 mg/kg BID for the following 6 weeks. 
Again, if tolerated and there are no signs of drug toxicity, the dose will be 
increased to 15 mg/kg BID for the remainder of the study. Placebo patients 
will be dosed in the same manner.   
 
Target Population: 
 
90 male and female patients with PKAN. 
Efficacy 
Endpoints: 
 
Co-Primary:  
o     Change in the Barry-Albright Dystonia Scale (BAD) total score 
from baseline to Month 18 in patients treated with deferiprone 
compared to placebo, as assessed by central blinded evaluation of 
video-tapes;  
o     Patient’s Global Impression of Improvement (PGI-I) from baseline 
to Month 18 in patients treated with deferiprone compared to 
placebo.  
Study will be considered positive if both co-primary endpoints reach 
statistical significance. 
Secondary (deferiprone vs. placebo): 
1. Proportion of patients with improved or unchanged BAD scale total 
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score between baseline and Month 18 (responder analysis). 
2. Change from baseline to Month 18 in BAD scale score per body region 
(eyes, mouth, neck, trunk, each upper and lower extremity), as 
assessed by central blinded evaluation of video-tapes 
3. Proportion of patients showing an improvement on PGI-I at the Month 
18 visit (responder analysis); 
4. Change from baseline to Month 18 in globus pallidus iron levels as 
measured by MRI R2* (subset of patients). 
5. Change from baseline to Month 18 in UPDRS Parts I, II, III and VI 
scores, respectively; 
6. Change from baseline to Month 18 in global WeeFIM score (or FIM 
for patients > 18 years); 
7. Change from baseline to Month 18 in WeeFIM (or FIM for patients > 
18 years) score per item; 
8. Change from baseline to Month 18 in quality of life (PedsQL); 
9. Change from baseline to Month 18 in quality of sleep (PSQI). 
  
Safety Endpoints: 1. Frequency of Adverse Events (AEs); 
2. Frequency of Serious Adverse Events (SAEs); 
3. Discontinuation due to AEs; 
4. Hematology assessments; 
5. Blood clinical biochemistry assessments; 
6. ECG. 
 
Pharmacokinetic 
Endpoints: 
 
 
Steady state pharmacokinetics of deferiprone and its 3-O-glucuronide 
metabolite will be assessed in a subset of up to 24 patients over 12 hours. 
The following standard pharmacokinetic parameters will be derived from 
plasma concentrations of deferiprone: 
o Cmax  
o Tmax  
o Cmin 
o AUCSS 
o CL/F 
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o T½ 
o Vd/F 
 
Sample Size: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample size estimation is based on BAD scores from literature, where a 
mean value of 21.0 BAD score points with a standard deviation of 6.3 
points was observed in 21 NBIA patients (Timmermann et al, 2010). 
Assuming a 2:1 randomization, an expected difference in change of BAD 
score of ≥5 points after 18 months between control and treatment group, a 
standard deviation of 6.3 points for the change from baseline, and a drop-
out rate of 30%, a total of 87 patients would be needed to achieve 80% 
power in detection of this clinically relevant effect size at a two-sided 0.05 
level of significance. The impact of the co-primary endpoint (PGI-I) on the 
power to demonstrate superiority of the treatment group over control should 
be small as a greater degree of difference in response for this endpoint is 
expected between the two groups.  The rationale behind is that the BAD 
score is based on assessment of dystonia in eight body regions.  To obtain a 
much higher score, in relation to the standard deviation, the active treatment 
would need to provide beneficial effect on multiple regions.  A much higher 
score in PGI-I can be achieved even if the active treatment performs well in 
one region only.  
 
Main Inclusion 
Criteria: 
 
 
 Males and females 4 years of age and older at screening visit; 
 Patients must have PKAN, confirmed by genetic testing; 
 Patients having a BAD total score ≥ 3 at the screening visit; 
 Patients who have Deep Brain Stimulation (DBS) systems or Baclofen 
pumps in place will be eligible for the study, but they must have had 
a stable setting for at least two months prior to the screening visit, 
and every effort should be made to maintain the stable setting for the 
duration of the study: 
 Enrollment of non-DBS patients will be given priority, to 
maximize the proportion that  can undergo imaging; 
 Sexually active female patients of childbearing potential must have a 
negative pregnancy test result at Screening Visit (if applicable; In 
cases where the Investigator determines there is no reasonable risk of 
pregnancy because of significant incapacity, pregnancy testing will 
not be performed);  
 Fertile sexually active males must use an effective method of 
contraception or must confirm partner’s use of effective 
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contraception; 
 Informed consent/assent obtained before any study-related activities are 
undertaken; 
  Ability and willingness to adhere to the protocol including 
appointments and evaluation schedule. 
Main Exclusion 
Criteria: 
 Evidence of iron deficiency defined by Fe:TIBC ratio<15%, or serum 
ferritin <12 ng/mL; 
 Treatment with deferiprone in the past 12 months; 
 Previous failure of treatment with deferiprone, or previous 
discontinuation of treatment with deferiprone due to adverse events; 
  Evidence of abnormal liver or renal function (serum liver enzyme 
level(s) > 3 times upper limit of normal at screening) or clinically 
significant abnormal creatinine levels at screening visit;  
      Disorders associated with neutropenia (ANC < 1.5 x 109/L) or 
thrombocytopenia (platelet count < 50 x 109/L) in the 12 months 
preceding the initiation of the study medication. Exception: for patients 
whose neutropenia was attributed by the treating physician to episodes of 
infection or to drugs associated with a decline in the neutrophil count and 
in whom the ANC has fully recovered at the screening visit; 
 Pregnant or nursing females,  females planning to become pregnant, 
and females of childbearing potential who are sexually active and are 
unwilling, or unable, to use an acceptable method of contraception 
according to local requirements; 
     Initiation or discontinuation of treatment with baclofen, 
trihexyphenidyl, clonazepam, tizanidine within 30 days prior to baseline; 
treatment with botox within 60 days of baseline; and initiation or 
discontinuation of treatment with tetrabenazine within 90 days prior to 
baseline; 
    Treatment with an investigational drug within 30 days or 5 half-lives 
(whichever is longer) preceding the baseline visit; 
    Currently taking iron chelators; 
 Patients who, in the opinion of the physician, represent a high medical 
or psychological risk; 
 History of or active drug or alcohol use or dependence that, in the 
opinion of the investigator, would interfere with adherence to study 
requirements; 
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 Patients and patient’s legal representative (if applicable) with a mental 
incapacity, unwillingness or language barriers precluding adequate 
understanding or co-operation; 
 Baclofen pump placement less than two months prior to the beginning 
of the study. 
Schedule of Study 
Procedures: 
Following screening and baseline assessments eligible patients will be 
randomized to deferiprone or placebo. 
Efficacy evaluations: 
The BAD score will be centrally measured using video-taping at baseline, 
Months 6, 12 and 18 (or early termination visit) study visits. Video-tapes 
will be assessed by blinded neurologists expert in movement disorders; 
The PGI-I will be performed at Months 6, 12 and 18 (or early termination 
visit) study visits; 
The MRI scan will be performed at baseline and Month 18 (or early 
termination visit) study visits in a subset of patients without deep brain 
stimulators for whom the use of anaesthesia (if required for the MRI scan) 
is deemed acceptable based on Investigator’s judgement ;  
The UPDRS Part I, II, III and VI will be performed at baseline, Months 6, 
12 and 18 (or early termination visit) study visits; 
The WeeFIM or FIM instrument will be performed at baseline, Months 6, 
12 and 18 (or early termination visit) study visits; 
The PedsQL will be performed at baseline, Months 6, 12 and 18 (or early 
termination visit) study visits; 
The PSQI will be performed at baseline, Months 6, 12 and 18 (or early 
termination visit) study visits. 
A Likert scale to evaluate the patient’s state with regards to its PKAN 
symptoms will be performed at baseline, Months 6, 12 and 18 (or early 
termination visit) study visits. 
 
Safety evaluations: 
Medical history will be collected at screening and reviewed at Month 18 (or 
early termination visit) study visits; 
Physical examination will be performed at screening, baseline, Months 1.5, 
3, 6, 12 and 18 (or early termination visit) study visits; 
Serology will be performed at screening visit; 
Vital signs, clinical chemistry, urinalysis, and pregnancy test will be 
performed at screening and Months 1.5, 3, 6, 12 and 18 (or early 
termination) study visits; 
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12-lead ECG will be performed at screening and Month 18 (or early 
termination) study visits; 
Hematology assessments will be performed at screening and baseline visits, 
and weekly during the study; 
Adverse events and use of concomitant medications will be followed at 
each study visit. 
A safety follow-up visit will be conducted 4 weeks after completion of the 
study. 
Pharmacokinetic evaluations: 
Steady state pharmacokinetics of deferiprone and its 3-O-glucuronide 
metabolite will be studied over 12 hours in a subset of up to 24 patients. 
Blood samples will be collected at pre-dose and 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 
12 hours post-dose. 
 
Data Analysis / 
Statistical 
Methods: 
 Co-Primary Efficacy Endpoints 
A Mixed-Effect Model Repeated Measure (MMRM) model will be used as 
the primary analysis method to assess the change in BAD total score and 
PGI-I from baseline to Month 18, with baseline value and age of onset of 
motor symptoms as covariates and treatment group as the main factor in the 
model. Age of onset of motor symptoms will be used as a stratification factor 
at randomization and thus will be included as a binary variable in all the 
models where it is used as a covariate. DBS settings change or use of 
medications that have the potential to affect dystonia symptoms during the 
study or the frequency of PRN drug or rescue medication use may confound 
the treatment effect assessment. These variables will also be included in the 
MMRM model. PGI-I is already a measurement of change from baseline and 
thus will be used directly as the outcome variable and baseline BAD score 
will be included as the baseline value in the model.  
Secondary Efficacy Endpoints 
The MMRM model used for the co-primary efficacy endpoints will also be 
used for the analysis of the secondary endpoints except for the proportion of 
responders, which will be analyzed by a logistic regression model.  
Subgroup Analysis 
In order to explore potential differences in treatment effect on efficacy 
endpoints across population subgroups, subgroup analyses will be performed 
on the co-primary efficacy endpoints on the following factors: Age at onset 
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of motor symptom (Age ≥6 vs. Age <6), DBS (Deep Brain Stimulation Yes 
vs. No), Baclofen pump (Yes vs. No), and Region (US vs. Europe). Forest 
plots will be drawn to compare subgroups of each factor. 
Notable improvements or worsening in patient’s condition that are not 
captured by the relevant scales will be documented. 
Safety Analysis 
The safety data for continuous variables will be summarized using 
descriptive statistics and the safety data for discrete variables will be 
tabulated with frequency tables.  
Pharmacokinetic Analysis 
The pharmacokinetics parameters will be summarized using descriptive 
statistics. 
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1 BACKGROUND AND RATIONALE 
This will be a randomized, double-blind, placebo-controlled trial of deferiprone in 
patients with pantothenate kinase-associated neurodegeneration (PKAN) 
 
1.1 Pantothenate Kinase-Associated Neurodegeneration  
 Pantothenate kinase-associated neurodegeneration (PKAN) is a rare disorder with 
progressive dystonia, parkinsonism, spasticity, and brain iron accumulation (Hayflick 
SJ et al. 2003; Zorzi G et al. 2011). PKAN is the most prevalent form of a group of 
progressive extrapyramidal disorders called neurodegeneration with brain iron 
accumulation (NBIA), characterized by iron accumulation in the brain (Hayflick SJ. 
2003). Although PKAN accounts for only approximately 50% of cases of NBIA 
(Kurian MA et al. 2011) until recently all patients with high brain iron were given a 
diagnosis of PKAN, despite the obvious clinical heterogeneity of the individual 
patients. With the advent of molecular genetic testing, it has become apparent that there 
are several genetically distinct disorders classified as NBIA.  
PKAN is an autosomal recessive inherited disorder caused by mutations in the 
pantothenate kinase 2 (PANK2) gene. PANK2 codes for the PANK2 enzyme, which 
phosphorylates pantothenate, the initial and rate-limiting step in coenzyme A 
biosynthesis. Coenzyme A has a vital role in adenosine triphosphate synthesis, and in 
fatty acid and neurotransmitter metabolism. Mitochondrial dysfunction is proposed to 
result from PANK2 mutations, leading to neurodegeneration. Abnormal PANK2 
function will lead to accumulation of the neurotoxic metabolites cysteine and 
pantetheine (Kurian MA et al. 2011).  
Although PANK2 is not directly involved in iron metabolism, its absence or abnormal 
function may contribute to iron accumulation in the brain, leading to neuronal death via 
a free-radical pathway. 
Because the basal ganglia are involved in mediating the initiation of movements, an 
accumulation of excess labile iron within this region would be expected to result in poor 
motor control, as a result of iron-related ROS-mediated damage, although proof that 
iron causes the neurodegeneration is lacking (Hayflick SJ & Hogarth. 2011). Common 
physiological features include abnormal movements and posture (dystonia), muscular 
rigidity and sudden involuntary muscle spasms (spasticity). These features can result in 
clumsiness, problems with gait and posture, difficulty controlling movement, and 
problems with speech. Progressive generalized dystonia is a major clinical feature of 
PKAN and can result in life-threatening complications (Castelnau P et al. 2005). 
Cranial and limb dystonia crises are frequent and are part of the natural history of the 
disease. These crises may lead to recurrent trauma to the tongue/mouth or to bone 
fractures, the latter being due to a combination of dystonic overstraining and inactivity-
related ostopenia (Gregory A et al. 2009). Another common feature is degeneration of 
the retina resulting in progressive night blindness and loss of peripheral vision. Hence, 
PKAN may manifest itself not only as movement disorders but as retinopathy, 
deterioration of cognition or hearing, or peripheral nerve changes. 
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Historically, PKAN has been described as either classical or atypical. The majority of 
PKAN cases are classical and therefore relatively homogeneous in their phenotype 
(Gregory A et al. 2009). Classical PKAN develops usually before 6 years of age 
(average age at development of symptoms is 3.5 years) (Gregory A et al. 2009; Kurian 
MA et al. 2011). Most patients lose the ability to walk independently 10-15 years after 
the beginning of symptoms. Many individuals with the classical form of PKAN require 
a wheelchair by their mid-teens (in some cases, earlier). Individuals with classical 
PKAN are also more likely to have specific eye problems. Approximately two-thirds of 
these patients will have retinal degeneration, resulting in tunnel vision, night blindness, 
and loss of peripheral vision. Loss of peripheral vision may contribute to the more 
frequent falls and gait disturbances in the early stages. Optic atrophy, a vision 
impairment caused by gradual degeneration of the nerves of the eyes, is found in 3% of 
patients (Kurian MA et al. 2011).  
Atypical PKAN usually becomes evident after the age of ten years and progresses more 
slowly. The average age at which symptoms develop is 13 years. Loss of independent 
ambulation often occurs 15-40 years after the initial development of symptoms. In 
general, atypical disease is less severe and more slowly progressive than classical 
PKAN. It is hypothesized that classical PKAN results from complete absence of the 
enzyme pantothenate kinase, whereas atypical disease results from a severe deficiency, 
i.e., individuals retain some level of enzyme activity. Clinically, the disease manifests 
as rigidity, dystonia and chorea (Gregory A et al. 2009). 
In the last decade, progress has been made in stratifying NBIA and PKAN according to 
gene mutations and phenotype. However, no genetic or other specific therapies are 
available for this condition (Gregory A & Hayflick. 1993; Hayflick SJ. 2010; Zorzi G et 
al. 2011). 
 
1.2 Deferiprone 
Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) is a bidentate iron chelator that 
preferentially binds trivalent iron cations (Fe3+) in a 3:1 (deferiprone:iron) complex. 
Ferriprox® is the ApoPharma oral formulation of deferiprone and is available as 
immediate release 500 mg  or 1000 mg tablets, and as an oral solution of 100 mg/mL. 
The effectiveness of deferiprone in reducing body iron in transfusional iron overload 
has been assessed by urinary iron excretion, sequential measurements of serum ferritin 
levels, iron concentration in the liver and in the heart, and by clinical outcomes such as 
its ability in preventing iron-induced cardiac disease and prolonging survival. The 
results of the ApoPharma-sponsored clinical studies and of independent trials 
demonstrate that therapy with Ferriprox® is associated with good compliance and 
stabilization or decline of the body iron load. 
In humans, deferiprone is rapidly absorbed from the upper part of the gastrointestinal 
tract after oral administration and appears in blood within 5 to 10 min. The mean time 
for deferiprone concentrations to peak in serum is 45 to 60 min in fasting patients and 
approximately 2.2 h in non-fasting patients. Less than 10% of deferiprone is bound to 
serum proteins. The majority of the administered dose of deferiprone is metabolized.  
TIRCON: Deferiprone PKAN Study Protocol           VERSION: Amendment 6 Final 
STUDY CODE: TIRCON2012V1                              DATE: 31 JUL 2013 
Page 20 of 150 
Deferiprone mainly undergoes Phase II metabolism through O-glucuronidation. In vitro 
studies suggest that UDP glucuronosyltransferase 1A6 is primarily responsible for the 
glucuronidation of deferiprone. The predominant deferiprone metabolite is a 3-O-
glucuronide conjugate, which is unable to bind iron because of inactivation of the 3-
hydroxy functional group. In most patients, more than 90% of deferiprone is eliminated 
from serum within 5 to 6 hours. The elimination half-life of deferiprone is 2 to 3 hours, 
with about 75% to 90% of the total deferiprone excreted in urine in the first 24 hours in 
the form of free deferiprone, the 3-O-glucuronide metabolite and iron-deferiprone 
complex. The pharmacokinetics of deferiprone is modified by food intake. Food 
decreased the rate of absorption of the parent drug, and the subsequent rate of formation 
of deferiprone glucuronide in healthy patients, while the overall bioavailability (AUC) 
remained unchanged.   
The safety profile of deferiprone has been extensively characterized in patients with 
systemic iron overload. The most serious AE associated with deferiprone use is 
agranulocytosis, defined as a confirmed absolute neutrophil count less than 0.5 × 109/L.   
In pooled clinical trials, the incidence of agranulocytosis was 1.7% of patients. The 
mechanism of deferiprone-associated agranulocytosis is unknown. Agranulocytosis 
usually resolves upon discontinuation of deferiprone, but there have been post-
marketing reports of agranulocytosis leading to death. 
The most common adverse reactions reported during clinical trials were chromaturia, 
nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and 
neutropenia (ApoPharma Inc. 2009).  
Deferiprone (Ferriprox®) was first approved for the treatment of iron overload in 
patients with thalassemia major in 1999 by the European Medicines Agency (EMA) and 
it is currently approved in over 60 countries. It was approved by the Food and Drug 
Administration (FDA) in October 2011 for the treatment of patients with transfusional 
iron overload due to thalassemia syndromes when current chelation therapy is 
inadequate. The recommended initial dose of deferiprone® in these patients is 25 mg/kg, 
orally, three times per day for a total of 75 mg/kg/day. The maximum dose is 33 mg/kg, 
three times per day for a total of 99 mg/kg/day. 
 
1.3 Study Rationale 
Deferiprone is proposed as a therapeutic method for the treatment of patients with 
PKAN given its unique ability to cross the blood brain barrier (Arthur AS et al. 1997; 
Roy S et al. 2010) and its neuroprotective effect as an iron chelator (Arthur AS et al. 
1997; Dexter DT et al. 2011; Roy S et al. 2010). 
Although iron is essential for normal physiological function, excessive amounts of iron 
or dysregulation of its metabolism is potentially toxic. Increased ‘free’ iron levels in 
tissues lead to the formation of highly reactive oxygen species, including the extremely 
damaging hydroxyl radical, causing localized toxicity (Poulsen HE. 2005; Singh KK. 
2006).  
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Neurodegeneration in patients with PKAN appears to be related to the intracellular 
mismanagement of iron, resulting in localized brain iron accumulation, iron toxicity and 
eventually cell death. The regions of the brain with the highest amounts of iron 
accumulation include those that control motor output. Thus, motor impairment 
associated with PKAN are thought to be due, at least in part, to the oxidative 
damage/necrosis that occurs as a result of long-term localized iron-induced damage 
(Kakhlon O et al. 2010). In patients with Friedreich’s Ataxia, another 
neurodegenerative condition involving regional iron deposition in the brain, deferiprone 
was able to reduce localized elevated levels of brain iron, as evidenced by MRI scans 
(Boddaert N et al. 2007). 
We therefore propose that if iron can be sequestered from brain regions with excess 
amounts of labile iron, prior to cell death, the clinical symptoms of PKAN could be 
reduced. In conditions of iron overload, the accepted therapeutic strategy for dealing 
with accumulation of iron is administration of iron chelators, which both increases iron 
excretion and prevents the toxic effects of iron excess. Although patients with PKAN do 
not have generalized iron overload, they have a mismanagement of intracellular iron, 
which results in a misdistribution of iron at the local level. One strategy for treating 
PKAN might be iron redistribution by “reversed siderophores”. The aim of chelation 
with reversed siderophores would be to bind excess labile cell iron and transfer it, 
directly or indirectly, to endogenous acceptors, like transferrin, for transport to other 
compartments inside or outside the cells (Kakhlon O et al. 2010). The oral chelator 
deferiprone appears to fulfill at least some of the criteria required for a reversed 
siderophore: 
 
o Ability to gain access to cells (Shanzer A et al. 1991) and effectively scavenge 
intracellular label iron pools (Zanninelli G et al. 1997), exiting cells bound to the 
iron as an iron-chelate; 
o Selectively bind iron in the various intracellular labile iron pools (Sohn YS et al. 
2008) and thereby reduce iron-dependent free radical formation (Glickstein H et 
al. 2005; Glickstein H et al. 2006; Molina-Holgado F et al. 2007);  
o Spare extracellular transferrin-bound iron and potentially transfer chelated iron to 
apotransferrin (Boddaert N et al. 2007; Breuer W et al. 2001; Evans RW et al. 
1992; Sohn YS et al. 2008); 
o Donate iron for metabolic reutilization (Sohn YS et al. 2008). 
 
Deferiprone possesses the ability to readily enter cells and bind iron intracellularly. 
Because of its low molecular weight and favorable physicochemical properties, the drug 
readily crosses the blood-brain barrier in animal studies (Waldmeier PC et al. 1993) and 
there is indirect evidence to suggest that it does so in humans as well (Boddaert N et al. 
2007). Pharmacokinetic studies have shown that deferiprone is rapidly absorbed, 
appearing in plasma within 5 to 10 minutes of ingestion, with a peak plasma level 
within 45-60 minutes. The 3:1 chelator:iron complex is excreted with the free drug and 
its glucuronide in urine and faeces. Because of its ability to penetrate the blood brain 
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barrier, enter and exit cells and allow iron to be passed to transferrin (and be 
subsequently used in normal endogenous processes), deferiprone could be exploited 
clinically for treating neurodegenerative diseases involving regional iron accumulation.  
The therapeutic approach that deferiprone provides involves targeting the site of iron 
accumulation within the brain, and removing excess iron, providing the potential to 
slow or halt the debilitation that accompanies the disease. 
 
2 OBJECTIVES 
2.1 Co-Primary Objective 
 To evaluate the change in severity of dystonia in patients with PKAN treated with 
deferiprone compared to placebo (BAD); 
 To evaluate the patient’s global impression of condition’s improvement in 
patients treated with deferiprone for 18 months compared to placebo (PGI-I). 
 
2.2 Secondary Objective 
The secondary objective is: 
o To evaluate the effect of deferiprone compared to placebo on the change in 
globus pallidus iron levels (MRI) (subset of patients); 
o To evaluate the effect of deferiprone compared to placebo on motor symptoms 
(UPDRS); 
o To evaluate the effect of deferiprone compared to placebo on a measure of 
functional independence (WeeFIM or FIM); 
o To evaluate the effect of deferiprone compared to placebo on quality of life 
(PedsQL); 
o To evaluate the effect of deferiprone compared to placebo on the patient’s 
quality of sleep (PSQI); 
o To evaluate the pharmacokinetics of deferiprone and its 3-O-glucuronide 
metabolite (subset of patients); 
o To evaluate the safety and tolerability of deferiprone in patients with PKAN. 
 
3 INVESTIGATIONAL PLAN 
3.1 Overall Study Design 
This is a multi-center, double-blind, randomized, placebo-controlled study in patients 
with PKAN. Approximately 90 patients will be enrolled and randomized with 2:1 
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(deferiprone:placebo) ratio. Patients will be stratified into two age groups: <6 yrs and 
≥6 yrs at onset of motor symptom.  
 
3.2 Discussion of Study Design 
This study has been designed to evaluate the efficacy and safety of deferiprone in 
patients with PKAN. Patients will participate in a Baseline Phase followed by a 
Treatment Phase. 
Baseline Phase: 
During the Baseline Phase, patients, and when applicable their legal representatives, 
who sign an informed consent/assent will undergo initial screening. On the final day of 
the Baseline Phase, patients’ eligibility will be determined, based on 
inclusion/exclusion criteria, and qualified patients will enter the Treatment Phase. 
Treatment Phase: 
The Treatment Phase will be 18 months in duration. At the beginning of the Treatment 
Phase, patients will be randomized in a double-blinded fashion to receive treatment with 
either deferiprone or placebo twice daily (BID). The minimum interval between doses 
of deferiprone should be eight (8) hours.  If a dose is missed the patient should receive 
it at the earliest opportunity, as long as it is at least eight (8) hours before the next dose. 
The patient should never receive more than two doses within a 24-hour period. A 24-
hour period of deferiprone will be from 00:01 hours until 24:00 hours on the following 
night. Doses must never be doubled up. Deferiprone may be taken with or without food, 
but if patients experience nausea or vomiting, it may help to take deferiprone with some 
food. If necessary, the total daily dose of study medication will be adjusted to maintain 
the prescribed dose weight ratio during study visits. 
Patients will initiate deferiprone at a dose of 5 mg/kg BID for the first 6 weeks. If the 
dose is tolerated and there are no signs of toxicity, the dose will be increased to 10 
mg/kg BID for the following 6 weeks at the Investigator’s discretion. Again, if tolerated 
and there are no signs of drug toxicity, the dose will be increased to 15 mg/kg BID for 
the remainder of the study at the Investigator’s discretion.  The dose may be adjusted 
during the study depending on tolerability, assessment of safety markers for adverse 
reactions that are possibly dose dependent such as gastrointestinal upset, increases in 
serum liver enzymes levels and arthropathies. For patients in whom a clinically 
significant decrease in serum ferritin is observed, iron supplements may be administered 
at the Investigator’s discretion.  
Efficacy, safety and tolerability evaluations will occur according to the schedule of 
events (Appendix 20.1). The use of rescue medication should be limited to 
circumstances judged as absolutely necessary by the Investigator. Rescue medication is 
defined as the introduction of a new medication, or a change in dosing of a current 
medication, that is prescribed because of a worsening of the patient’s condition and that 
has the potential to have an effect on dystonia symptoms. Such medications may 
include, but are not limited to, baclofen, trihexyphenidyl, clonazepam, tizanidine, 
tetrabenazine, and botox. If a patient is administered rescue medications for more than 
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two events, the Investigator should notify the Sponsor to discuss the patient’s continued 
participation in the study. A list of rescue medications is provided in Appendix 20.3. 
Pharmacokinetics evaluation of deferiprone and its 3-O-glucuronide metabolite will be 
conducted in a subset of up to 24 patients at the Month 6 visit according to the schedule 
of events (Appendix 20.1). 
If a patient withdraws from the study, he or she will return to the clinic for an Early 
Termination Visit as soon as possible, but no later than 1 month following treatment 
discontinuation. All of the efficacy and safety evaluations will be performed at the last 
study visit or the Early Termination visit, whichever comes first. 
 
3.3 Study Sites and Study Duration 
The study will be conducted at five sites: four sites in Europe, and one in the United 
States of America. 
 Each patient is expected to participate in the study for approximately 20 months (from 
the Screening Visit to the Follow-up Visit). 
 
4 STUDY POPULATION 
4.1 Number of Patients 
Ninety male and female patients with PKAN will be randomized into the study (60 
patients randomized to deferiprone and 30 patients to placebo). Of the 90 patients with 
PKAN randomized into the study, a subset of up to 24 patients will be involved in the 
pharmacokinetics evaluation of deferiprone and its 3-O-glucuronide metabolite.  
Patients who are considered Screen Failures might be rescreened following approbation 
by Sponsor. Patients who withdraw from the study after starting treatment will not be 
replaced.  
 
4.2 Inclusion Criteria 
Patients will be eligible for the study only if they meet all of the following criteria: 
1.  Males or females 4 years of age and older at screening visit; 
2.  Have PKAN, confirmed by genetic testing (supporting evidence required); 
3. BAD total score ≥ 3 at the screening visit; 
4. Patients who have Deep Brain Stimulation (DBS) systems or Baclofen pumps in 
place will be eligible for the study, but they must have had a stable setting for at 
least two months prior to the screening visit, and every effort should be made to 
maintain the stable setting for the duration of the study:   
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 Enrollment of non-DBS patients will be given priority, to maximize the 
proportion that can undergo imaging; 
5. Informed consent/assent obtained before any study-related activities; 
6. Ability and willingness to adhere to the protocol including appointments and 
evaluation schedule; 
7.  Sexually active female patients of childbearing potential must have a negative 
pregnancy test result at Screening Visit (if applicable; In cases where the 
Investigator determines there is no reasonable risk of pregnancy because of 
significant incapacity, pregnancy testing will not be performed). In addition, if 
applicable, females of childbearing potential must: 
  Use an effective method of contraception according to local 
requirements, OR 
  Have had a tubal ligation (supporting evidence required), OR 
  Have had a hysterectomy (supporting evidence required), OR 
  Participates in a non-heterosexual lifestyle, OR 
 Have a male sexual partner has been sterilized (supporting evidence 
required).  
Effective methods of contraception according to local requirements may 
include abstinence from sexual intercourse, or hormonal contraceptives, 
providing they are used with condom or diaphragm or spermicide. 
Diaphragm and condom may also be used, providing they are used with 
spermicide. The primary contraception with hormones should be highly 
effective with a Pearl index < 1%. Supporting evidence for sterilization 
consists of a surgical report or letter from the family physician;  
8.  If the patient is a sexually-active male, patient must confirm that he and/or his 
female partner will use an effective method of contraception according to local 
requirements for the length of the trial and for 30 days following completion of 
the study or early termination. Effective methods of contraception for males 
include condoms or sterilization or abstinence from sexual intercourse. 
 
4.3 Exclusion Criteria 
Patients will not be eligible for the study for any of the following reasons: 
1. Evidence of iron deficiency defined by Fe:TIBC ratio <15%, or serum ferritin <12 
ng/mL; 
2. Treatment with deferiprone in the past 12 months; 
3. Previous failure of treatment with deferiprone, or previous discontinuation of 
treatment with deferiprone due to adverse events; 
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4. Conditions known to contraindicate the use of deferiprone (history of 
agranulocytosis or recurrent episodes of neutropenia); 
5. A serious, unstable chronic illness not related to PKAN during the past 3 months 
before screening visit including but not limited to: hepatic, renal, gastro-
enterologic, respiratory, cardiovascular, endocrinologic, neurologic or 
immunologic disease; 
6. A serious, unresolved acute illness at the screening visit including but not limited 
to: hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, 
neurologic or immunologic disease; 
7.   Initiation or discontinuation of treatment with baclofen, trihexyphenidyl, 
clonazepam, tizanidine within 30 days prior to baseline; treatment with botox 
within 60 days of baseline; and initiation or discontinuation of treatment with 
tetrabenazine within 90 days prior to baseline; 
8. Evidence of abnormal liver or renal function (serum liver enzyme level(s) > 3 
times upper limit of normal at screening) or clinically significant abnormal 
creatinine levels at screening visit; 
9. Disorders associated with neutropenia (ANC < 1.5 x 109/L) or thrombocytopenia 
(platelet count < 50 x 109/L) in the 12 months preceding the initiation of the 
study medication. Exception: for patients whose neutropenia was attributed by 
the treating physician to episodes of infection or to drugs associated with a 
decline in the neutrophil count and in whom the ANC has fully recovered at the 
screening visit; 
10. History of malignancy; 
11. QTcF interval > 450 msec at screening; 
12. HIV positive; 
13. Myocardial infarction, cardiac arrest or cardiac failure within 1 year before 
screening visit; 
14. Bowel disease causing malabsorption; 
15. History of or active drug or alcohol use or dependence that, in the opinion of the 
investigator, would interfere with adherence to study requirements;; 
16. Treatment with an investigational drug within 30 days or 5 half-lives (whichever 
is longer) preceding the baseline visit; 
17. Currently taking iron chelators; 
18. Pregnant or nursing females, females planning to become pregnant, and  females 
of childbearing potential who are sexually active and are unwilling, or unable, to 
use an acceptable method of contraception according to local requirements; 
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19. Males who are sexually active and are unwilling, or unable, to use an acceptable 
method of contraception according to local requirements; 
20. History or presence of hypersensitivity or idiosyncratic reaction to deferiprone; 
21. Patients and patient’s legal representative (if applicable) with a mental incapacity, 
unwillingness or language barriers precluding adequate understanding or co-
operation; 
22. Any condition that, in investigator’s opinion, would adversely affect the patient’s 
ability to complete the study or its assessments. 
23. Baclofen pump placement less than two months prior to the screening visit; 
24. Current and ongoing participation in other clinical studies. 
 
4.4 Enrolment Violations 
The criteria for enrolment must be followed explicitly.  If there is inadvertent enrolment 
of patients who do not meet enrolment criteria, these patients should be withdrawn from 
the study. 
 
4.5 Treatment Discontinuations 
Patients are free to discontinue treatment at any time without discrimination from the 
Investigator.  A patient may be withdrawn from the study at any time, at the discretion 
of either the Investigator or the Sponsor (or its delegate), for any of the following 
reasons: 
 Patient request; 
 Medical or safety reasons considered significant by the patient, Investigator, 
and/or Sponsor (or its delegate);  
 Requirement for concomitant medication/therapy that is contraindicated; 
 Occurrence of other illnesses that affect the patient’s further participation in the 
study or evaluation of study treatment; 
 A protocol deviation that may interfere with study assessments as judged by 
the Sponsor (or its delegate); 
 The patient is repetitively non-compliant with the protocol or instruction of the 
Investigator; 
 Significant changes in QTc interval (defined as QTcF change of greater than 60 
ms) are noted; 
 Patient participation in other clinical studies throughout this study; 
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 Any other situation where, in the opinion of the Investigator, continuation of 
the study would not be in the best interest of the patient. 
A patient must be withdrawn from the study if any of the following conditions 
apply: 
 Pregnant or planning to become pregnant (see Section 10.2 Procedures in case 
of Pregnancy); 
 Occurrence of any adverse event characterized as life-threatening or 
disabling not associated with the patient’s condition;  
 Non-compliance with weekly blood counts (three or more consecutively 
missed visits will result in automatic withdrawal); 
 Termination of the study by the Sponsor; 
 Patient experiences moderate neutropenia or severe 
neutropenia/agranulocytosis (Refer to Section 9.2.4.9 for follow-up 
procedures). 
A patient has the right to withdraw from the study at any time and for any reason 
without consequence to future care by the Investigator or study center. Whenever 
possible, a reason for withdrawal will be obtained. 
When a patient decides to withdraw participation in the study, he/she should always be 
contacted to determine, if possible, the reason for withdrawing from the study, any 
adverse events (AEs) and used any concomitant medications.  All investigational 
product and materials should be returned.  If any AEs occurred, the Investigator must 
attempt to follow up the outcome for 30 days post-termination. 
Data collected for patients who withdraw from the study after receiving the study drug 
will be evaluated for efficacy and safety (if possible).  
If, for any reason, the Sponsor (or its delegate)  and/or Investigator decide to withdraw a 
patient before completing the study, the reason for withdrawal must be entered on the 
source document and on the Disposition page of the electronic Case Report Form 
(eCRF), and all other appropriate eCRF pages must be completed. A withdrawn patient 
should return for the Early Termination Visit and a Follow-up Visit. 
After a patient is randomized, it is the Investigator’s responsibility to make a reasonable 
effort to correct any deviation from the protocol and to maintain the patient in the study, 
if no safety issues are involved. 
 
4.6 Treatment Interruptions 
Treatment will be interrupted for ANY of the following reasons: 
 If the patient develops an infection while on study medication, therapy must be 
interrupted based on Investigator’s judgement   and neutrophil count should be 
obtained and monitored more frequently if ANC <1.5 x 109/L.  
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 If a patient develops a fever (defined as 38.5 ºC or greater), therapy must be 
interrupted immediately and a CBC and differential should be obtained. 
Patients should be advised to report promptly to their physician any symptoms 
indicative of infection such as fever, or flu-like symptoms. Patients will be provided 
with an emergency services card with contact information and patients will be advised 
to carry this card at all times. Therapy with study medication can be re-initiated once all 
symptoms have been resolved and it is deemed safe by the Investigator. 
 
4.7 Pregnancy 
All sexually active female participants of childbearing potential will be administered a 
pregnancy test prior to drug treatment (if applicable; in cases where the Investigator 
determines there is no reasonable risk of pregnancy because of significant incapacity, 
pregnancy testing will not be performed). A negative test will be required prior study 
entry. Patients of childbearing potential should not become pregnant during the study 
and therefore must agree to use an approved method of contraception (as defined in 
Appendix 20.2) for 30 days prior to Day 1 (at least 3 months for hormonal 
contraceptives), throughout the course of the trial and for 30 days following. 
In the situation where a female patient is withdrawn from the study because of a 
pregnancy, the medication must be stopped immediately, the sponsor must be informed 
immediately via the pregnancy report form and the patient must be closely followed-up 
during her pregnancy. Update reports should be provided to the Sponsor’s 
Pharmacovigilance group at mid-pregnancy and at delivery or at termination of the 
pregnancy. 
Male patients must inform investigator if their female partner becomes pregnant during 
the trial or within one month after trial completion 
 
5 TREATMENT ALLOCATION  
5.1 Randomization 
Study medication will be allocated to patients according to a randomization list issued 
by the Sponsor’s biostatisticians, using a computer random number generator. 
Approximately 90 patients from 5 study sites will be randomized into this study. A 
centralized randomization will be used for all study sites. Patients will be randomly 
assigned at a 2:1 ratio to take either deferiprone or placebo. A stratified randomization 
will be performed based on patient’s age at disease diagnostic, hereby two separate sets 
of randomization lists will be generated for the age group of < 6 years at motor 
symptom onset and the age group of ≥ 6 years at motor symptom onset. A block 
randomization of the multiple of size 3 will be employed so that approximately the 2:1 
ratio between deferiprone and placebo can be maintained during the study.  
The randomization lists will consist of randomization code and treatment code. A 
randomization code will consist of nine alphanumeric characters. The first six 
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characters will represent age group (AGE<6 or AGE≥6) and will be followed by a 
hyphen. The next three numeric characters will be a three-digit number that will start at 
001 and increase sequentially. For example, the randomization codes “AGE<6-001” and 
“AGE≥6-001” will represent the first patient to be randomized from the age group of < 
6 years at motor symptom onset and the age group of ≥ 6 years at motor symptom onset, 
respectively. Each randomization code will have a treatment code of either 
“DEFERIPRONE’ or “PLACEBO”. 
Once the patient has met all Inclusion Criteria and no Exclusion Criteria, the site will 
submit a completed Patient Eligibility/Randomization Form signed by the Investigator 
to the Sponsor. Once the completed form is reviewed by the Sponsor, the confirmation 
indicating the randomization code and study medication bottle number for the patient 
will be sent to the site. The randomization code and the study medication bottle number 
will be documented in the CRF and accountability log.  
 
5.2 Allocation of Patient Numbers 
After signing of the Informed Consent/Assent Form (ICF/AF) by patients and/or 
patients’ legal representatives, if applicable, patients will be assigned a unique patient 
ID number.  
A patient ID number will contain a six-digit number.  The first three numbers represent 
the site code (00X for the X site). This number is to be used in combination with a 
three-digit rolling number that will be sequentially assigned by the site to patients who 
sign the ICF/AF.  This number would start at 001 for each site.  For example, if site 
00X has eight patients, the patient ID number would be 00X001 to 00X008. The patient 
ID number would start again for site 002 at 002001. If a patient is withdrawn after 
receiving his or her patient ID number, the number will not be reused.  For the purpose 
of the trial, patients will be referred to by their patient ID number. 
 
6 STUDY PROCEDURES  
6.1 Entry Procedures 
An Informed Consent/Assent Form (ICF/AF) approved by a recognized IRB/IEC, and 
local regulatory bodies, if applicable, will be signed and dated by the patient and when 
applicable, the patient’s authorized legal representative prior to the patient’s 
participation in this study.  The patient and/or legal representative, if applicable, will 
then be provided with a copy of the signed ICF/AF. The original ICF/AF will be kept 
by the Investigator. Patients and/or parent and/or legal representative who sign an 
ICF/AF will undergo screening procedures. 
 
6.2 Screening Visit (Day -30 to DAY -1) 
Assessment of eligibility: 
The following procedures will take place at the Screening visit: 
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 Explain the study to the patients and/or parent/ legal representative and obtain 
written informed consent/assent and provide a copy to the patient and/or parent/ 
legal representative; 
 Assign the patient ID number (see Section 5.2); 
 Confirm genetic PKAN diagnosis (supporting evidence required) or collect blood 
sample for genetic confirmation of PKAN diagnosis; 
 Record demographic information; 
 Obtain medical history; 
 Record prior and current medications for at least three months prior to screening; 
 Collect blood sample for hematology, biochemistry and serology (to be conducted 
within 14 days prior to starting study treatment). An ANC value of  > 1.5 x 
109/L and platelet count of >50 x 109/L will be required for start of dosing; 
  Collect blood sample for pregnancy testing for all sexually active females of 
childbearing potential. A negative result will be required for start of dosing (if 
applicable; in cases where the Investigator determines there is no reasonable risk 
of pregnancy because of significant incapacity, pregnancy testing will not be 
performed); 
 Collect urine for urinalysis (to be conducted within 14 days prior to starting study 
treatment); 
 Take vital signs (including weight and height); 
 Perform 12-lead ECG (to be conducted within 14 days prior to starting study 
treatment); 
 Complete the BAD scale (to be completed by an Qualified Investigator or a 
qualified delegate); 
 Conduct contraceptive counselling for all sexually active patients; 
 Perform physical examination (to be completed by a Qualified Investigator, or 
qualified delegate); 
 Review inclusion/exclusion criteria; 
 Determine if patient has had any medical events. If so document them as specified 
in Section 9.2.4.3; 
 Instruct the patient and/or parent/legal representative of the following: 
o For patients treated on a regular dosing regimen with a medication that 
has the potential to have an effect on dystonia prior to start of this study: 
- Medication(s) must have been initiated at least 30 days prior to baseline 
for baclofen, trihexyphenidyl, clonazepam, tizanidine; 60 days prior to 
baseline for botox; and 90 days prior to baseline for tetrabenazine. The 
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patient must stay on the same dose and dosing regimen up to the 
baseline visit. 
- Remind the patient to stay on the same dose and dosing regimen for the 
duration of the study. Any changes should be limited to circumstances 
judged as absolutely necessary by the Investigator.  
o For patients treated with baclofen, trihexyphenidyl, clonazepam, 
tizanidine, botox, or tetrabenazine on a PRN (as needed) dosing regimen 
prior to the start of this study: 
- Instruct the patient to interrupt treatment as per the table below: 
Medication Treatment interruption period prior 
to baseline visit 
Baclofen 30 days  
Trihexyphenidyl 30 days 
Clonazepam 30 days 
Tizanidine 30 days 
Botox 60 days 
Tetrabenazine 90 days 
 
o Remind the patient that the DBS stimulation parameters or Baclofen 
pump settings must remain stable up to the baseline visit. 
 Schedule next study visit. 
 
Eligibility/Randomization: 
Once the above data have been collected, it should be reviewed against the 
Inclusion/Exclusion Criteria to confirm the patient’s eligibility to enter the trial. If the 
patient is determined to be eligible, complete the Patient Eligibility/Randomization 
Form and submit the completed form signed by the Investigator to ApoPharma Inc. 
 
6.3 Baseline Visit (Day 0) 
 Verify that the dose and dosing regimen of patients treated on a regular dosing 
regimen with a medication that has the potential to have an effect on dystonia 
symptoms prior to start of this study remained stable since the screening visit 
(refer to Appendix 20.3 for a list of medications); 
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 Verify that patients treated with baclofen, trihexyphenidyl, clonazepam, 
tizanidine, botox, or tetrabenazine on a PRN (as needed) dosing regimen prior to 
the start of this study interrupted treatment according to the following table. 
Medication Treatment interruption period prior 
to baseline visit 
Baclofen 30 days 
Trihexyphenidyl 30 days 
Clonazepam 30 days 
Tizanidine 30 days 
Botox 60 days 
Tetrabenazine 90 days 
 
 Verify that the DBS stimulation parameters or Baclofen pump settings remained 
stable since the screening visit 
 Take vital signs (including weight). Patient must be afebrile prior to therapy start;  
 Collect urine sample for pregnancy testing for all sexually active females of 
childbearing potential. A negative result will be required for start of dosing (if 
applicable; In cases where the Investigator determines there is no reasonable risk 
of pregnancy because of significant incapacity, pregnancy testing will not be 
performed); 
 Conduct contraceptive counselling for all sexually active patients; 
 Determine if patient has had any medical events or used any new 
medications/changed medications since the screening visit. If so document them 
as specified in Sections 9.2.1 and 9.2.4.3;  
 Complete the Likert scale; 
 A Qualified Investigator or a qualified delegate must complete the following: 
o Record administration of BAD in a standardized manner on videotape 
and transmit tape to the evaluation center; 
o Complete UPDRS Parts I, II, III and VI; 
o Complete WeeFIM or FIM scales; 
o Complete PedsQL; 
o Complete PSQI scale; 
TIRCON: Deferiprone PKAN Study Protocol           VERSION: Amendment 6 Final 
STUDY CODE: TIRCON2012V1                              DATE: 31 JUL 2013 
Page 34 of 150 
 Perform brain MRI of globus pallidus  (subset of patients ) and transmit to a 
central laboratory for interpretation (to be conducted within one month of 
starting study treatment; will be considered as the baseline procedure); 
 Perform dose calculation; 
 Dispense study medication as per Section 8.4; 
 Instruct the patient on how to take the medication; 
 Remind the patient that all used (empty bottles) and unused medication must be 
returned at Month 1.5 study visit; 
 Remind the patient to carefully keep track of adverse events and medication used; 
 Remind the patient that if treatment is stopped early, patient must return to the 
clinic for an Early Termination Visit as soon as possible, but no later than 1 
month following treatment discontinuation;  
 Remind patients to interrupt therapy immediately if they develop a fever (defined 
as 38.5ºC or greater). Patients must be advised to report promptly to the 
Investigator any symptoms indicative of infection such as fever, and flu-like 
symptoms. 
 Provide patient with an emergency card and advise them to carry this card at all 
times 
 For patients treated prior to start of this study on either a regular or a PRN (as 
needed) dosing regimen with a medication that has the potential to have an effect 
on dystonia symptoms  (refer to Appendix 20.3 for a list of medications): 
- Remind the patient to stay on the same dose and dosing regimen for the 
duration of the study. Any change in dose and dosing regimen should be 
limited to circumstances judged as absolutely necessary by the Investigator  
 Remind the patient that every effort should be made to maintain the same DBS 
stimulation parameters or Baclofen pump settings for the duration of the study. 
Any changes in settings should be limited to circumstances judged as absolutely 
necessary by the Investigator 
 Schedule next study visit. 
 
6.4  Week 1, 2, 3, 4 and 5 Telephone Contacts   
The patient and/or legal representative must be contacted by telephone weekly (every 7 
 3 days) on Weeks 1, 2, 3, 4 and 5 to ensure the treatment is proceeding satisfactorily. 
If the patient appears to be having difficulty with the treatment, patient and/or legal 
representative should be contacted again, as frequently as necessary. 
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Remind the patient/legal representative that if treatment is stopped early, patient must 
return to the clinic for an Early Termination Visit as soon as possible, but no later than 
1 month following treatment discontinuation. 
Remind patients to interrupt therapy immediately if they develop a fever (defined as 
38.5 ºC or greater). Patients must be advised to report promptly to the Investigator any 
symptoms indicative of infection such as fever and flu-like symptoms. 
All telephone contacts must be fully documented as followed: 
 Date and time of contact; 
 Person contacted (patients, parent, legal representative); 
 Remind the patient and/or legal representative of the study medication dose and 
instructions on how to take medication; 
  Any adverse events, serious adverse events or used any concomitant 
medications/therapies. If so, document them as specified in Sections 9.2.4.3, 9.2.4.8 
and 9.2.1; 
 Reconfirm the next study visit; 
 Name and signature of the person contacting the patient. 
 
6.5  Weekly Assessment  
Weekly assessment can be conducted at local laboratories and/or local doctor offices. 
Weekly (every 7  3 days) assessment will consist of the following procedure: 
 Collect blood sample for hematology.  
 
6.6 Month 1.5 Visit (Week 6) 
For patients living far away from study site and with conditions not allowing frequent 
travel, Month 1.5 visit may be conducted at patient’s local doctor office. In that case, 
specific information regarding this study and the procedures for that visit will be given 
to the patient and/or legal representative and local doctor.  
Month 1.5 visit assessments will consist of the following procedures. The visit could 
occur between -7 to +7 days from the indicated visit day. 
 Perform physical examination (to be completed by a Qualified Investigator, or 
qualified delegate); 
 Take vital signs (including weight); 
 Collect blood sample for hematology and biochemistry; 
 Collect blood sample for pregnancy testing for all sexually active females of 
childbearing potential. A negative result will be required for study continuation 
(if applicable; In cases where the Investigator determines there is no reasonable 
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risk of pregnancy because of significant incapacity, pregnancy testing will not 
be performed); 
 Collect urine for urinalysis; 
 Determine if patient has had any adverse events, serious adverse events or used 
any concomitant medications/therapies. If so, document them as specified in 
Sections 9.2.4.3, 9.2.4.8 and 9.2.1; 
 Receive and account for the medication dispensed at the previous applicable visit; 
 Determine, based on the investigator’s evaluation of the patient’s tolerance to 
treatment, if her/his dose can be increased to 10 mg/kg BID; 
 Conduct contraceptive counselling for all sexually active patients; 
 Perform dose calculation; 
 Dispense study medication as per Section 8.4; 
 Instruct the patient on how to take the medication; 
 Remind the patient that all used (empty bottles) and unused medication must be 
returned at Month 3 study visit; 
 Remind the patient to carefully keep track of adverse events and medication used; 
 Remind the patient that if treatment is stopped early, patient must return to the 
clinic for an Early Termination Visit as soon as possible, but no later than 1 
month following treatment discontinuation;  
 Remind patients to interrupt therapy immediately if they develop a fever (defined 
as 38.5 ºC or greater). Patients must be advised to report promptly to the 
Investigator any symptoms indicative of infection such as fever and flu-like 
symptoms. 
 For patients treated on either a regular or a PRN (as needed) dosing regimen with 
a medication that has the potential to have an effect on dystonia symptoms  (refer 
to Appendix 20.3 for a list of medications): 
- Remind the patient to stay on the same dose and dosing regimen for the 
duration of the study. Any change in dose and dosing regimen should be 
limited to circumstances judged as absolutely necessary by the Investigator. 
 Remind the patient that every effort should be made to maintain the same DBS 
stimulation parameters or Baclofen pump settings for the duration of the study. 
Any changes in settings should be limited to circumstances judged as absolutely 
necessary by the Investigator. 
 Schedule next study visit. 
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6.7  Month 2 Telephone Contact (Week 8)   
The patient and/or legal representative must be contacted by telephone on Week 8 to 
ensure the treatment is proceeding satisfactorily. This telephone contact should occur 
between -3 to +3 days from the indicated day. 
If the patient appears to be having difficulty with the treatment, patient and/or legal 
representative should be contacted again, as frequently as necessary. 
Remind the patient/legal representative that if treatment is stopped early, patient must 
return to the clinic for an Early Termination Visit as soon as possible, but no later than 
1 month following treatment discontinuation. 
Remind patients to interrupt therapy immediately if they develop a fever (defined as 
38.5 ºC or greater). Patients must be advised to report promptly to the Investigator any 
symptoms indicative of infection such as fever and flu-like symptoms. 
All telephone contacts must be fully documented as followed: 
 Date and time of contact; 
 Person contacted (patients, parent, legal representative); 
 Remind the patient and/or legal representative of the study medication dose and 
instructions on how to take medication; 
  Any adverse events, serious adverse events or used any concomitant 
medications/therapies. If so, document them as specified in Sections 9.2.4.3, 9.2.4.8 
and 9.2.1; 
 Reconfirm the next study visit; 
 Name and signature of the person contacting the patient. 
 
6.8 Month 3 Visit (week 12) 
For patients living far away from study site and with conditions not allowing frequent 
travel, Month 3 visit may be conducted at patient’s local doctor office. In that case, 
specific information regarding this study and the procedures for that visit will be given 
to the patient and/or legal representative and local doctor.  
Month 3 visit assessments will consist of the following procedures. The visit could 
occur between -7 to +7 days from the indicated visit day. 
 Perform physical examination (to be completed by a Qualified Investigator, or 
qualified delegate); 
 Take vital signs (including weight); 
 Collect blood sample for hematology and biochemistry; 
  Collect blood sample for pregnancy testing for all sexually active females of 
childbearing potential. A negative result will be required for study continuation 
(if applicable; In cases where the Investigator determines there is no reasonable 
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risk of pregnancy because of significant incapacity, pregnancy testing will not 
be performed); 
 Collect urine for urinalysis; 
 Determine if patient has had any adverse events, serious adverse events or used 
any concomitant medications/therapies. If so document them as specified in 
Sections 9.2.4.3, 9.2.4.8 and 9.2.1; 
 Receive and account for the medication dispensed at the previous applicable visit; 
 Conduct contraceptive counselling for all sexually active patients; 
 Determine, based on the investigator’s evaluation of the patient’s tolerance to 
treatment, if her/his dose can be increased to 15 mg/kg BID; 
 Perform dose calculation; 
 Dispense study medication as per Section 8.4; 
 Instruct the patient on how to take the medication; 
 Remind the patient that all used (empty bottles) and unused medication must be 
returned at Month 6 study visit; 
 Remind the patient to carefully keep track of adverse events and medication used; 
 Remind the patient that if treatment is stopped early, patient must return to the 
clinic for an Early Termination Visit as soon as possible, but no later than 1 
month following treatment discontinuation;  
 Remind patients to interrupt therapy immediately if they develop a fever (defined 
as 38.5 ºC or greater). Patients must be advised to report promptly to the 
Investigator any symptoms indicative of infection such as fever and flu-like 
symptoms. 
 Schedule next study visit; 
 Remind patient participating in the pharmacokinetics evaluation that she/he must 
report to the site prior to dosing on Month 6 visit. 
 Instruct the patient and/or parent/legal representative of the following: 
o For patients treated on a regular dosing regimen with a medication that 
has the potential to have an effect on dystonia symptoms  (such 
medication may include, but is not limited to, baclofen, trihexyphenidyl, 
clonazepam, tizanidine, botox, and tetrabenazine):  
- Remind the patient to stay on the same dose and dosing regimen for 
the duration of the study. Any change in dose and dosing regimen 
should be limited to circumstances judged as absolutely necessary by 
the Investigator. 
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o For patients treated with baclofen, trihexyphenidyl, clonazepam, 
tizanidine, botox, or tetrabenazine on a PRN (as needed) dosing regimen: 
- Remind the patient to make an effort to interrupt treatment as per the 
table below. Administration of these medications during this period 
should be limited to circumstances judged as absolutely necessary by 
the Investigator. 
Medication Treatment interruption period prior 
to Month 6 visit 
Baclofen 30 days 
Trihexyphenidyl 30 days 
Clonazepam 30 days 
Tizanidine 30 days 
Botox 60 days 
Tetrabenazine 90 days 
o Remind the patient that every effort should be made to maintain the same 
DBS stimulation parameters or Baclofen pump settings for the duration of 
the study. Any changes in settings should be limited to circumstances 
judged as absolutely necessary by the Investigator. 
 
6.9 Month 6 and Pharmacokinetics Visit (Week 26) 
Patients participating in the pharmacokinetics evaluation must report to the site 
prior to dosing. Month 6 (Week 26) visit assessments will consist of the following 
procedures. The visit could occur between -14 to +14 days from the indicated visit day. 
For the subset of patients participating in the pharmacokinetic evaluation, 
please proceed with the pharmacokinetic assessments as per Section 6.9.1 
below. 
 Verify if any changes were made to the dose and dosing regimen of patients 
treated on a regular dosing regimen with a medication that has the potential to 
have an effect on dystonia symptoms   (refer to Appendix 20.3 for a list of 
medications); 
 Verify if patients treated with baclofen, trihexyphenidyl, clonazepam, tizanidine, 
botox, or tetrabenazine on a PRN (as needed) dosing regimen interrupted 
treatment according to the following table: 
Medication Treatment interruption period prior 
to Month 6 visit 
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Baclofen 30 days 
Trihexyphenidyl 30 days 
Clonazepam 30 days 
Tizanidine 30 days 
Botox 60 days 
Tetrabenazine 90 days 
 
 Verify if any changes were made to DBS stimulation parameters or Baclofen 
pump settings; 
 Complete the Likert scale; 
 A Qualified Investigator or a qualified delegate must complete the following: 
o Perform physical examination; 
o Record administration of BAD in a standardized manner on videotape 
and transmit tape to the evaluation center; 
o Complete UPDRS Parts I, II, III and VI; 
o Complete WeeFIM or FIM scales; 
o Complete PedsQL; 
o Complete PSQI scale; 
o Administer PGI-I scale;  
 Take vital signs (including weight); 
 Collect blood sample for hematology and biochemistry; 
  Collect blood sample for pregnancy testing for all sexually active females of 
childbearing potential. A negative result will be required for study continuation 
(if applicable; In cases where the Investigator determines there is no reasonable 
risk of pregnancy because of significant incapacity, pregnancy testing will not 
be performed); 
 Collect urine for urinalysis; 
 Determine if patient has had any adverse events, serious adverse events or used 
any concomitant medications/therapies. If so document them as specified in 
Sections 9.2.4.3, 9.2.4.8 and 9.2.1; 
 Receive and account for the medication dispensed at the previous applicable visit; 
 Conduct contraceptive counselling for all sexually active patients; 
 Verify/adjust dose level as applicable; 
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 Dispense study medication as per Section 8.4; 
 Instruct the patient on how to take the medication; 
 Remind the patient that all used (empty bottles) and unused medication must be 
returned at Month 12 study visit; 
 Remind the patient to carefully keep track of adverse events and medication used; 
 Remind the patient that if treatment is stopped early, patient must return to the 
clinic for an Early Termination Visit as soon as possible, but no later than 1 
month following treatment discontinuation;  
 Remind patients to interrupt therapy immediately if they develop a fever (defined 
as 38.5 ºC or greater). Patients must be advised to report promptly to the 
Investigator any symptoms indicative of infection such as fever and flu-like 
symptoms. 
 Instruct the patient and/or parent/ legal representative of the following: 
o For patients treated on a regular dosing regimen with a medication that 
has the potential to have an effect on dystonia symptoms (such 
medication may include, but is not limited to baclofen, trihexyphenidyl, 
clonazepam, tizanidine, tetrabenazine and botox): 
- Remind the patient to make an effort to stay on the same dose and 
dosing regimen for the duration of the study. Any change in dose and 
dosing regimen should be limited to circumstances judged as 
absolutely necessary by the Investigator 
o For patients treated with baclofen, trihexyphenidyl, clonazepam, 
tizanidine, botox, or tetrabenazine on a PRN (as needed) dosing regimen: 
- Remind the patient to interrupt treatment as per the table below. 
Administration of these medications during this period should be 
limited to circumstances judged as absolutely necessary by the 
Investigator: 
Medication Treatment interruption period prior 
to Month 12 visit 
Baclofen 30 days 
Trihexyphenidyl 30 days 
Clonazepam 30 days 
Tizanidine 30 days 
Botox 60 days 
Tetrabenazine 90 days 
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o Remind the patient that every effort should be made to maintain the same 
DBS stimulation parameters or Baclofen pump settings for the duration of 
the study. Any changes in settings should be limited to circumstances 
judged as absolutely necessary by the Investigator. 
 Schedule next study visit. 
 
6.9.1  Pharmacokinetics Assessment (Subset of patients)  
Steady state pharmacokinetics of deferiprone and its 3-O-glucuronide metabolite 
will be assessed in a subset of up to 24 patients over 12 hours. In this subset of 
patients please perform the following assessments:  
 Collect pharmacokinetic pre-dose blood sample; 
 Administer dose of study medication; 
 Collect pharmacokinetic blood sample at the following time points post-dose: 1, 
1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours; 
 
6.10  Month 9 Telephone Contact (Week 40)   
The patient and/or legal representative must be contacted by telephone on Month 9 to 
ensure the treatment is proceeding satisfactorily. This telephone contact should occur 
between -7 to +7 days from the indicated day. 
If the patient appears to be having difficulty with the treatment, patient and/or legal 
representative should be contacted again, as frequently as necessary. 
Remind the patient/legal representative that if treatment is stopped early, patient must 
return to the clinic for an Early Termination Visit as soon as possible, but no later than 
1 month following treatment discontinuation. 
Remind patients to interrupt therapy immediately if they develop a fever (defined as 
38.5 ºC or greater). Patients must be advised to report promptly to the Investigator any 
symptoms indicative of infection such as fever and flu-like symptoms. 
All telephone contacts must be fully documented as followed: 
 Date and time of contact; 
 Person contacted (patients, parent, legal representative); 
 Remind the patient and/or legal representative of the study medication dose and 
instructions on how to take medication; 
  Any adverse events, serious adverse events or used any concomitant 
medications/therapies. If so, document them as specified in Sections 9.2.4.3, 9.2.4.8 
and 9.2.1; 
 Reconfirm the next study visit; 
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 Name and signature of the person contacting the patient. 
 
6.11 Month 12 Visit (Week 52) 
Month 12 (Week 52) visit assessments will consist of the following procedures. This 
visit could occur between - 14 to +14 days from the indicated visit day. 
 Verify if any changes were made to the dose and dosing regimen of patients 
treated on a regular dosing regimen with a medication that has the potential to 
have an effect on dystonia symptoms   (refer to Appendix 20.3 for a list of 
medications); 
 Verify if patients treated with baclofen, trihexyphenidyl, clonazepam, tizanidine, 
botox, or tetrabenazine on a PRN (as needed) dosing regimen interrupted 
treatment according to the following table: 
Medication Treatment interruption period prior 
to Month 12 visit 
Baclofen 30 days 
Trihexyphenidyl 30 days 
Clonazepam 30 days 
Tizanidine 30 days 
Botox 60 days 
Tetrabenazine 90 days 
 
 Verify if any changes were made to DBS stimulation parameters or Baclofen 
pump settings;  
 Complete the Likert scale; 
 A Qualified Investigator or a qualified delegate must complete the following: 
o Perform physical examination; 
o Record administration of BAD in a standardized manner on videotape 
and transmit tape to the evaluation center; 
o Complete UPDRS Parts I, II, III and VI; 
o Complete WeeFIM or FIM scales; 
o Complete PedsQL; 
o Complete PSQI scale; 
o Administer PGI-I scale;  
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 Take vital signs (including weight and height); 
 Collect blood sample for hematology and biochemistry; 
  Collect blood sample for pregnancy testing for all sexually active females of 
childbearing potential. A negative result will be required for study continuation 
(if applicable; In cases where the Investigator determines there is no reasonable 
risk of pregnancy because of significant incapacity, pregnancy testing will not 
be performed); 
 Collect urine for urinalysis; 
 Determine if patient has had any adverse events, serious adverse events or used 
any concomitant medications/therapies. If so document them as specified in 
Sections 9.2.4.3, 9.2.4.8 and 9.2.1; 
 Receive and account for the medication dispensed at the previous applicable visit; 
 Conduct contraceptive counselling for all sexually active patients; 
 Verify/adjust dose level as applicable; 
 Dispense study medication as per Section 8.4; 
 Instruct the patient on how to take the medication; 
 Remind the patient that all used (empty bottles) and unused medication must be 
returned at Month 18 study visit; 
 Remind the patient to carefully keep track of adverse events and medication used; 
 Remind the patient that if treatment is stopped early, patient must return to the 
clinic for an Early Termination Visit as soon as possible, but no later than 1 
month following treatment discontinuation;  
 Remind patients to interrupt therapy immediately if they develop a fever (defined 
as 38.5 ºC or greater). Patients must be advised to report promptly to the 
Investigator any symptoms indicative of infection such as fever and flu-like 
symptoms. 
 Instruct the patient and/or parent/ legal representative of the following: 
o For patients on a regular dosing regimen with a medication that has the 
potential to affect dystonia symptoms (such medication may include, but 
is not limited to baclofen, trihexyphenidyl, clonazepam, tizanidine, 
tetrabenazine and botox): 
- Remind the patient to stay on the same dose and dosing regimen for 
the duration of the study. Any change in dose and dosing regimen 
should be limited to circumstances judged as absolutely necessary by 
the Investigator. 
o For patients treated with baclofen, trihexyphenidyl, clonazepam, 
tizanidine, botox, or tetrabenazine on a PRN (as needed) dosing regimen: 
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- Remind the patient to make an effort to interrupt treatment as per the 
table below. Administration of these medications during this period 
should be limited to circumstances judged as absolutely necessary by 
the Investigator: 
Medication Treatment interruption period prior 
to Month 18 visit 
Baclofen 30 days 
Trihexyphenidyl 30 days 
Clonazepam 30 days 
Tizanidine 30 days 
Botox 60 days 
Tetrabenazine 90 days 
 
o Remind the patient that every effort should be made to maintain the same 
DBS stimulation parameters or Baclofen pump settings for the duration of 
the study. Any changes in settings should be limited to circumstances 
judged as absolutely necessary by the Investigator. 
 Schedule next study visit. 
 
6.12  Month 15 Telephone Contact (Week 64)   
The patient and/or legal representative must be contacted by telephone on Month 15 
(week 64) to ensure the treatment is proceeding satisfactorily. This telephone contact 
should occur between -7 to +7 days from the indicated day. 
If the patient appears to be having difficulty with the treatment, patient and/or legal 
representative should be contacted again, as frequently as necessary. 
Remind the patient/legal representative that if treatment is stopped early, patient must 
return to the clinic for an Early Termination Visit as soon as possible, but no later than 
1 month following treatment discontinuation. 
Remind patients to interrupt therapy immediately if they develop a fever (defined as 
38.5 ºC or greater). Patients must be advised to report promptly to the Investigator any 
symptoms indicative of infection such as fever and flu-like symptoms. 
All telephone contacts must be fully documented as followed: 
 Date and time of contact; 
 Person contacted (patients, parent, legal representative); 
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 Remind the patient and/or legal representative of the study medication dose and 
instructions on how to take medication; 
  Any adverse events, serious adverse events or used any concomitant 
medications/therapies. If so, document them as specified in Sections 9.2.4.3, 9.2.4.8 
and 9.2.1; 
 Reconfirm the next study visit; 
 Name and signature of the person contacting the patient. 
 
6.13 Month 18 (Week 78) or Early Termination Visit (End of Study 
Assessment) 
The End of Study assessment (at Week 78   14 days from the start of treatment) or 
Early Termination will consist of the following procedures: 
 Verify if any changes were made to the dose or dosing regimen of patients treated 
on a regular dosing regimen with a medication that has the potential to have an 
effect on dystonia symptoms   (refer to Appendix 20.3 for a list of medications); 
 Verify if patients treated with baclofen, trihexyphenidyl, clonazepam, tizanidine, 
botox, or tetrabenazine on a PRN (as needed) dosing regimen  interrupted 
treatment according to the following table: 
Medication Treatment interruption period prior 
to Month 18 visit 
Baclofen 30 days 
Trihexyphenidyl 30 days 
Clonazepam 30 days 
Tizanidine 30 days 
Botox 60 days 
Tetrabenazine 90 days 
 
 Verify if any changes were made to DBS stimulation parameters or Baclofen 
pump settings; 
 Complete the Likert scale; 
 A Qualified Investigator or a qualified delegate must complete the following: 
o Perform physical examination; 
o Record administration of BAD in a standardized manner on videotape 
and transmit tape to the evaluation center; 
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o Complete UPDRS Parts I, II, III and VI;  
o Complete WeeFIM or FIM scales; 
o Complete PedsQL; 
o Complete PSQI scale; 
o Administer PGI-I scale; 
 Take vital signs (including weight and height); 
 Perform 12-lead ECG; 
 Review medical history and concurrent medications; 
 Collect blood sample for hematology and biochemistry;  
 Collect blood sample for pregnancy testing for all sexually active females of 
childbearing potential (if applicable; In cases where the Investigator determines 
there is no reasonable risk of pregnancy because of significant incapacity, 
pregnancy testing will not be performed); 
 Collect urine for urinalysis; 
 Conduct contraceptive counselling for all sexually active patients; 
 Determine if patient has had any adverse events, serious adverse events or used 
any concomitant medications/therapies. If so document them as specified in 
Sections 9.2.4.3, 9.2.4.8 and 9.2.1; 
 Perform brain MRI of globus pallidus (subset of patients ) and transmit to a 
central laboratory for interpretation; 
 Receive and account for the medication dispensed at the previous applicable visit; 
 Explain to the patient that she or he should inform the site if the she/he experience 
any serious medical problems (SAEs) in the 30 days following the last dose; 
 Schedule follow-up study visit, as applicable. 
 
Any ongoing AEs and/or SAEs should be followed until one of the following: 
o Resolution OR  
o Condition stabilizes OR  
o Event is otherwise explained OR  
o Lost to Follow-up. 
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6.14 Premature Discontinuation (Early Termination) 
Patients can be withdrawn from the study at any time. Reasons for withdrawal will be 
documented in the eCRF and early termination visit procedures should be performed 
within 1 month of treatment discontinuation. 
These data should be recorded and entered in the study database, as they comprise 
essential evaluations that should be done prior to discharging any patient from the 
study. 
 
6.15 Follow-Up Visit 
A follow-up visit will occur 4 weeks following Month 18 or Early Termination Visit. 
This visit will be conducted only in patients not enrolled in maintenance protocol or 
compassionate use program (if applicable). The following assessments will be 
performed: 
 Review prior and current concomitant medications/therapies; 
 Perform physical examination; 
 Collect blood sample for hematology; 
 Take vital signs, including weight;  
 Collect AEs that have occurred within 14 days after treatment discontinuation; 
 Determine if patient has had any serious adverse events in the 30 days following 
the last dose. If so document them as specified in Section 9.2.4.8. 
 
7 TREATMENT 
7.1 Study Medication 
The treatment phase of the study will last for 18 months, beginning on the day of the 
first dose of the study medication.  Dispense the study medication as per Section 8.4. 
Eligible patients will receive deferiprone oral solution 80 mg/ml (ApoPharma Toronto, 
Ontario, Canada) or the matching placebo oral solution.   
Patients are to be administered deferiprone or placebo in a double-blinded fashion twice 
daily (BID). The minimum interval between doses of deferiprone should be eight (8) 
hours.  If a dose is missed the patient should receive it at the earliest opportunity, as 
long as it is at least eight (8) hours before the next dose. The patient should never 
receive more than two doses within a 24-hour period. A 24-hour period of deferiprone 
will be from 00:01 hours until 24:00 hours on the following night. Doses must never be 
doubled up. Deferiprone may be taken with or without food, but if patients experience 
nausea or vomiting, it may help to take Deferiprone with some food. If necessary, the 
total daily dose of study medication will be adjusted to maintain the prescribed dose 
weight ratio during study visits. 
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Patients will initiate deferiprone at a dose of 5 mg/kg BID for the first 6 weeks. If the 
dose is tolerated and there are no signs of toxicity, the dose will be increased to 10 
mg/kg BID for the following 6 weeks. Again, if tolerated and there are no signs of drug 
toxicity, the dose will be increased to 15 mg/kg BID for the remainder of the study.  
The dose may be adjusted during the study depending on tolerability, assessment of 
safety markers for adverse reactions that are possibly dose dependent such as 
gastrointestinal upset, increases in serum liver enzymes levels and arthropathies. For 
patients in whom a clinically significant decrease in serum ferritin is observed, iron 
supplements may be administered at the Investigator’s discretion.  
As per Section 4.6.5 and 4.6.6 of the ICH Consolidated Guideline on GCP, the 
investigator is responsible to ensure that the investigational products are used only in 
accordance with the approved protocol; that the correct use of the medication has been 
clearly explained by the investigator or delegate to each patient and that the patient 
continues to take the medication according to those instructions throughout the trial. 
If the preliminary evidence indicates deferiprone is safe and effective in patients with 
PKAN, a compassionate use of deferiprone may be offered to patients (irrespective of 
whether they were in the deferiprone or in the placebo arm) until approval of 
deferiprone for use in patients with PKAN, or until termination of development of 
deferiprone for PKAN.  
 
7.2 Rationale for Selection of Doses 
Two published studies, evaluating the safety and efficacy of the use of deferiprone in 
PKAN patients, were used to establish the selection of doses used in this study.  
The first study was a 12-month, multi-center, unblinded, single-arm pilot study that was 
conducted to evaluate the safety and efficacy of deferiprone for reducing cerebral iron 
accumulation in patients with a clinical diagnosis of NBIA (Abbruzzese G et al. 2011).  
Four patients with genetically-confirmed PKAN, and two with parkinsonism and focal 
dystonia (specific condition unidentified due to inconclusive genetic tests) received 15 
mg/kg deferiprone twice a day. Magnetic resonance imaging and neurological 
examinations were conducted at baseline, 6 and 12 months.  
Chelation treatment caused no apparent hematologic or neurologic side effects. 
Magnetic resonance imaging quantitative iron assessment on three patients (due to the 
presence of signal interferences from metallic oral devices in other patients) revealed 
decreased iron accumulation in the globus pallidus of the three patients. Clinical rating 
scales (UPDRS/III, UDRS and ICARS) and blinded video rating evaluations 
documented mild-to-moderate motor improvement in three patients.  
These results suggest that chelating treatment might be effective in improving 
neurologic manifestations associated with iron accumulation. 
The second study was a 6-month pilot study conducted to evaluate the safety and 
efficacy of deferiprone in 10 patients affected by PKAN (Zorzi G et al. 2011). 
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Patients received deferiprone 25 mg/kg/day orally in two divided doses (12.5 mg/kg 
twice a day) for 6 months.  
Deferiprone was well tolerated overall, and associated with a significant median 
reduction in globus pallidus iron content, as assessed by magnetic resonance imaging.  
There was no change in the scores, using the Burke-Fahn and Marsden Dystonia Rating 
scales. However, the authors concluded that future trials with a longer treatment period 
are warranted.  
In addition to the published literature cases and studies on patients with PKAN, two 
case reports demonstrating the effect of deferiprone in patients with PKAN were made 
available through the Company’s compassionate use program. Both PKAN cases were 
patients of Dr. Elliott Vichinsky from the Children’s Hospital and Research Center in 
Oakland, United States.  
The first case was a young, third-grade (8-year-old) patient diagnosed with PKAN. In 
March 2006, he underwent placement of bilateral DBS in hopes of reducing symptoms 
of dystonia. He continued to deteriorate.  
Deferiprone was obtained in November 2007 under a treatment Investigational New 
Drug (IND). Deferiprone therapy was initiated at 20 mg/kg/day and gradually increased 
to 30 mg/kg/day. At that time, he was wheelchair-dependent with major dystonic 
movements and had difficulty speaking.  
During the 15 months of treatment with weekly laboratory testing, he demonstrated no 
significant laboratory abnormalities. Significant clinical improvement was noted. 
The second case was a 12-year-old patient with PKAN who began deferiprone 
treatment for severe progressive dystonia and spastic cerebral palsy with opisthotonic 
posturing. He was unable to sit in a wheelchair and could only be accommodated in a 
wagon. He was also legally blind secondary to retinitis pigmentosa and unable to speak. 
Prior to age 10, the child had no physical limitations. At age 10 he had a rapid clinical 
deterioration, despite interventions including DBS and intrathecal baclofen.  
Since September 2009 the patient has been maintained on deferiprone at dose of 28 
mg/kg/day (14 mg/kg BID). There has been a dramatic progressive improvement in the 
patient’s condition that has resulted in national attention by the media and the NBIA 
Disorders Association. In January 2010, he was able to sit in a wheelchair with 
improved head control and muscle strength.  He was able to purposefully move his arms 
above his head and relax his hands. Fine motor skills improved; with his index finger he 
could activate his wheelchair. His range of motion and activities of daily life improved. 
For the first time, he sustained oral rather than nasogastric feeding. His pain scale 
ratings using a Face, Legs, Arm, Cry, Consolability Scale (FLACC) were significantly 
lower. In April 2010, he was talking in phrases of 2 to 5 words long. His neck spasms 
significantly decreased. In the last year, the patient has continued to make progress and 
is undergoing surgical correction of his contracture with the goal of ambulation outside 
of a wheelchair. He continues to show no toxicity from deferiprone therapy. 
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An additional PKAN case treated with deferiprone was reported in Italy (Zuccarelli A et 
al. 2008). The patient was diagnosed with PKAN in June 2005, when she was 8 years 
old.  
Clinical situation did not improve but got progressively worse after the patient started 
taking pantothenic acid, idebenone and baclofen. The patient started therapy with 
deferiprone in December 2007, at 25 mg/kg in a single morning dose. The patient 
tolerated the therapy well and clinical conditions improved. There was improvement in 
the muscle tone of her limbs, a reduction in the excursion of the tibiotarsal joints and the 
patient has also started to eat autonomously, say a few words and take a few steps 
without support.  
 
The proposed starting dose for this study is 5 mg/kg BID; lower than the doses 
described in literature that have been well tolerated by PKAN patients. Patients’ dose 
will be increased (to a maximum of 15 mg/kg BID) only after safety and tolerability 
have been demonstrated at this low dose.  
 
7.3 Concomitant Therapy 
Medications considered necessary for the patient’s welfare may be given at the 
discretion of the Investigator.  The administration of all medication (including study 
product) must be recorded in the source document and the appropriate sections of the 
eCRF.  During treatment with deferiprone oral solution, patients must not receive any 
other investigational product or any drugs that are known to cause neutropenia or 
agranulocytosis. See Appendix 20.4 for list of prohibited drugs. 
 
7.4 Rescue Medication 
The use of rescue medication should be limited to circumstances judged as absolutely 
necessary by the Investigator. Rescue medication is defined as the introduction of a new 
medication, or a change in dosing of a current medication, that is prescribed because of 
a worsening of the patient’s condition and that has the potential to have an effect on 
dystonia symptoms. Such medication may include, but are not limited to baclofen, 
trihexyphenidyl, clonazepam, tizanidine, tetrabenazine and botox. If a patient is 
administered rescue medications for more than two events, the Investigator should 
notify the Sponsor to discuss the patient’s continued participation in the study. A list of 
rescue medications is provided in Appendix 20.3. 
7.5 Treatment Compliance 
Patients will be instructed on how to take the study medication. Compliance will be 
evaluated by calculating the volume of medication dispensed and the volume of unused 
drug supply remaining in the bottle. The investigator should discuss compliance with 
the patient and, if applicable, his/her parent or legal representative at each visit. 
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8 MATERIALS AND SUPPLIES  
8.1 Study Medication  
Deferiprone oral solution, 80 mg/mL and the matching placebo oral solution will be 
manufactured and distributed by Apotex Inc., Richmond Hill, Ontario, Canada and will 
have been tested and released according to relevant standards and regulations.  
All study medication will be supplied to study sites by the Sponsor. 
 
8.2 Packaging and Labelling 
All study medication will be supplied in 500 mL round amber PET bottles with white 
polypropylene child-resistant pictorial caps and with syringes for dosing.  
The contents of the label will be in accordance with all applicable regulatory 
requirements. The label will include protocol number, expiry date, lot/batch number, 
investigational statement, storage temperature, study medication bottle number, dosage 
and name and address of the Sponsor. 
 
8.3 Storage and Disposition of Study Medications 
A “Product Receipt Form and Temperature Verification log”, will be provided by the 
Sponsor with each shipment of investigational product to each study site.  The 
Investigator or designate will sign and date this receipt to acknowledge receiving the 
product and add the time the “TempTale 4” (Sensitech Inc.) monitoring device was 
removed and stopped.  The Investigator will fax a copy of this receipt form to the 
Sponsor and retain the original in their Master File. 
After receipt of a supply of the study medication(s) by the Investigator or designate, the 
study medication will be stored in a locked room/cabinet at each site. The supply of 
study medication will be kept at room temperature (15-30ºC) in a secure location under 
the control of the Investigator. The clinical centres will use a digital temperature 
monitoring device and a temperature log to facilitate daily recording of the temperature 
of the study medication storage facility.  
 
8.4 Drug Dispensing Procedures  
Patients will be dispensed study medication at baseline, and Months 1.5, 3, 6 and 12 
visits. Dispensing of study medication should be done by appropriately qualified staff 
(i.e. Physician, Pharmacist, Nurse).  
 Patients reporting that their medication has been lost or misplaced will be asked to 
attend the study site to receive replacement medication. This visit will be an 
Unscheduled Visit and details of this visit will be recorded in the eCRF. Requests for 
replacement must be made in writing to the Clinical Research Associate (CRA), who 
will review and forward the request for replacement drug to the Sponsor, who will 
ensure that the site is supplied with appropriate treatment. All information related to 
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lost/misplaced medication and the replacement medication will be recorded in the drug 
accountability forms. 
 
8.5 Study Medications Accountability and Inventory Control 
A “Site Investigational Drug Inventory Record” and “Patient Investigational Drug 
Dispensing Record” form will be provided by the Sponsor to the Investigator.   
Investigational product accountability lies with the Investigator at all times.  The 
Investigator must maintain an updated Site Investigational Drug Inventory Record at the 
study site.  This log will include: 
 Name of Sponsor 
 Name of Investigator 
 Study identifier 
 Date and quantity of investigational product received from the Sponsor 
 Lot/Batch number 
 Study medication bottle number 
For each patient, the Investigator must maintain an updated Patient Investigational Drug 
Dispensing Record. This log will include: 
 Patient identification number 
 Date of dispensing and return 
 Dispenser’s initials 
 Quantity dispensed and returned 
 Study medication bottle number 
Patients will be instructed on the administration of the investigational product. 
At the conclusion of the study, a final inventory must be performed by the investigator 
(or delegate). If any bottles or quantity of medication in a bottle are missing, this must 
be indicated on the study drug accountability form, together with an explanation of the 
discrepancy. These forms must be available for clinical monitoring as well as for audit 
and regulatory authority inspection purposes at any time.  
All investigational products that have been returned by the patient or that are unused for 
any other reasons will be returned to the Sponsor or discarded at the pharmacy 
according to their internal procedures which must include the issuance of appropriate 
signed destruction certificates including mode of destruction and complete drug 
accountability of destroyed materials. 
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9 MEASUREMENTS AND EVALUATIONS 
The following efficacy and safety measurements/evaluations will be performed at visits 
outlined in Appendix 20.1 – Schedule of Events.  
 
9.1 Efficacy 
 9.1.1 Barry-Albright Dystonia Scale 
Dystonia is defined as sustained muscle contractions causing twisting and repetitive 
movements or abnormal postures. The Barry-Albright Dystonia (BAD) scale is a 
reliable and responsive rating scale for dystonia that interferes with function. It consists 
of a five-point ordinal scale for secondary dystonia, which rates severity of dystonia in 
eight body regions; eyes, mouth, neck, trunk, each upper and each lower extremity 
(Barry MJ et al. 1999). The individual scores will be summed to provide a total score. 
The BAD total score ranges from 0 to 32 and the larger the score is, the more severe the 
patient’s dystonia is (Appendix 20.5.1). 
 
The BAD scale will be administered at screening, baseline, Months 6, 12 and 18 (or 
early termination visit) study visits. 
 
An Operations Manual will be prepared by a selected group of experts to define a 
standardized way to administer and read the BAD test. The standardized administration 
will include a provocation test to better capture episodic or non-continuous symptoms. 
The BAD scale will be completed at screening by a qualified Investigator or a qualified 
delegate. At the baseline, Months 6, 12 and 18 (or early termination visit) study visits, a 
qualified Investigator will administer and video-record the administration of the BAD 
test and transmit the videotape to a designated center of experts for objective 
evaluation.Results will be entered by the study site staff in the eCRF. 
 
 9.1.2 Patient’s Global Impression of Improvement 
The Patient Global Impression of Improvement (PGI-I) is a global index used to rate the 
response of a condition to a therapy. Patient will be asked at Month 6, 12 and 18 (or 
early termination visit) study visits to rate their total improvement since the beginning 
of the study. A 7 point rating scale will be used as: 1, very much improved; 2, much 
improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 
7, very much worse (Appendix 20.5.2). In cases where the patient cannot complete the 
scale by him/herself, the parent or legal representative will complete the scale. 
Results will be entered by the study site staff in the eCRF. 
  
 9.1.3 Globus Pallidus MRI  
Neurodegeneration in patients with PKAN appears to be related to the intracellular 
mismanagement of iron, resulting in localized brain iron accumulation, iron toxicity and 
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eventually cell death. The regions of the brain with the highest amounts of iron 
accumulation include those that control motor output; specifically, the globus pallidus.  
 
An MRI scan will be performed at baseline and Month 18 (or early termination visit) 
study visits in a subset of patients without deep brain stimulators for whom the use of 
anesthesia (if required for the MRI scan) is deemed acceptable based on Investigator’s 
judgement. MRI of the globus pallidus will be transferred to the Newcastle Magnetic 
Resonance Centre at the University of Newcastle and assessed by staff blinded to study 
treatment. R2* will be measured directly from the R2* map which will be calculated 
from the multiGE sequence.  Results will be entered by the study site staff in the eCRF. 
 
 9.1.4 UPDRS  
The Unified Parkinson’s Disease Rating Scale (UPDRS) has long been the major rating 
scale that is used to assess severity of symptoms of Parkinson’s disease. The original 
version of the scale assessed daily activities, motor skills and mental capacity (including 
behavior and mood). An updated version of the scale was recently developed. The 
updated version adds new assessments of non-motor symptoms. The UPDRS scale is 
made up of the following sections: Part I: Mentation, Behaviour and Mood; Part II: 
Activities of Daily Living; Part III: Motor Examination; Part IV: Complications of 
Therapy; Part V: Modified Hoehn and Yahr staging; and Part VI: Schwab and England 
Activities of Daily Living Scale (Appendix 20.5.3). 
The Investigator or qualified delegate will complete Parts I, II, III and VI at baseline, 
Months 6, 12 and 18 (or early termination visit) study visits. Results will be entered by 
the study site staff in the eCRF. 
 
 9.1.5 WeeFIM scale (or FIM score for patients > 18 years) 
The Functional Independence Measure (FIM) (Appendix 20.5.4) or pediatric version 
(WeeFIM) (Appendix 20.5.5) scale assesses physical and cognitive disability in four 
areas (self care, mobility, communication and social cognition). Items are scored on the 
level of assistance required for an individual to perform activities of daily living; a score 
of 1-2 indicates that the patient is completely dependent on a helper to perform the 
tasks, a score of 3-5 indicates that the patient is moderately dependent on a helper to 
perform the tasks and a score of 6-7 indicates that no help is required to perform the 
tasks. Scores from each of the four areas are added to obtain the global FIM score.  
 
The Investigator or qualified delegate will complete the WeeFIM or FIM scales at 
baseline, Months 6, 12 and 18 (or early termination visit) study visits. Results will be 
entered by the study site staff in the eCRF. 
 
 9.1.6 Peds QL  
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The Pediatric Quality of Life (Peds QL) is a questionnaire used to measure functional 
health and well-being from the patient's point of view. Versions of the Peds QL 
questionnaire exist for children, young adults (18-25 yrs) and for adults (>25 yrs). 
Patients are asked to complete the survey based on how they have felt over the past 4 
weeks (1 month). Twenty-three questions are used to generate an overall score 
(Appendix 20.5.6).  
 
The Peds QL will be completed by the patient or legal representative at baseline, 
Months 6, 12 and 18 (or early termination visit) study visits. Results will be entered by 
the study site staff in the eCRF. 
 
 9.1.7 Pittsburgh Sleep Quality Index PSQI 
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses 
sleep quality and disturbances over a 1-month time interval. Nineteen individual items 
generate seven “component” scores: Subjective sleep quality, sleep latency, sleep 
duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and 
daytime dysfunction (Appendix 20.5.7). 
 
The PSQI will be completed by the patient or legal representative at baseline, Months 6, 
12 and 18 (or early termination visit) study visits. Results will be entered by the study 
site staff  in the eCRF. 
 
9.1.8 Likert Scale 
The Likert scale is a psychometric scale used in this study to rate the patient’s state with 
regards to its PKAN symptoms on a specific day. Patients will be asked at Baseline, 
Month 6, 12 and 18 (or early termination visit) study visits how they would rate their 
day with regards to their PKAN symptoms on that day. A 5 point rating scale will be 
used as: 1, very good; 2, good; 3, neutral; 4, bad; 5, very bad (Appendix 20.5.8). In 
cases where the patient cannot complete the scale by him/herself, the parent or legal 
representative will complete the scale. 
Results will be entered by the study site staff in the eCRF. 
 
Notable improvements or worsening in patient’s condition, which are not captured by 
the relevant scales will be documented. 
 
 
9.2 Safety 
The Investigator is responsible for monitoring the safety of patients who have entered 
the study.  Safety and tolerability of deferiprone oral solution will be assessed during 
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the study by physical examinations, clinical laboratory tests and spontaneous reporting 
of symptoms by patients, nursing and physicians’ observations. 
 
9.2.1 Medical History, Physical Examination, Vital Signs and Prior and 
Concomitant Medication/Therapy Use 
 Medical history will be performed at screening and reviewed at Month18 (or early 
termination visit) study visits. History of PKAN symptoms, including dystonia, 
will be collected for the two years prior to the screening visit. Only 
improvements of certain conditions will captured at Month 18, as any 
worsening/new occurrences will be captured as AEs. 
 
 Physical examination will consist of an exam of the head, ears, eyes, nose, throat 
and neck, the respiratory system, cardiovascular system, gastrointestinal system, 
musculoskeletal system, central and peripheral system, skin, thyroid and general 
constitution. Physical examination will be performed at screening, baseline, 
Month 1.5, 3, 6, 12 and 18 (or early termination visit) study visits. Any 
abnormalities noted at the screening and baseline visits will be recorded as 
medical history while any abnormalities noted during treatment will be recorded 
as adverse events. 
 
 Vital signs (temperature, and resting heart rate, respiration rate and blood 
pressure) and weight will be taken at screening and each study visit. Height will 
be measured only at screening, Month 12 and 18 (or early termination) study 
visits. 
 
 Information about prior or concomitant medications/therapies will be collected at 
each study visit following start of dosing with deferiprone. The following must 
be recorded in the Source Documents and eCRFs: 
 
o All medications used within 3 months prior to the screening visit; 
 
o All medications and therapies taken for dystonia symptoms, including 
DBS, within two years prior to the screening visit and during the study 
 Frequency of change and reason for change in dosage and settings 
must also be documented 
 
o Any medications that the patient continues to take during the trial; 
 
o Any medications which the patient starts to take during the trial. 
 
o The name, dose, route, frequency, indication, and start and stop dates of 
all medications used during the trial must be noted in the Source 
Documents and eCRFs as well as whether or not the medication was 
used to treat a medical event/adverse event. 
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9.2.2 Clinical Laboratory Tests 
Lab reports must be reviewed and interpreted by the investigator. Any clinically 
relevant changes which are not part of a larger medical condition which is already 
recorded as an adverse event, and which occur during the trial must be recorded on the 
source documents and the Adverse Events section of the eCRF. 
 
The following clinical laboratory tests will be performed: 
 
Hematology: 
Hematology assessments (full blood test including total WBC, ANC, platelet count and 
haemoglobin) will be performed at screening, baseline and weekly after the start of 
dosing.  
 
Biochemistry: 
Biochemistry assessments will be performed at the screening and Month 1.5, 3, 6, 12 
and 18 (or early termination) study visits. Biochemistry evaluation will consist of serum 
ferritin; total protein; GGT; LDH; sodium, potassium, chloride, glucose; total, direct 
and indirect bilirubin; AST; ALT; albumin; blood urea nitrogen; calcium; creatinine; 
uric acid; alkaline phosphatase; and amylase. 
 
Serology: 
Serology assessments will be performed at screening visit. Serology evaluation will 
consist of HIV testing. 
 
Urinalysis: 
Urinalysis assessments will be performed at screening and Month 1.5, 3, 6, 12 and 18 
(or early termination) study visits. Urinalysis evaluation will consist of pH, specific 
gravity, glucose, protein, ketones, blood by urine dipstick. If indicated by the dipstick, 
sediment microscopy will be performed. 
 
Pregnancy Test: 
Serum pregnancy tests will be performed at screening and Month 1.5, 3, 6, 12 and 18 
(or early termination) study visits for all sexually active females of childbearing 
potential (if applicable)*. Urine pregnancy test will be performed at the baseline visit 
for all sexually active females of childbearing potential (if applicable)*. 
 
* In cases where the Investigator determines there is no reasonable risk of pregnancy 
because of significant incapacity, pregnancy testing will not be performed 
 
9.2.3 ECG 
A standard 12-lead ECG shall be performed at screening and Month 18 (or early 
termination) study visits. At a minimum, the following parameters will be assessed: HR, 
PR, QRS, QT, QTcF, QTcB. 12-Lead ECG will be interpreted by local cardiologists. 
The overall interpretation will also be documented. 
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9.2.4 Adverse/Medical Events and Serious Adverse Events 
All adverse/medical events encountered during the study will be reported on the source 
documents and the eCRF and carefully monitored and assessed in terms of their 
seriousness, severity, and relationship to the study or study drug.  Adverse/medical 
events will be followed until the event is resolved or explained or the patient is lost to 
follow up.  It is the responsibility of the Investigator to ensure that adequate medical 
care is provided to patients during the study.  All SAEs occurring within 30 days 
following the completion/discontinuation of the study must be reported to the Sponsor 
regardless of the suspected drug/event causal relationship.  SAEs for which the 
Investigator suspects causal relationship to the study drug must be reported to the 
Sponsor irrespective of the time elapsed since the last dose of the study drug. 
 
9.2.4.1 Definition of Medical/Adverse Events 
Medical Event: Any new untoward medical occurrence or worsening of a pre-existing 
condition in a patient that occurs after signing the ICF, but before receiving an 
investigational product.  
 
Adverse Event:  An AE is any untoward medical occurrence in a clinical investigation 
in a patient administered a pharmaceutical or other therapeutic product, not necessarily 
having a causal relationship with this treatment. An AE can therefore be any 
unfavourable and unintended sign, symptom or disease temporally associated with the 
use of a product, whether or not considered related to that product. 
 
An AE does include: 
 exacerbation of a pre-existing illness 
 an increase in frequency or intensity of a pre-existing episodic event or condition 
 a condition detected or diagnosed after study treatment administration, even 
though it may have been present prior to the start of the study 
 a continuous persistent disease or symptom present at baseline that worsens 
following the start of the study 
 
An AE does not include: 
 a pre-existing disease or condition present or detected at the start of the study that 
does not worsen 
 the disease or disorder being studied, or a sign or symptom associated with the 
disease or disorder, unless it has worsened 
 an overdose of either the study treatment or concurrent medication without any 
signs of symptoms 
 
9.2.4.2 Adverse/Medical Event Considerations 
Note that the definition of AEs/MEs could include accidents (e.g., motor vehicle 
accidents) and the reasons for changes in concomitant medication (drug and/or dose), 
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medical, nursing and/or pharmacy consultation, admission to hospital and surgical 
operations, and the worsening of a pre-existing medical condition. 
Planned hospital admissions and/or surgical operations/procedures for an illness or 
disease that existed before the investigational product was given or the patient was 
enrolled in a clinical trial are not to be considered AEs/MEs, unless a worsening of the 
illness or disease lead to an earlier hospitalization. 
If a patient’s dosage is reduced or treatment is discontinued as a result of an AE, study 
site personnel must clearly document the circumstances and data leading to any such 
dosage reduction or discontinuation of treatment. 
Prior to enrolment, study site personnel will note the occurrence and nature of each 
patient’s medical condition(s) in the source documents and the appropriate section of 
the eCRF.  During the study, site personnel will again note any change in the 
condition(s) and the occurrence and nature of any AEs/MEs. 
Laboratory results will be recorded in a central database. Nonetheless abnormal 
laboratory findings (e.g., clinical chemistry, hematology, urinalysis), ECG 
abnormalities or other abnormal assessments (e.g. vital signs) which are not part of a 
larger medical condition which is already recorded as an adverse event and which are 
judged by the investigator to be clinically significant must be recorded as AEs or SAEs 
if they meet the definition of an AE as defined in Section 9.2.4.1 or SAE as defined in 
Section 9.2.4.6. The investigator should exercise his or her medical and scientific 
judgement in deciding whether an abnormal laboratory finding or other abnormal 
assessment is clinically significant. 
9.2.4.3 Procedures for Adverse/Medical Event Monitoring and Recording 
MEs will be collected from the time the ICF is signed and AEs will be collected from 
the time the treatment starts. 
Patients will be instructed to report AEs/MEs to the Investigator.  Reports of adverse 
events will be elicited using a verbal probe and recorded in the source documentation 
and on the Adverse Event page of the Case Report Form. The investigator or delegate 
should always ask the same open-ended and non-leading verbal questioning of the 
patient should be used to inquire about AE/ME occurrence.  Appropriate questions 
include: 
“How are you feeling?” or “How do you feel?” or for pediatric studies, “How does your 
child seem to feel?” 
“Have you had any (other) medical problems since your last visit/assessment?” or 
“Have you felt any different in any way since starting the new medication/treatment or 
since your last visit/assessment?” or for pediatric studies, “Has your child had any 
(other) medical problem or seemed to act differently in any way since his/her last 
visit/assessment?” 
“Have you taken any new medicines, other than those provided in this study, since your 
last visit/assessment?” or for pediatric studies, “Has your child needed to take any 
medicines, other than those provided in this study, since his/her last visit/assessment?” 
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Based on the patient’s response to this question, the investigator should ask additional 
questions relevant to the specific complaint, such as: 
 How severe is/was the symptom? 
 How often did the symptom occur? 
 How long did the symptom last? 
 
All AEs/MEs will be recorded and evaluated for their seriousness, severity, and 
relationship to the investigational product or study by the Investigator.   
The investigator should attempt to establish a diagnosis of the Adverse Event based on 
signs, symptoms, and/or other clinical information. Wherever possible, a diagnosis 
should be documented rather than the individual signs/symptoms.  
The investigator must also question the patient about any previously reported adverse 
events that have not resolved.  
The investigator will then rate the intensity, seriousness, and causality of the AEs and 
will also document any measures taken to address the AE. Causality should be rated in 
terms of relationship to the study medication as follows: not related, possibly related, 
probably related, definitely related. See Section 9.2.4.4 for further definitions of 
relationship to study medication. All of this information should be clearly recorded in 
the Source Documents. 
The investigator should employ this probe at each assessment. AEs will be collected 
throughout the study. 
All AEs must be followed until resolution, until the condition stabilizes, until the event 
is otherwise explained, or until the patient is lost to follow-up. The investigator is 
responsible to ensure that follow-up includes any supplemental investigations as may be 
indicated to elucidate as completely as practical the nature and/or causality of the AE. 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals. 
 
9.2.4.4 Causality 
The relationship of an adverse event to study drug should be determined by the 
Investigator or study physician after thorough consideration of all facts that are 
available. Assessment of causality is based on considering associative connections (time 
or place), pharmacological explanations, previous knowledge of the drug, presence of 
characteristic clinical or pathological phenomena, exclusion of other causes, and/or 
absence of alternative explanations. The causal relationship of an adverse event to study 
drug will be assessed according to the following criteria (based on World Health 
Organization definitions): 
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Not related:  Temporal relationship to study drug administration is missing or 
implausible, or there is no evident cause. 
 
Possibly related:   Reasonable time sequence to administration of study drug, but event 
could also be explained by concurrent disease or other drugs or 
chemicals - information on drug withdrawal could also be lacking. 
 
Probably related:  Reasonable time sequence to administration of study drug, but 
unlikely to be attributed to concurrent disease or other drugs or 
chemicals, and which follows a clinically reasonable response on 
withdrawal (de-challenge). Re-challenge information is not required. 
 
Definitely related: Plausible time relationship to study drug administration; event cannot 
be explained by concurrent disease or other drugs or chemicals. The 
response to withdrawal of the drug (de-challenge) should be 
clinically plausible. The event must be definitive pharmacologically 
or phenomenologically, using a satisfactory rechallenge procedure if 
necessary.  
 
9.2.4.5 Severity 
Severity refers to the accumulated intensity of discomfort/impairment of health since 
the last recording of AEs.  The investigator will rate the intensity, seriousness, and 
causality of the AEs. To achieve maximum consistency in the assessment of severity of 
adverse/medical events, it is recommended that National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE) scale be used whenever 
possible, to assist the investigator in determining the severity of adverse/medical event.  
Severity of adverse/medical events will be reported on the CRF as mild, moderate, or 
severe according to the definitions provided below. Grading based on CTCAE scale 
will not be entered into the CRFs. 
Severity Corresponding 
NCI CTCAE Grade 
Mild: awareness of a sign or symptom but easily tolerated 1 
Moderate: discomfort sufficient to cause interference with 
normal daily activities 
2 
Severe: resulting in inability to do work or perform normal 
daily activities 
3-5 
 
9.2.4.6 Serious Adverse Event 
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An SAE is any adverse event occurring at any dose that results in any of the following 
outcomes: 
 
1) Death 
2) A life-threatening adverse event 
3) Inpatient hospitalization or prolongation of existing hospitalization 
4) A persistent or significant disability or incapacity 
 5) A congenital anomaly in the offspring of a patient who received the study 
treatment 
 6) Important medical events that may not result in death, be life threatening, or 
require hospitalization but which in the investigator’s judgement may jeopardize 
the patient and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition. Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, blood dyscrasias or convulsions that do not result in inpatient 
hospitalization, or the development of drug dependency or treatment-related 
substance abuse.  
 
Clarifications: 
 Life threatening means that the patient was, in the view of the investigator, 
at immediate risk of death from the event as it occurred. This definition does 
not include an event that, had it occurred in a more severe form, might have 
caused death. 
 Hospitalisation for elective treatment of a pre-existing condition that did not 
worsen during the study is not considered an AE. 
 Complications that occur during hospitalisation are AEs. If a complication 
prolongs hospitalisation, the event is an SAE. 
 “Inpatient” hospitalisation means the patient has been formally admitted to a 
hospital for medical reasons. This may or may not be overnight. It does not 
include presentation at a casualty or emergency room unless the event meets 
one of the other criteria for being a Serious Adverse Event. 
 With regard to the criteria in (6) above, medical and scientific judgement 
should be used in deciding whether prompt reporting is appropriate in this 
situation. 
 
9.2.4.7 Procedures for Serious Adverse Event Reporting 
Patients will be instructed to report SAEs to the Investigator immediately (within 24 
hours) by telephone.  The Investigator must report all SAEs to the Sponsor within 24 
hours of occurrence or notification by the patient.  These events must be faxed to the 
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Sponsor using ApoPharma’s standard SAE form.  The Sponsor (or its delegate) will 
provide a list of project contacts for SAE receipt, fax numbers and telephone numbers. 
The Investigator will always provide an assessment of causality at the time of the initial 
report. 
A follow-up SAE form must be completed by the responsible Investigator/delegate and 
faxed to the Sponsor within 5 calendar days.  Furthermore, as additional relevant 
follow-up information becomes available, the Investigator must complete a follow-up 
SAE form and fax it to the Sponsor.  The Sponsor (or its delegate) will submit serious 
adverse drug reactions (SADRs) to the appropriate Regulatory Agencies, in line with 
local regulatory requirements and timelines. 
Investigators must also report all SAEs to their respective IRB/IEC responsible for the 
study.  The Sponsor (or its delegate) will promptly inform all other sites of SAEs 
occurring at a single site, at least possibly related to the study medication and 
unexpected.  All site Investigators will report these events to their IRB/IEC following 
the same timelines as above or following local IRB/IEC policy, whichever takes 
precedence.  SAEs will be monitored until they are resolved or condition has stabilized 
or patient is lost to follow-up. The Sponsor will be informed of the resolutions. 
 
9.2.4.8 Follow-up and Documenting of SAEs 
SAEs that occur during the study and for 30 days after the patient takes his/her last dose 
of Study Medication must be documented in the patient’s medical record and on the 
SAE Report. A separate SAE Report form should be used for each SAE. The 
investigator should attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis should be 
documented as the SAE and not the individual signs/symptoms.   
All SAEs must be followed until resolution, until the condition stabilizes, until the event 
is otherwise explained, or until the patient is lost to follow-up. The investigator is 
responsible to ensure that follow-up includes any supplemental investigations as may be 
indicated to elucidate as completely as practical the nature and/or causality of the SAE. 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals. 
The sponsor  may request that the investigator perform or arrange for the conduct of 
supplemental measurements and/or evaluations. If a patient dies during participation in 
the study or during a recognized follow-up period, the sponsor  should be provided with 
a copy of any post-mortem findings, including histopathology. New or updated 
information should be recorded on the originally completed SAE page, with all changes 
signed and dated by the investigator. 
The CRA will verify the Original SAE Report form against the Source Documents at 
the next monitoring visit. 
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9.2.4.9 Adverse Event of Special Interest – Neutropenia (Definitions and 
Management) 
Definitions  
Mild Neutropenia: A confirmed ANC ≥1.0 x 109/L and < 1.5 x 109/L. 
Moderate Neutropenia: A confirmed ANC ≥ 0.5 x 109/L and < 1.0 x 109/L.  
Severe Neutropenia/Agranulocytosis: A confirmed ANC < 0.5 x 109/L.  
 
An Absolute Neutrophil Count (ANC) is confirmed as being less than a specified value 
if counts on two consecutive counts are both less than the specified value. If both 
consecutive counts are below 1.5 x 109/L but not in the same severity category of 
neutropenia, a third count will be required to determine the severity. 
 
Management 
All patients and their primary physicians will be promptly notified when neutropenia 
occurs. All patients would have been given thermometers at the onset of the study and 
trained in their use. Any patient with a fever defined as 38.5ºC or greater will be 
instructed to immediately discontinue treatment, obtain a CBC and differential and 
notify their primary physician in order to detect sudden neutropenia in addition 
to routine weekly laboratory counts. If the site principle investigator is not the 
responsible clinical physician, daily contact must be maintained with the primary care 
physician. 
 
Mild Neutropenia (Two consecutive Absolute Neutrophil Counts ≥1.0 x 109/L and < 1.5 
x 109/L): 
Patients who experience mild neutropenia (ANC ≥1.0 x 109/L and < 1.5 x 109/L) will be 
followed daily until two consecutive ANCs are ≥1.5 x 109/L. The following procedure 
must be followed: 
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 Discontinue treatment immediately 
 Provide protective isolation (if possible). 
 Call the 24-hour number to contact an investigator that will be 
responsible to answer toxicity questions. 
 Notify the Sponsor by fax. 
 Examine patient the same day to physical examination and review 
drug history (if possible). If the patient cannot be examined the 
same day, contact the patient by phone to obtain AEs and 
concomitant medications/therapies. 
 Therapy re-initiation: 
o If the patient is not febrile or does not have an infection, 
therapy with study medication can be re-initiated once two 
successive ANCs are >1.5 x 109/L and it is deemed safe by the 
Investigator. 
o If the patient is febrile or have an infection, therapy with study 
medication can be re-initiated once all symptoms have been 
resolved and it is deemed safe by the Investigator.  
 
Moderate Neutropenia (Two consecutive Absolute Neutrophil Counts ≥ 0.5 x 109/L and 
< 1.0 x 109/L): 
Patients who experience moderate neutropenia (ANC ≥ 0.5 x 109/L and < 1.0 x 109/L) 
will be followed daily until two successive ANCs are ≥1.5 x 109/L. The following 
procedure must be followed: 
 Discontinue treatment immediately 
 The patient will be withdrawn from the study and monitored until 
resolution of the event.  
 Provide protective isolation; if clinically indicated, admit patient to 
hospital and obtain q4h vital signs. 
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 All patients with fever 38.5ºC or greater and moderate neutropenia 
will be seen by their physician within 4 hours and undergo an 
infectious evaluation, including at least a blood culture. Antibiotics 
will be initiated prior to results of cultures and will be maintained 
until patient becomes afebrile, resolution of moderate-severe 
neutropenia, and negative blood cultures for a minimum of 72 or 
more hours. Antibiotics chosen should be based on local microbial 
prevalence and antibiotic sensitivity patterns. Broad spectrum 
antibiotics should be used in order to cover the risk of gram negative 
and gram positive organisms.  
 Call the 24-hour number to contact an investigator that will be 
responsible to answer toxicity questions. 
 Notify the Sponsor by fax. 
 Review patient the same day including drug history and physical 
examination. 
 If possible obtain viral studies (CMV, parvovirus, hepatitis A/B/C), 
serum ALT, BUN, creatinine, and 10 mL serum split into two 5-mL 
aliquots for frozen storage. 
 
Severe Neutropenia/Agranulocytosis (Two consecutive Absolute Neutrophil Counts < 
0.5 x 109/L): 
Patients who experience severe neutropenia/agranulocytosis (ANC < 0.5 x 109/L) will 
be followed daily until two successive ANCs are ≥1.5 x 109/L. The following procedure 
must be followed: 
 Discontinue treatment immediately. 
 The patient will be withdrawn from the study and monitored until 
resolution of the event.  
 Provide protective isolation; if clinically indicated, admit patient to 
hospital and obtain q4h vital signs. (It is recommended to 
hospitalize patients with severe neutropenia (ANC < 0.5 x 109/L)). 
 Obtain q4h temperatures from patient (monitored by family at home 
if patient is not in the hospital). 
 All patients with fever 38.5ºC or greater and moderate neutropenia 
will be seen by their physician within 4 hours and undergo an 
infectious evaluation, including at least a blood culture. Antibiotics 
will be initiated prior to results of cultures and will be maintained 
until patient becomes afebrile, resolution of moderate-severe 
neutropenia, and negative blood cultures for a minimum of 72 or 
more hours. Antibiotics chosen should be based on local microbial 
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prevalence and antibiotic sensitivity patterns. Broad spectrum 
antibiotics should be used in order to cover the risk of gram negative 
and gram positive organisms.  
 Call the 24-hour number to contact an investigator that will be 
responsible to answer toxicity questions. 
 Notify the Sponsor by fax. 
 Review patient the same day including drug history and physical 
examination. 
 If possible obtain viral studies (CMV, parvovirus, hepatitis A/B/C), 
serum ALT, BUN, creatinine, and 10 mL serum split into two 5-mL 
aliquots for frozen storage. 
 Collect a blood sample to attempt to identify genetic or other 
biomarkers related to agranulocytosis (patient’s consent needs to be 
obtained). 
 If possible obtain bone marrow aspirate for:  
o Histology 
o Progenitor culture 
o Frozen storage (1 mL sample) 
 If possible obtain bone marrow biopsy (minimum length 3 mm). 
 Perform septic work-up including chest X-ray, blood, urine and 
throat, cultures. 
 If warranted, administer granulocyte stimulating factors, such as G-
CSF 10 μg/kg, as an inpatient if possible, beginning the same day 
that the ANC is confirmed as < 0.5 x 109/L; administer daily until 
ANC is > 1.5 x 109/L on two consecutive days. 
 If ANC < 0.5 x 109/L for 7 days, repeat bone marrow biopsy and 
aspirate weekly during the period of agranulocytosis, if warranted. 
 
9.3 Pharmacokinetics 
Blood samples for the pharmacokinetic analyses of deferiprone and its 3-O-glucuronide 
metabolite will be collected at specific timepoints/schedule during the Month 6 visit. 
Blood samples will be collected at pre-dose and 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours 
post-dose. Pharmacokinetic parameters will be derived by non-compartmental analysis. 
The following parameters will be derived from individual plasma deferiprone and its 3-
O-glucuronide metabolite concentration-time profiles: 
 
 Cmax   Maximum observed plasma concentration over a dosing interval 
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Tmax  Time of occurrence of Cmax 
Cmin   Minimum observed plasma concentration over a dosing interval 
AUCSS Area under the plasma concentration versus time curve within a 
complete dosing interval at steady state 
CL/F Apparent clearance 
T½ Elimination half-life at steady state 
Vd/F Apparent volume of distribution 
 
10 PROCEDURES IN CASE OF MEDICAL EMERGENCY 
The Investigator is responsible for ensuring that procedures and expertise are available 
to cope with medical emergencies during the study period.  An emergency may 
constitute a SAE. 
Each site will be provided with code break instructions. In the event of an emergency, 
the randomisation code may only be broken if knowledge of the respective treatment is 
necessary for adequate treatment of the emergency. Further information regarding 
contacts will be provided in the SAE Report Form Completion Guidelines. 
 
10.1 Precautions/Overdosage 
Deferiprone use can be associated with neutropenia, including agranulocytosis. All 
patients must have their neutrophil count monitored weekly and have therapy 
interrupted at the first sign of neutropenia.  Recommended management of neutropenia 
is outlined in Section 9.2.4.9.  Treatment with deferiprone should not be initiated in 
patients with a history of recurrent neutropenia or a single episode of agranulocytosis.  
Overdose per se will not be reported as an AE, unless associated with one.  The signs 
and symptoms or clinical sequelae resulting from overdose will be reported if they 
fulfill the AE or SAE definition. 
Neurological disorders such as cerebellar symptoms, diplopia, lateral nystagmus, 
psychomotor slowdown, hand movements and axial hypotonia, have been observed in 2 
children with thalassemia who were treated with deferiprone for more than 1 year with 
more than twice the maximum recommended dose of 99 mg/kg/day for transfusion-
related iron overload. The neurological disorders progressively regressed after 
deferiprone discontinuation. 
 
10.2 Procedures in Case of Pregnancy 
If a female study patient or a female partner of a male study patient becomes pregnant, 
or plans to become pregnant, during the course of the study, the patient must inform the 
investigator and the patient will be immediately withdrawn from the Clinical trial. The 
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investigator must report all pregnancies that occur during the study and within 30 days 
after the last dose of study medication using the Pregnancy Reporting Form and AE 
page of the CRF within 24 hours. The patient will be followed up and the pregnancy 
outcome will be reported.  Pregnancy outcomes include live birth, spontaneous 
abortions (loss of pregnancy before 20 weeks of gestation), elective termination, fetal 
death/still births (loss of pregnancy after 20 weeks of gestation).  Within any of these 
categories the fetus or infant must be evaluated for the presence of any congenital 
anomalies. Any maternal/fetal complications should be also reported.  If possible, the 
health of the child will be followed for 1 year. 
The same pregnancy and post-gestation monitoring procedures will also apply in the 
case that a male patient reports that his female partner has become pregnant. In this 
case, however, there will be no requirement for the patient to withdraw from the trial. 
11 LABORATORY PROCEDURES 
Specimens will be collected by venipuncture.  Each serum separator tube will be 
labelled with the sample code, patient ID number, date the sample was drawn 
(dd/mmm/yyyy), participant's date of birth (dd/mmm/yyyy). All samples will be sent to 
the local lab.  
Investigators must document their review of each laboratory report by signing or 
initialling, and dating each report.  
Laboratory values that fall outside a clinically accepted range or values that differ 
significantly from previous values must be evaluated and commented on by the 
Investigator by marking each value CS (clinically significant) or NCS (not clinically 
significant).  Any laboratory value that is clinically significant or that differs 
importantly from a previous value should be further explained on the laboratory report 
and should be reported as an AE. The Investigator may use the CTCAE scale as a guide 
to determine the severity of the laboratory finding. 
Images of patients undergoing MRI imaging will be identified with the patient ID 
number and will locally receive image identifier codes (one for each local imaging 
procedure). Images will be electronically transferred to a designated image analysis 
center at the University of Newcastle. 
12 STUDY COMMITTEES 
12.1 Data Safety Monitoring Board  
An independent Data Safety Monitoring Board (DSMB) will be established to monitor 
the safety of patients during the course of the study. The DSMB will be responsible for 
overseeing the conduct of the trial and will be empowered to recommend stopping the 
trial if in their judgement continuation is not ethically acceptable on the grounds of 
safety. 
TIRCON: Deferiprone PKAN Study Protocol           VERSION: Amendment 6 Final 
STUDY CODE: TIRCON2012V1                              DATE: 31 JUL 2013 
Page 71 of 150 
 The following will trigger an evaluation by the data safety monitoring board (DSMB) 
for recommending stopping the study at any time point following initiation of study 
medication: 
1.  Death or life-threatening event that is deemed to be at least possibly related to 
the study medication by either the Investigator, or the Sponsor in any of the 
patients randomized in the study. 
2.  Occurrence of Serious Adverse Events that: 
a. are not associated with exacerbation of a pre-existing condition and; 
b. are deemed to be at least possibly related to the study medication by either 
the Investigator, or the Sponsor and; 
c. affect at least 2 subjects randomized and exposed to active medication in 
the study. 
No study stopping decision will be made without prior consultation with the Sponsor, 
FDA and EMA. 
The operating model and the frequency of the interim safety review meetings will be 
laid out in the DSMB charter.   The DSMB will be constituted prior to the enrolment of 
any patients into the study.  The DSMB will be notified of any changes to the protocol 
or the study conduct. The DSMB will be included in the review of any substantive 
changes to the protocol that could affect patient safety prior to their submission to 
IRB/IEC for implementation approval. All DSMB meeting minutes and board 
composition will be submitted to the regulatory authorities with the Final Clinical 
Report.   
13 DATA HANDLING and STATISTICAL ANALYSIS 
13.1 Data-collection and Handling Procedures 
13.1.1 Documentation of Data 
All subject data obtained during the study will be entered by the Investigator or 
designee using the electronic Case Report Forms (eCRFs) provided the Sponsor.  
Clinical data will be entered and stored into a validated database.  The data will be 
coded using the MedDRA (Medical Dictionary for Regulatory Activities) and WHODD 
(World Health Organization Drug Dictionary) dictionaries.  The electronic CRFs will 
be provided in the Remote Data Capture (RDC) system hosted by the Sponsor. Trained 
users will access the system via a secured gateway.  Users will be authorized to access 
data only for their own study site. Data will be entered directly into the system from the 
source documents in lieu of the paper CRFs. On line and off line edit checks will be 
used to prompt the user to provide clean and accurate data.  Clinical Data Management 
will code and monitor the data for accuracy.  An electronic signature will be required by 
the Investigator on the eCRFs and the monitor will verify the eCRFs on line. 
 
 
TIRCON: Deferiprone PKAN Study Protocol           VERSION: Amendment 6 Final 
STUDY CODE: TIRCON2012V1                              DATE: 31 JUL 2013 
Page 72 of 150 
13.1.2 Corrections to Study Documentation 
Any errors in the study documentation must be crossed out with a single line, leaving 
the original entry legible. The correction must then be dated and initialled. Incorrect 
entries must not be covered with correcting fluid, obliterated, or made illegible in any 
way. 
 
13.1.3 Data Processing 
Data will be entered by clinical study site personnel from the source data directly into 
the eCRF. Support is provided to data entry users at the site via a Help Desk. 
During the study, the statistician will have read-only access to the data for program 
development. Integrity of the database will be assured by limiting access through 
passwords and account control and through regular, secure backups of both the clinical 
data management files and SAS-related files. 
 
13.1.4 Coding 
The following coding dictionaries will be used: 
Medical History: MedDRA 
Adverse events: MedDRA 
Drugs: WHO Drug Dictionary  
 
13.1.5 Data-Handling 
Discrepancies are reviewed and resolved on-line by the clinical study site users or 
reviewed off line by Clinical Data Management, CRO and/or Sponsor and sent to the 
study site. A Patient Data Report (PDR) is a generated compilation of data from the 
database that is presented in a pdf document. The PDR originates from the same HTML 
files as the electronic case report forms (eCRFs) and can either be generated with no 
data, with patient and eCRF information (such as patient ID number #, site name, etc.), 
and/or with all collected response data. This report can be used for electronic 
submissions and as a print out for review. A copy of the final PDRs is sent to the 
clinical study site after database freeze. 
 
13.1.6 Missing, Unused and Spurious Data 
All missing data will be subject to data queries as specified above. All eCRF data will 
be included into the electronic database and will be considered for analysis as specified 
in the statistical analysis plan.  
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13.2 Statistical Analysis 
13.2.1 Co-Primary Efficacy Endpoint 
- Change in the BAD total score from baseline to Month 18 in patients treated with 
deferiprone compared to placebo, as assessed by central blinded evaluation of 
video-tapes; 
- Patient’s global impression of improvement from baseline to Month 18 in patients 
treated with deferiprone compared to placebo. 
Study will be considered positive if both co-primary endpoints reach statistical 
significance. 
 
13.2.2 Secondary Efficacy Endpoints 
- Proportion of patients with improved or unchanged BAD scale total score between 
baseline and Month 18 (defined as responders, with change in total score from 
baseline to Month 18 to be ≤0). 
- Change in BAD scale per body region (eyes, mouth, neck, trunk, each upper/lower 
extremity) from baseline to Month 18; 
- Proportion of patients showing an improvement on PGI-I at the Month 18 visit 
(responders  are defined as patients whose conditions have not deteriorated; patients 
who have “not change”, or are “minimally improved”, “much improved” or “very 
much improved” in the PGI-I questionnaire at the last study visit); 
- Change in globus pallidus iron levels as measured by MRI R2* from baseline to 
Month 18; 
- Change from baseline to Month 18 in UPDRS Parts I, II, III and VI scores; 
- Change in global WeeFIM score (or FIM for patients > 18 years) from baseline to 
Month 18; 
- Change in WeeFIM (or FIM for patients > 18 years) score per item from baseline to 
Month 18; 
- Change in quality of life (PedsQL) from baseline to Month 18; 
- Change in quality of sleep (PSQI) from baseline to Month 18.  
 
 13.2.3 Safety Endpoints 
- Frequency of Adverse Events (AEs); 
- Frequency of Serious Adverse Events (SAEs); 
- Discontinuation due to AEs; 
- Hematology assessments; 
- Blood clinical biochemistry assessments; 
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- 12-lead ECG. 
  
13.2.4 Pharmacokinetics Endpoints 
To examine the steady state pharmacokinetic profile of deferiprone and deferiprone 
3-O-glucuronide following the administration of twice daily deferiprone oral dose, the 
following analyses will be performed: 
PK parameters for serum deferiprone and deferiprone 3-O-glucuronide will be 
calculated as follows: 
    Cmax   Maximum observed plasma concentration over a dosing interval 
Tmax  Time or occurrence of Cmax 
Cmin   Minimum observed plasma concentration over a dosing interval 
AUCSS Area under the plasma concentration versus time curve within a 
complete dosing interval at steady state 
CL/F Clearance 
T½ Half-life 
Vd/F Volume of distribution 
Parameters will not be calculated for subjects with only 2 or fewer time points with 
detectable concentrations. 
 
13.2.5 Determination of Sample Size 
Sample size estimation is based on BAD scores from literature, where a mean value of 
21.0 BAD score points with a standard deviation of 6.3 points was observed in 21 
NBIA patients (Timmermann et al, 2010). Assuming a 2:1 randomization, an expected 
difference in change of BAD score of ≥5 points after 18 months between control and 
treatment group, a standard deviation of 6.3 points for the change from baseline, and a 
drop-out rate of 30%, a total of 90 patients would be needed to achieve 80% power in 
detection of this clinically relevant effect size at a two-sided 0.05 level of significance. 
The impact of the co-primary endpoint (PGI-I) on the power to demonstrate superiority 
of the treatment group over control should be small as a greater degree of difference in 
response for this endpoint is expected between the two groups.  The rationale behind is 
that the BAD score is based on assessment of dystonia in eight body regions.  To obtain 
a much higher score, in relation to the standard deviation, the active treatment would 
need to provide beneficial effect on multiple regions.  A much higher score in PGI-I can 
be achieved even if the active treatment performs well in one region only.   
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13.2.6 Study Population 
Study populations intended for analysis will be defined as follows: Intent-to-treat (ITT), 
Modified Intent-to-treat (mITT), Per-Protocol (PP), Safety and Pharmacokinetics. The 
mITT population will represent the primary analysis population to evaluate the 
treatment groups on all efficacy endpoints. The co-primary efficacy endpoints will also 
be analyzed for the PP population, which is the secondary analysis population. 
 
13.2.6.1 Intent-to-treat Population 
The ITT population is defined as all randomized patients.  
  
13.2.6.2 Modified Intent-to-treat Population 
The mITT population is defined as all randomized patients who received at least one 
dose of study drug and have a baseline and at least one post-baseline efficacy 
assessment. All efficacy analyses will be based on the mITT population.  
 
13.2.6.3 Per-Protocol Population 
The PP population will include all randomized patients who complete the study, have 
no major protocol violations, and have an efficacy assessment at the end of the study. 
Prior to database lock, protocol violations will be reviewed for their seriousness and 
patients with major violations will be excluded from the PP population. Only the co-
primary efficacy endpoints will be analyzed for the PP population. 
 
13.2.6.4 Safety Population 
The Safety population will include all randomized patients who took at least one dose 
of study drug.  
 
13.2.6.5 Pharmacokinetics Population 
The Pharmacokinetics population will include all patients participating in the 
pharmacokinetic evaluation who have sufficient PK data to derive at least one PK 
parameter.  
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13.3 Statistical Analysis Plan 
A separate statistical analysis plan (SAP) detailing the specifications given below will 
be prepared and approved prior database lock. Any changes in the planned statistical 
methods will be documented in the final study report. 
 
13.4 Definition of Analysis 
For safety data analysis, no imputation will be performed on the missing data and 
analysis will be based on observed cases (OC).  
For continuous efficacy data, a Mixed-Effect Model Repeated Measure (MMRM) 
model will be used as the primary analysis method and the analysis will be based on 
observed cases data set. As a sensitivity analysis, an analysis of covariance (ANCOVA) 
model will be used as the secondary analysis method with missing data being imputed 
using the imputation rule as described below. 
For patients who were terminated from the study prior to Month 18, if their last efficacy 
measures were obtained within 90 days of Month 18, the data obtained will be treated as 
the Month 18 data.  For early termination that occurred outside this window, the last 
observation carried forward (LOCF) method will be used to fill the missing data when 
the early termination was not caused by worsening of disease conditions or inadequate 
efficacy of the drug. For early termination due to worsening of disease conditions or 
inadequate efficacy of the drug, as indicated in the CRF, the “worst score” method will 
be used.  That is, for continuous variables such as BAD total score at a particular time 
point, the average score of the placebo arm at that time point will be used to impute the 
missing data of the placebo group while the worst score of all patients for the active 
group will be used to impute the missing data at that time point. Similarly, for 
categorical variable such as responder, the worst category (treatment failure) will be 
assigned for the missing data.  For missing data due to missed visit, the LOCF method 
will be used to fill the void.   
 
13.4.1 Planned Analysis 
13.4.1.1 Patient Disposition and Drug Exposure 
Patient disposition, based on the ITT population, will be summarized and presented, 
including the number and percentages of patients who were screened, were enrolled, 
completed the study, and withdrawn (including reasons for withdrawals).  
For each patient, the number of doses taken will be computed from the study drug 
dispensing and accountability CRFs obtained at each visit. The extent of exposure to the 
study medication as well as the number of doses taken during study will be summarized 
with descriptive statistics. 
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13.4.1.2 Patient Characteristics 
Baseline characteristics will be summarized by: mean, standard deviation, minimum, 
median and maximum values (by mITT and PP populations). Medical history and prior 
medications will be summarized descriptively (number of patients and percentage). 
 
13.4.1.3 Efficacy Analyses 
Co-Primary Efficacy Endpoints 
A Mixed-Effect Model Repeated Measure (MMRM) model will be used as the primary 
analysis method to assess the change in BAD total score and PGI-I from baseline to 
Month 18, with baseline value and age of onset of motor symptoms as covariates and 
treatment group as the main factor in the model. Age of onset of motor symptoms will 
be used as a stratification factor at randomization and thus will be included as a binary 
variable in all the models where it is used as a covariate. DBS settings change or use of 
medications that has the potential to affect dystonia symptoms during the study or the 
frequency of PRN drug or rescue medication use may confound the treatment effect 
assessment. These variables will also be included in the MMRM model appropriately. 
PGI-I is already a measurement of change from baseline and thus will be used directly 
as the outcome variable, and baseline BAD score will be included as the baseline value 
in the model. 
The MIXED procedure in SAS will be used for the MMRM model analysis using the 
observed data. Data within each patient at different visits will be considered repeated 
measures. UN (Unstructured) covariance structure will be used to model the correlation 
between repeated measures within the same patient and Kenward and Roger’s method 
will be used to estimate the denominator degrees of freedom. The 95% confidence 
interval (CI) for the difference between the two treatments will be calculated by the 
LSMEANS statement. 
As a sensitivity analysis, an analysis of covariance (ANCOVA) model will be used as 
the secondary analysis method to assess the change in value from baseline to Month 18 
for co-primary efficacy endpoints only. The model will be similar to the MMRM model. 
The LOCF imputation method described in Section 13.4 will be employed for imputing 
missing data. 
If the blinded review of the efficacy data performed before the breaking of the treatment 
codes indicates a severe non-normality of the data, an appropriate  transformation (for 
example, log transformation) will be applied to the data, or nonparametric statistical 
methods based on ranks will be employed, if warranted. This analysis will be treated as 
a secondary analysis and will be analyzed with the ANCOVA model only. 
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Secondary Efficacy Endpoints 
The MMRM model will also be used for the analysis of the secondary endpoints except 
for the proportion of responders, which will be analyzed by a logistic regression model 
with age of onset of motor symptoms and baseline BAD score as covariates and 
treatment group as the main factor.  The GENMOD procedure in SAS will be used to 
perform the logistic regression.   
With regard to the secondary efficacy endpoints, DBS settings change or use of 
medications that has the potential to affect dystonia symptoms during the study or the 
frequency of PRN drug or rescue medication use may also confound the treatment effect 
assessment. These variables will also be included in the MMRM model and the logistic 
regression model appropriately. 
 
Subgroup Analysis 
In order to explore potential differences in treatment effect on efficacy endpoints across 
population subgroups, subgroup analyses will be performed on the co-primary efficacy 
endpoints for the mITT population on the following factors: Age at onset of motor 
symptom (Age ≥6 vs. Age <6), DBS (Deep Brain Stimulation Yes vs. No), Baclofen 
pump (Yes vs. No), and Region (US vs. Europe).    Forest plots will be drawn to 
compare subgroups of each factor. 
 
13.4.1.4 Safety Analyses 
All safety data collected will be presented in listings and summary tables to give an 
overview of the safety findings.  
Adverse Events 
A summary table of adverse events will include the following information: 
 number of patients exposed to study treatment, 
 number of patients experiencing at least one AE,  
 number of patients experiencing at least one severe AE,  
 number of patients experiencing at least one serious AE,  
 number of patients experiencing at least one drug-related AE, 
 number of deaths, 
 total number of patients withdrawn,  
 number of withdrawals due to AEs.  
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All adverse experiences will be coded using the MedDRA (Medical Dictionary for 
Regulatory Activities). Adverse events will be defined as: 1) AEs that occurred or 
worsened (increased in severity and/or frequency) on or after the first dose of study 
medication. 2) AEs with a missing start date and a stop date on or after the first dose of 
study medication. 3) AEs with both a missing start and stop date. AEs will be 
summarized by treatment and by MedDRA SOC and Preferred Term. AEs that occurred 
within 14 days after treatment discontinuation will be considered AEs. Serious adverse 
events occurred within 30 days after treatment discontinuation will be included in the 
database.  
Adverse events (AEs) will be summarized using the total number of AEs, the total 
number and percent of patients who experience an AE, and the number and percent of 
patients who experienced an AE within each system organ class (and preferred term 
within a system organ class). AEs will also be presented by severity (mild, moderate, 
severe), by seriousness (serious, non-serious) and by relationship to study medication 
(at least possibly related, not-related). The number of patients withdrawn will also be 
presented.  
To count the number of patients who experienced each AE, patients having experienced 
the same AE multiple times will only be counted once for the corresponding preferred 
term. Similarly, if a patient experiences multiple AEs within the same system organ 
class, that patient will be counted only once for that system organ class. AEs will be 
tabulated presenting the system organ class alphabetically and within each of them, the 
preferred term will be presented in decreasing order of the total number of patients who 
experienced each AE. In summaries presenting the incidence of AEs by severity, 
seriousness and relation to study medication, a patient with multiple events coded to a 
given preferred term or system organ class will be counted once for that preferred term 
or system organ class according to the most severe event, the most serious event or the 
event with the closest relationship to study medication. 
Listing of serious adverse events and listing of withdrawals due to AEs will be 
presented. Patient deaths will be listed separately and discussed with patient narratives. 
Vital Signs 
Descriptive statistics (mean, median, standard deviation, minimum and maximum) will 
be presented for temperature, heart rate, respiratory rate, systolic blood pressure, 
diastolic blood pressure, weight, height, at screening or baseline and each relevant visit. 
Changes from baseline to each post-baseline time-point will also be presented. Data will 
also be presented graphically for examination of possible trend. 
ECGs 
Clinically significant ECG abnormalities will be reported. The number and percentage 
of patients with normal and abnormal ECG results will be provided. 
Biochemistry, Hematology and Urinalysis 
Descriptive statistics for each clinical laboratory test will be presented for each 
scheduled visit. Change from baseline to each visit will also be presented. According to 
the laboratory normal ranges, laboratory test results will be categorized as low (< lower 
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normal limit), normal (within normal range), and high (> upper normal limit). Shift 
tables comparing the distributions of these three categories at baseline versus end of 
treatment will be presented. Continuous data will also be presented graphically for 
examination of possible trend. 
Clinically significant laboratory values will be reported in the adverse event analysis. 
Concomitant Medications 
Medications will be coded using the WHO Drug dictionary. Medications taken during 
the course of the trial (on or after the first study drug dose and before or on the study 
termination date) will be considered as concomitant medications. Medications started 
after the study termination date will not be reported in tables, but will be presented in 
patient data listings. Concomitant medications used to treat adverse events will be 
differentiated from others. 
Concomitant medications will be summarized according to the preferred terms only. To 
count the number of patients who took a medication, a patient taking the same 
medication multiple times will only be counted once for that medication. Medications 
will be tabulated in decreasing order of the total number of patients who took each 
medication. In addition, the total number of patients to ever take any concomitant 
medications will be presented. 
Concomitant medications will be presented based on the Safety population. 
 
13.4.1.5Pharmacokinetics Analyses 
Pharmacokinetic parameters will be derived by non-compartmental analysis. Actual 
sampling times will be used for pharmacokinetic evaluations.  Descriptive statistics 
(Arithmetic means, SD, CV, median, minimum and maximum values) will be presented 
for the concentrations and the pharmacokinetics parameters.  
Additional pharmacokinetics analyses may be performed if deemed appropriate. 
 
14 DATA MANAGEMENT CONSIDERATIONS  
14.1 Data Management 
The Sponsor’s Clinical Data Management group will be responsible for the processing, 
coding and validating/cleaning of clinical study data.  Patient data will be entered by the 
Investigator or designee using the electronic Case Report Forms (eCRFs) provided by 
the Sponsor.  Clinical data will be entered and stored into a validated database.  The 
data will be coded using the MedDRA (Medical Dictionary for Regulatory Activities) 
and WHO Drug dictionary (World Health Organization Drug Dictionary).  The eCRFs 
will be provided in the Remote Data Capture (RDC) system hosted by the Sponsor. 
Trained users will access the system via a secured gateway.  Users will be only 
authorized to access data for their study site. Data will be entered directly into the 
system from the source documents in lieu of the paper CRFs. On line and off line edit 
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checks will be used to prompt the user to provide clean and accurate data.  Clinical Data 
Management will code and monitor the data for accuracy.  An electronic signature will 
be required by the Investigator on the electronic CRFs and the monitor will verify the 
eCRFs on line. 
Clinical data management activities will be performed by the Sponsor in accordance 
with applicable standards and data cleaning procedures of the Sponsor.  An audit trail of 
all data processing will be stored in the database.  The study biostatistician will be 
notified when all patient data are ready for analysis. 
Integrity of the database will be assured by limiting access through username/password 
combination and account control. Authorized access to the database will be provided to 
those individuals with an inspection/auditing function (Regulatory Authorities/Quality 
Assurance); "read only" access will be provided to avoid unintentional corruption of the 
database.  
The database will be backed up daily. 
 
14.2 Source Documents 
The Investigator will maintain adequately detailed source documents supporting 
significant source data for each patient.  Source data are defined as all information in 
original records and/or certified copies of original records of Clinical findings, 
observations, or other activities in a Clinical trial necessary for the reconstruction and 
evaluation of the trial.  Examples include medical history; physical examination; 
laboratory results; X-ray/ultrasound findings; and ECG results. 
The Investigator will also retain all patients’ specific printouts, reports of tests and 
procedures performed as requirements of the study.  The source documents must be 
available at the time of any site visit from the Sponsor/CRO and/or regulatory 
authorities.  
During monitoring visits the monitor will need to validate data in the eCRFs against 
these sources of data. 
For every patient, the hospital/patient records should clearly indicate at least and not 
limited to: 
 That he/she participated in the study, e.g. by including patient identification (patient 
ID number) and study identification (study code or other). 
 Medical History. 
 A list of prior and concomitant medications/therapies prior to participation in the 
study. 
 A list of treatments, including investigational product(s), received or changed 
during the study. 
 A record of all visits to the study site during the study period, including those for 
study purposes only. 
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 A list of all AEs, including SAEs, ADRs, and SADRs 
 
14.3 Electronic Data Capture (EDC) 
The Sponsor will provide the Investigators and site staff with training on the system. 
Data is entered by clinical study site personnel from the source data directly into the 
eCRF. Support is provided to data entry users at the site via a Help Desk. 
Discrepancies are reviewed and resolved on line by the clinical study site users or 
reviewed off line by Clinical Data Management, CRO and/or Sponsor and sent to the 
study site. A Patient Data Report (PDR) is a generated compilation of data from the 
database that is presented in a pdf document. The PDR originates from the same HTML 
files as the electronic case report forms (eCRFs) and can either be generated with no 
data, with patient and eCRF information (such as patient ID number #, site name, etc.), 
and/or with all collected response data. This report can be used for electronic 
submissions and as a print out for review. A copy of the final PDRs is sent to the 
clinical study site after database freeze. 
15 MONITORING, AUDITS AND INSPECTIONS 
15.1 Monitoring 
The Sponsor has the obligation to follow this study closely throughout its course.  
Monitoring of the investigational sites will be conducted by the Sponsor or contracted 
to a qualified (through audit) CRO who will provide an appropriately trained CRA. The 
CRA will have regular contacts with the investigational site.  These contacts will 
include visits to confirm that facilities remain acceptable, that the investigational site is 
adhering to the protocol and that data are being accurately recorded in the CRFs, and to 
provide information and support the Investigator.  The CRA will ensure that the 
investigational product is accounted for and that written informed consent/assent form 
(where applicable) was obtained for each patient.  Source data will be verified, and the 
data in the CRF compared with the source data.  The source documents must be 
available at the time of the site visit. 
 
15.2 Audits and Inspections 
In accordance with the principles of ICH E6 Guideline for Good Clinical Practice, the 
study may be inspected by regulatory authorities and audited by the Sponsor or their 
designees. The Investigator and relevant Clinical support staff will be required to attend 
audits and inspections and make all necessary documentation and data available upon 
request. 
During the course of the study or after study completion, one or more investigator site 
audits may be undertaken by auditors from the Sponsor or their delegates. The purpose 
of these audits is to determine whether or not the study is being/has been conducted and 
monitored in compliance with the ICH E6 Guideline for Good Clinical Practice, 
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approved protocol and amendment requirements, applicable local Standard Operating 
Procedures (SOPs) and local laws and regulations. It is the investigator’s and his/her 
staff’s responsibility to promptly address deficiencies stemming out of regulatory 
inspections and the Sponsor’s or delegated audits, as well as to ensure that agreed-upon 
corrective and preventative actions are implemented promptly. 
An inspection by any regulatory authority or a sponsor’s audit may occur at any time 
during or after completion of the study. If an Investigator is contacted by a regulatory 
authority for the purpose of conducting an inspection or to discuss any compliance 
issues, he/she is required to contact the Sponsor immediately  who will assist the site in 
preparation for the audit/inspection. 
16 REGULATORY REQUIREMENTS AND OBLIGATIONS 
16.1 Informed Consent/Assent  
The Investigator or his/her designee will ensure that the patient and/or his/her legal 
representative is given full and adequate oral and written information about the nature, 
purpose, possible risks and possible benefits of the study. 
The Investigator or his/her designee must make a conscientious effort to be fully 
satisfied that the patient and/or his/her legal representative has truly understood that for 
which the consent has been given.  The patient and/or his/her legal representative must 
also be notified that he/she is free to withdraw his/her participation in the study at any 
time, and that such withdrawal will not affect his/her present or future care. 
The patient and/or his/her legal representative should be given ample opportunity to ask 
questions and discuss the study with the family.  The consent document signed by the 
patient must not be phrased in a manner that might be understood to abrogate the rights 
of the patient and/or his/her legal representative or the responsibility of the Investigator 
or Sponsor.  The consent/assent form used to obtain the patient’s consent must be the 
most up-to-date consent/assent form approved by the IRB/IEC. 
Written informed consent/assent will be obtained from the study patient and/or legal 
representative as described in the Declaration of Helsinki, June 1964, as clarified by the 
World Medical Association (WMA) General Assembly, Washington 2002, CFR Part 50 
prior to entering the patient  into the study.  The consent/assent form will be signed and 
dated by the patient or legal representative prior to the first study intervention.  A 
completed copy of each patient’s signed and dated consent/assent form will be retained 
in the patient’s chart. 
The patient will be provided with a copy of the signed and dated ICF/assent form.  Site 
variations may occur owing to the individual preferences of each ethics committee.  
Copies of the consent/assent form intended for use at each Clinic will be forwarded to 
the Sponsor. 
Should a protocol amendment be made, the ICF/assent may need to be revised to reflect 
the changes to the protocol.  The revised consent/assent form will be forwarded to the 
Sponsor.  The Investigator must then ensure firstly that the revised consent/assent form 
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is reviewed and receives favourable written approval from the IRB or IEC, and 
secondly that it is signed by all patients subsequently entered in the trial and those 
currently in the trial.  The Investigator must provide written approval from the IRB/IEC 
to the Sponsor. 
 
16.2 Institutional Review Board/Independent Ethics Committee 
The Investigators agree to provide the IRB/IEC with all appropriate documents, 
including a copy of the protocol/amendments, ICFs, advertising text (if any), 
Investigator’s brochure (if any) and any written information to be given to the patient.  
The Investigators must obtain IRB/IEC favourable written approvals for the 
protocol/amendments, the ICFs and any applicable translations, and any written 
information to be given to the patient prior to their enrolment, and any advertising to be 
used for patient recruitment.  The Investigator must provide a copy of the written 
approval of the IRB/IEC to the Sponsor before commencement of the study.  The names 
of the members of IRB/IEC and their title/institutional affiliation will be provided to the 
Sponsor and the Investigators prior to the start of the study.  The Sponsor  further 
requires copies of all correspondence with the IRB/IEC. 
In the event that the protocol is amended, the protocol amendment must be approved by 
the IRB/IEC prior to its implementation, unless the changes are administrative in 
nature.  If an ICF needs to be revised to reflect the changes to the protocol, the revised 
consent form will be forwarded to the Sponsor for approval prior to the submission to 
the IRB/IEC.  The Investigator must then ensure firstly that the revised consent form is 
reviewed and receives favourable written approval from the IRB/IEC, and secondly that 
it is signed by all patients subsequently entered in the trial and those currently in the 
trial.  The Investigator must provide the written approval to the Sponsor. 
The Investigator is also obliged to report all SAEs to the IRB/IEC as per local 
requirements.  The Investigator must submit reports of the study at least annually to the 
IRB/IEC for review. 
The Investigator must notify the IRB/IEC that the study has been completed within 3 
months of its completion.  A final Clinical report will be made available to the 
IRB/IEC.  The Investigator must maintain an accurate and complete record of all 
submissions made to the IRB/IEC, including a list of reports and documents. 
 
16.3 Patient Data Protection 
To ensure the patient’s identity remains unknown to the Sponsor (or its delegate), the 
Sponsor (or its delegate) will identify all data by patient ID number. 
The Investigator must inform patients of the possibility that representatives from 
regulatory authorities and/or the Sponsor (or its delegate) may require access to hospital 
or study site records for verification of data pertinent to the study, including medical 
history.  
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The Investigator is responsible for keeping a patient identification list or form of all 
patients entered, including enrolment code, patient ID number, full name, and last 
known address. 
 
16.4 Assumption of Liability and Indemnification 
The Sponsor shall indemnify, defend, and hold harmless the Investigator(s) (which term 
includes the Investigator(s)’s Institutions, employees, agents, representatives and 
associates) from and against any demands, claims, costs, judgments, liabilities, 
damages, losses and expenses, including reasonable legal fees (collectively, a “Loss”), 
that may be suffered or incurred by the Investigator(s) as a result of personal injuries or 
damage to property due to or arising out of the conduct of this Clinical trial. 
Notwithstanding the foregoing, the Sponsor shall have no obligation or liability 
pursuant to the foregoing indemnity should the Loss result directly or indirectly from 
the Investigator(s)’s: 
a. negligence or wilful misconduct; 
b. failure to comply with the terms of the protocol or written instructions regarding 
the use of any product(s) used in this Clinical trial; 
c. failure to adhere to any government regulations or requirements; or 
d. failure to conduct the study in accordance with standard medical practice. 
The Investigators shall promptly notify the Sponsor in writing of any demand, claim, 
proceeding or other matter (a “Claim”) for which indemnity may be claimed.  The 
notification shall specify the all known particulars of the Claim, including, if available, 
the amount of the Claim.  If the Investigator(s) fails to give timely notice of any Claim 
and as a result the Sponsor is prevented from effectively contesting liability for the 
Claim, the Sponsor shall be relieved of its obligations hereunder.  The Investigator(s) 
shall take all commercially reasonable action to preserve the right to object to and 
defend against any Claim. 
The Investigator(s) shall fully co-operate with the Sponsor with respect to all Claims 
and shall keep the Sponsor fully advised with respect thereto, including promptly 
supplying copies of all relevant documentation as it becomes available. 
The Sponsor shall have the right but not the obligation, at its expense, and at any and all 
times participate in or assume control of the negotiation, settlement or defence of any 
Claim.  Should the Sponsor elect not to assume control of the negotiation, settlement or 
defence of a Claim, the Investigator shall not settle the Claim without the written 
consent of the Sponsor, which consent shall not be unreasonably withheld.  
If the Sponsor assumes control of the defence of a Claim, which it thereafter fails to 
defend, the Investigator shall be entitled to assume control thereof and the Sponsor shall 
be bound by the results obtained by the Investigator with respect to the Claim. 
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16.5 Compliance 
This study will be conducted in compliance with the study protocol, ICH GCP E6, the 
Organization for Economic Co-operation and Development (OECD) Good Laboratory 
Practices and all applicable regulations, including the Federal Food, Drug and Cosmetic 
Act, U.S. applicable Code of Federal Regulations Title 21, Parts 50, 54 (financial 
disclosure), 56, 312 and 314, Directive 2001/20/EC of the European Parliament and of 
the Council of 04 April 2001, on the approximation of the laws, regulations and 
administrative provisions of the Member States relating to the implementation of good 
Clinical practices in the conduct of Clinical trials on medicinal products for human use; 
any IRB requirements relative to Clinical studies and the Declaration of Helsinki 
(Appendix 20.6), June 1964, as clarified by the WMA General Assembly, Washington 
2002 and Directive 2005/28/EC of the European Parliament and of the Council of 8 
April 2005 laying down principles and detailed guidelines for good clinical practice as 
regards investigational medicinal products for human use, as well as the requirements 
for authorisation of the manufacturing or importation of such products. 
 
16.6 Amendments to the Protocol 
No amendments may be made to this protocol without the agreement of both the 
Sponsor, and the Investigators.  All changes to this protocol must be documented by 
signed protocol amendment. 
The amendment will be implemented by the study site from the day the document is 
signed by the Investigator and the Sponsor, whichever comes later, and once all 
applicable regulatory and IRB/IEC approvals have been obtained.  If the change affects 
the safety of patients or involves intervening in the patient’s treatment of care, the scope 
of the investigation or the scientific quality of the study, the amendment must also have 
IRB/IEC approval, and it also has to be notified to or approved by regulatory authorities 
before it is implemented.  Examples of these types of changes include: 
 Any change in drug dosage or duration of exposure of individual patients to the 
study agent beyond that in the current protocol, or any significant change in the 
number of patients under study. 
 Any significant change in the design of a protocol (such as the addition or dropping 
of a control group). 
 The addition or dropping of a test or procedure. 
A change intended to eliminate an apparent immediate hazard to patients may be 
implemented immediately and without written amendment to this protocol, provided 
that the regulatory authorities and the IRB/IEC are notified as soon as possible 
afterwards. 
When a proposed change to the protocol meets the statutory criteria for amendment as 
defined by FDA and EMA substantially alters the study design or potential risk to the 
patient, the patient’s re-consent to continue participation will be obtained.  This action 
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will require a revised ICF.  The revised ICF will require approval from the Sponsor and 
the IRB/IEC. 
 
16.7 Sponsor’s Obligations 
The obligations described below contain excerpts from the ICH guidelines (Good 
Clinical Practice: Consolidated Guidance: E6, 1996) and the Sponsor’s policy 
governing Sponsor and Investigator obligations. 
The Sponsor (or its delegate) is responsible for implementing and maintaining quality 
assurance and quality control systems with written SOPs to ensure that trials are 
conducted and data are generated, documented (recorded) and reported in compliance 
with the protocol, GCP guidelines and the appropriate regulatory requirements. 
The Sponsor will have the ultimate and final authority in the trial on matters of policy 
and finance. At the time the study is initiated, the protocol and CRFs will be reviewed 
thoroughly with the Clinical Investigators and their staff. During the course of the 
study, the CRA and a Sponsor representative will be available to discuss by telephone, 
questions regarding AEs, removal of patients from the trial, conduct of the study and 
other Clinical study matters. 
The Sponsor or its delegate will be responsible for: 
1. Reporting the occurrence of SAEs to the Investigators and to regulatory agencies of 
findings that could affect adversely the safety of patients, impact the conduct of the 
trial, or alter the IRB/IEC approval/favourable opinion to continue the trial. 
2. Providing adequate support to the Investigators so that the trial is conducted safely 
and effectively according to the standards of GCP. 
3. Reporting the findings of this study annually, or as required, to regulatory agencies 
and providing a written report of the study upon its completion. 
4. Retaining all documentation and records as required by the relevant regulatory 
agencies. 
5. Monitoring and auditing of data at the Clinical sites for the duration of the trial to 
ensure the study is being conducted according to ICH GCP E6 as well as any 
applicable local regulations and laws (e.g. adherence to the protocol, patient 
enrolment, investigational product accountability, and accuracy of data forms). 
 
16.8 Investigators’ Obligations 
1. Investigators must be registered Clinical practitioners, qualified to carry out the 
study, taking into account the nature of the study and the particular phase and nature 
of the investigation undertaken. 
2. Investigators must provide the Sponsor (or its delegate) with appropriate regulatory 
documentation and up-to-date curricula vitae for themselves and co-Investigators 
participating in the Clinical trial. They must also furnish the Sponsor (or its 
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delegate) with the names of all ancillary staff (pharmacists, nurses, etc.) who are 
directly involved in the study. 
3. Investigators are responsible for providing suitable facilities to allow the study to be 
conducted efficiently and effectively. 
4. Investigators are responsible for obtaining written IRB/IEC approval before initiation 
of the study from their respective institutions. This also includes an IRB/IEC 
approval of the ICF and any applicable amendments. 
5. Investigators are responsible for obtaining written informed consent/assent from the 
patients and/or legal representatives, prior to the initiation of any study procedures. 
The patient should receive a copy of the written ICF. 
6. Investigators are responsible for conducting the study according to the protocol for 
the accurate and complete reporting of results in accordance with GCP, and for 
maintaining accurate investigational product accountability records. 
7. Investigators must record in detail all AEs occurring during the course of the study.  
They must report all SAEs immediately to the Sponsor (or its delegate) and the 
IRB/IEC, and notify the Sponsor (or its delegate) immediately when a patient has 
been removed from the study because of a SAE. The responsible Investigators 
should institute appropriate diagnostic and therapeutic measures and should keep 
the patient under observation for as long as it is medically indicated. 
8. Investigators must provide completed eCRFs and resolve discrepancies in a timely 
manner. 
9. Investigators must ensure that the study documents are retained in a safe and secure 
location for 15 years following the completion of the study.  No documents may be 
destroyed without written permission of the Sponsor . 
 
16.9 Data Quality Compliance 
To ensure accurate, complete, and reliable data, the Sponsor will do the following: 
The Clinical Research Division will: 
 Provide instructional material to the study sites. 
 Sponsor a Start-up Training Session to instruct the Investigators and study 
coordinators. This session will give instruction on the protocol, the completion of 
the CRFs, study procedures, GCP and ICH guidelines and the Operations Manual. 
 Make periodic visits to the study sites. 
 Be available for consultation with the study site personnel by mail, telephone and 
fax. 
The Clinical Data Management Division will: 
 Review and evaluate CRF data and use standard computer edits to detect errors in 
data collection. 
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 Conduct a quality review of the database. 
The Quality Assurance Division will: 
 Audit all or parts of the study and all or parts of its documentation including those 
generated at investigators’ sites, local and central laboratories and support sites. 
 Audit the final report to ensure that, as far as can be reasonably established, the 
methods described and the results reported accurately reflect the raw data 
generated during the study. 
 Conduct, if necessary, process Audits including samples of data and documentation 
to assure compliance with ICH GCP E6, applicable local regulations, guidelines 
and laws as well as the study protocol and relevant Sponsor Standard Operating 
Procedures and Work Instructions. 
 
16.10 Study Reports 
One report on safety and efficacy will be prepared by the Sponsor (or its delegate) at the 
completion of the study.  The lead Investigator and/or members of the Steering 
Committee may have an opportunity to review the study report.  The Chair of the 
Steering Committee and appropriate Sponsor members will be signing the study report 
to indicate approval. 
The Sponsor will be responsible for all submissions to the regulatory agencies. 
 
16.11 Ownership 
The terms of the TIRCON FP7 Grant Agreement No. 277984 and the TIRCON internal 
Consortium Agreement, as agreed upon and signed by all parties, shall apply. 
 
16.12 Publications/Poster/Presentation 
The terms of the TIRCON FP7 Grant Agreement No. 277984 and the TIRCON internal 
Consortium Agreement, as agreed upon and signed by all parties, shall apply. 
 
16.13 Early Study Termination 
The Sponsor or its delegate reserves the right to discontinue this trial at any time.   The 
study may be terminated by the Investigator at his/her respective site following 
consultation with the Sponsor .  The Investigator will immediately, on discontinuance 
of the Clinical trial, in its entirety or at a Clinical trial site, inform both the Clinical trial 
patients and the IRB/IEC responsible for the study of the discontinuance, provide them 
with the reasons for the discontinuance and advise them in writing of any potential risks 
to the health of Clinical trial patients or other persons. It is the Sponsor’s (or its 
delegate) responsibility to report discontinuance of the study to regulatory agencies, and 
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provide them with the reasons for the discontinuance and advise them in writing of any 
potential risks to the health of Clinical trial patients or other persons. The Sponsor (or 
its delegate) must then inform the Investigators. 
In the event of a discontinuation, the Investigators will ensure return of all 
investigational products to the Sponsor with all outstanding investigational materials 
(e.g. CRFs, SAE forms) within 1 month.  If possible, Investigators should complete all 
assessments as per the study termination assessments (see Section 6.13). 
 
If there is any conflict between the terms of section 16.13 and the TIRCON FP7 Grant 
Agreement No. 277984 and the internal Consortium Agreement, the terms of the 
TIRCON FP7 Grant Agreement No. 277984 and internal Consortium Agreement shall 
take precedence. 
17 CONFIDENTIALITY 
The terms of the TIRCON FP7 Grant Agreement No. 277984 and the TIRCON internal 
Consortium Agreement, as agreed upon and signed by all parties, shall apply. 
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19 SIGNED AGREEMENT TO THE PROTOCOL 
19.1 Principal Investigator Signature Page 
I confirm that I have read this protocol and I understand it. I agree to conduct this study 
in accordance with ICH Good Clinical Practice guidelines, all of the specifications in 
this study protocol, and local regulatory requirements.  I will be responsible for 
obtaining approval from the IRB/IEC responsible for my institution before the start of 
the study.  I will adhere to the protocol and comply with the guidelines. I agree to fully 
co-operate with compliance checks by allowing access to all documentation by 
authorized individuals. 
 
Study Title: A randomized, double-blind, placebo-controlled trial of deferiprone 
in patients with pantothenate kinase-associated neurodegeneration 
(PKAN) 
 
Study Code: 
 
TIRCON2012V1 
Study Site:  
 
 
Investigator Name    
 
Investigator Signature   Date: (DD MMM YYYY) 
 
Name of Facility   
 
Location of Facility  
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20 APPENDICES 
20.1 Schedule of Events 
STUDY PROCEDURE 
Screening/ 
Baseline Phase 
Treatment Phase 
Screening Baseline Telephone 
Contact 
Week 1, 2, 
3, 4 and 5 
Weekly  
Assessments 
Month 1.5
(Week 6) 
Visit 
Telephone 
Contact 
Month 2 
Month 3 
(Week 12) 
Visit 
Month 6  
(Week 26) 
Visit 
Telephone 
Contact 
Month 9 
Month 12 
(Week 52) 
Visit 
Telephone 
Contact 
Month 15
Month 18 / Early 
termination2  
(Week 78) Visit
Follow-up  
Visit3 
Informed Consent/Assent X             
Review Inclusion and Exclusion 
Criteria 
X X            
Confirmation of PKAN diagnosis  X             
Confirmation of eligibility  X            
Randomization X             
Record demographic information X             
Medical history X           X  
Prior and current medications X            X 
Physical examination X    X  X X  X  X X 
Hematology X1   X X  X X  X  X X 
Biochemistry X1    X  X X  X  X  
Serology X1             
Serum pregnancy testing (females 
only) 
X    X  X X  X  X  
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STUDY PROCEDURE 
Screening/ 
Baseline Phase 
Treatment Phase 
Screening Baseline Telephone 
Contact 
Week 1, 2, 
3, 4 and 5 
Weekly 
Assessments
Month 1.5 
(Week 6) 
Visit 
Telephone 
Contact 
Month 2 
Month 3 
(Week 12) 
Visit 
Month 6 
(Week 26) 
Visit 
Telephone 
Contact 
Month 9 
Month 12
(Week 52)
Visit 
Telephone 
Contact 
Month 15
Month 18 / Early 
termination2 
(Week 78) Visit
Follow-up 
Visit3 
Urine pregnancy testing (females only)  X            
Urinalysis X1    X 
 X
 
X
  
X
  X  
Vital signs (including weight) X X   X  X X  X  X X 
Height X         X  X  
12-lead ECG X1           X  
Contraceptive counselling X X   X  X X  X  X  
Brain MRI  of globus pallidus (subset 
of patients) 
 X          X  
Likert Scale  X      X  X  X  
BAD (completed by a qualified 
Investigator or qualified delegate) 
X             
BAD scale Videotaping  X      X  X  X  
PGI-I        X  X  X  
UPDRS I, II, III and VI  X      X  X  X  
WeeFIM/FIM  X      X  X  X  
PedsQL  X      X  X  X  
PSQI  X      X  X  X  
Pharmacokinetic samples collection        X      
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X- To do 
1. Screening procedures must be performed within 14 days prior to baseline visit (start of dosing). Females of childbearing potential must use an approved birth control 
method at least 30 days prior to baseline visit. 
2. Discontinuation: if subject withdraws from the study prior to Month 18, the subject must be seen for an Early Termination Visit within 30 days after treatment 
discontinuation. 
3. Follow-up visit should be conducted 4 weeks after Month 18/Early Termination visit. 
STUDY PROCEDURE 
Screening/ 
Baseline Phase 
Treatment Phase 
Screening Baseline Telephone 
Contact 
Week 1, 2, 3, 
4 and 5 
Weekly  
Assessments 
Month 1.5 
(Week 6)  
Visit 
Telephone 
Contact 
Month 2 
Month 3 
(Week 12) 
Visit 
Month 6  
(Week 26 
Visit 
Telephone 
Contact 
Month 9 
Month 12 
(Week 52)
Visit 
Telephone 
Contact 
Month 15
Month 18 / Early 
termination2  
(Week 78) Visit
Follow-up  
Visit3 
Dose calculation  X   X  X       
Verify/Adjust dose level        X  X    
Dispense study medication  X   X  X X  X    
Medical events X X            
Adverse events   X  X X X X X X X X X 
Concomitant Medications  X X  X X X X X X X X  
Return used and unused study 
medication 
    X  X X  X  X  
Compliance     X  X X  X  X  
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20.2 Acceptable Methods of Contraception and Definitions Related to 
Childbearing Potential 
 
1. Approved methods of contraception will consist of the following for the purposes of this 
study or must follow local requirements: 
 Oral contraceptive medications with condom, or diaphragm or spermicide 
 Hormonal implants with condom, or diaphragm or spermicide 
 Injectable contraceptive medications with condom, or diaphragm or spermicide 
 Diaphragm or condom used with spermicide. 
 
If the hormonal contraception is used, it should have a Pearl index <1%. 
 
2. Women who are not able to bear children and therefore do not need to practice a medically 
accepted method of contraception will include those who: 
 Have had a tubal ligation 
 Are post-menopausal (i.e. last menstrual period was more than 2 years ago) 
 Have had an hysterectomy or oophrectomy 
 Participates in a non-heterosexual lifestyle,  
  Have a male sexual partner has been sterilized (supporting evidence required).  
 
3. Patients who are peri-menopausal (i.e. less than 2 years since their last menstrual period), 
must have a pregnancy test and must use one of the medically accepted methods listed above 
(under point 2) if they wish to participate in the study. 
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20.3 List of Rescue Medications 
Any use of the rescue medications listed below must be documented including the reason.  
Rescue medication is defined as the introduction of a new medication, or a change in 
dosing of a current medication, that is prescribed because of a worsening of the patient’s 
condition and that has the potential to have an effect on dystonia symptoms. 
 
1. Baclofen (including baclofen pump)  
2. Trihexyphenidyl 
3. Clonazepam 
4. Tizanidine 
5. Tetrabenazine 
6. Botox 
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20.4 List of Prohibited Drugs 
The use of the following medications is precluded by protocol TIRCON2012V1. All 
exceptions must be approved by the Sponsor  
1. Any investigational drug 
2. Chloramphenicol (CHLOROMYCETIN) 
3. Clozapine (CLOZARIL), Doxepin HCl (SINEQUAN), Amitriptyline 
HCl/Perphenazine (ETRAFON) and other tricyclic antidepressants 
4. Clomipramine hydrochloride (ANAFRANIL) 
5. Propranolol hydrochloride (INDERAL) 
6. Bepredil (VASCOR) 
7. Aminoglutethimide (CYTADREN) 
8. Interferon (INTRON A) 
9. Para-aminophenol (e.g., paracetamol or acetaminophen) or pyrazolone 
         derivatives 
10. Phenytoin (DILANTIN), Carbamazepine 
11. Chlordiazepoxide (LIBRIUM) and other benzodiazepines 
12. Phenylbutazone 
13. Mefenamic Acid (PONSTAN) 
14. Metoclopramide  HCl (REGLAN) 
15. Chlorpromazine, prochlorperazine and other phenothiazines 
16. Procainamide 
17. Levamisole (ERGAMISOLE) 
18. Diclofenac Sodium (VOLTAREN) 
19. Hydroxyurea (Hydrea) 
20. Trimethoprim/sulfamethoxazole (Bactrim/Septra) 
21. Aminopyrine 
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20.5 Rating Scales 
20.5.1 BAD 
 
Permission granted by Blackwell Publishing Ltd.  
 
Barry-Albright Dystonia Scale 
Patient’s Number:__________________________________         Date: _____________ 
 
Directions: Assess the patient for dystonia in each of the following regions: eyes, mouth, 
neck, trunk, each upper and lower extremity (8 body regions). Write the scores on the lines 
provided (whole numbers only). Rate severity based only on dystonia as evidenced by 
abnormal movements or postures. 
 
Dystonia: sustained muscle contractions causing twisting and repetitive movements or 
abnormal postures. 
Spasticity: velocity-dependent resistance to passive stretch. 
Athetosis: distal writhing or contorting movements. 
Chorea: brief, rapid, unsustained, irregular movements. 
Ataxia: incoordination of movement characterized by wide-based unsteady gait, falling 
movements. 
 
 
Eyes: Signs of dystonia of the eyes include: Prolonged eyelid spasms and/or forced eye 
deviations. 
0____ Absence of eye dystonia. 
1____ Slight. Dystonia less than 10% of the time. 
2____ Mild. Frequent blinking without prolonged spasms of eye closure and/or eye 
movements less than 50% of the time. 
3____ Moderate. Prolonged spasms of eyelid closure, but eyes open most of the time. 
4____ Severe. Prolonged spasms of eyelid closure, with eyes closed at least 30% of the 
time. 
*____ Unable to assess eye movements. 
 
Eyes: ______ 
 
 
Mouth: Signs of dystonia of the mouth include: Grimacing, clenched or deviated jaw, 
forced open mouth, and/or forceful tongue thrusting. 
0____ Absence of mouth dystonia. 
1____ Slight. Dystonia less than 10% of the time and does not interfere with speech or 
feeding. 
2____ Mild. Dystonia less than 50% of the time and does not interfere with speech or 
feeding. 
3____ Moderate. Dystonia more than 50% of the time, or dystonia that interferes with 
speech or feeding. 
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4____ Severe. Dystonia more than 50% of the time or dystonia that prevents speech or 
feeding. 
*____ Unable to assess mouth movements. 
 
Mouth: ______ 
 
 
Neck: Signs of dystonia of the neck include: Pulling of the neck into any plane of motion: 
Extension, flexion, lateral flexion or rotation. 
0____ Absence of neck dystonia. 
1____ Slight. Pulling less than 10% of the time and does not interfere with lying, sitting, 
standing or walking. 
2____ Mild. Pulling less than 50% of the time and does not interfere with lying, sitting, 
standing or walking. 
3____ Moderate. Pulling more than 50% of the time or dystonia that interferes with lying, 
sitting, standing or walking. 
4____ Severe. Pulling more than 50% of the time or dystonia that prevents sitting in 
standard wheelchair, standing or walking (i.e. requires more than standard head rest 
for seating). 
*____ Unable to assess neck movements. 
 
Neck: ______ 
 
 
Trunk: 
0____ Absence of trunk dystonia. 
1____ Slight. Pulling less than 10% of the time and does not interfere with lying, sitting, 
standing or walking. 
2____ Mild. Pulling less than 50% of the time and does not interfere with lying, sitting, 
standing or walking. 
3____ Moderate. Pulling more than 50% of the time or dystonia that interferes with lying, 
sitting, standing or walking. 
4____ Severe. Pulling more than 50% of the time or dystonia that prevents sitting in 
standard wheelchair, standing or walking. 
*____ Unable to assess trunk movements. 
 
Trunk: ______ 
 
 
Upper Extremities: 
0____ Absence of upper extremity dystonia. 
1____ Slight. Dystonia less than 10% of the time and does not interfere with normal 
positioning or functional activities. 
2____ Mild. Dystonia less than 50% of the time and does not interfere with normal 
positioning or functional activities. 
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3____ Moderate. Dystonia more than 50% of the time or dystonia that interferes with 
normal positioning or upper extremity function. 
4____ Severe. Dystonia more than 50% of the time or dystonia that prevents normal 
positioning or upper 
extremity function; i.e., arms restrained in wheelchair to prevent injury. 
*____ Unable to assess upper extremity movements. 
 
Left Upper Extremity: ______ 
Right Upper Extremity: ______ 
 
 
Lower Extremities: 
0____ Absence of lower extremity dystonia. 
1____ Slight. Dystonia less than 10% of the time and does not interfere with normal 
positioning or functional activities. 
2____ Mild. Dystonia less than 50% of the time and does not interfere with normal 
positioning or functional activities. 
3____ Moderate. Dystonia more than 50% of the time or dystonia that interferes with 
normal positioning or lower extremity weight bearing or function. 
4____ Severe. Dystonia more than 50% of the time or dystonia that prevents normal 
positioning or lower extremity weight bearing or function. 
*____ Unable to assess lower extremity movements. 
 
Left Lower Extremity: ______ 
Right Lower Extremity: ______ 
 
 
Total Score: ________                                         Rater’s Initials: _______ 
TIRCON: Deferiprone PKAN Study Protocol             VERSION: Amendment 6 Final 
STUDY CODE: TIRCON2012V1                                 DATE: 31 JUL 2013 
Page 105 of 150 
 
20.5.2 PGI-I 
 
The Patient Global Impression of Improvement (PGI-I) is a global index used to rate the 
response of a condition to a therapy. Patients are asked to rate their total improvement 
since the beginning of the study. A 7 point rating scale is used as:  
1, very much improved;  
2, much improved;  
3, minimally improved;  
4, no change;  
5, minimally worse;  
6, much worse; or  
7, very much worse  
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20.5.3 UPDRS 
 
UNIFIED PARKINSON'S DISEASE RATING SCALE (UPDRS) 
 
Original Source: Fahn S, Elton RL, Members of the UPDRS Development Committee. 
The unified Parkinson’s Disease Rating Scale. In Fahn S, Marsden CD, Calne DB, 
Goldstein M, eds: Recent Developments in Parkinson’s Disease, Vol. 2. Florham Park, NJ: 
Macmillan Healthcare Information, 1987. pp 153-163, 293-304. 
 
 
APPENDIX 1 
Unified Parkinson’s Disease Rating Scale 
Version 3.0 – February 1987 
Definitions of 0-4 Scale 
 
I. MENTATION, BEHAVIOR AND MOOD 
1. Intellectual Impairment: 
0 = None. 
1 = Mild. Consistent forgetfulness with partial recollection of events and no other 
difficulties. 
2 = Moderate memory loss, with disorientation and moderate difficulty handling complex 
problems. 
Mild but definite impairment of function at home with need of occasional prompting. 
3 = Severe memory loss with disorientation for time and often to place. Severe impairment 
in handling problems. 
4 = Severe memory loss with orientation preserved to person only. Unable to make 
judgements or solve problems. Requires much help with personal care. Cannot be left 
alone at all. 
 
2. Thought Disorder: (DUE TO DEMENTIA OR DRUG INTOXICATION) 
0 = None. 
1 = Vivid dreaming. 
2 = "Benign" hallucinations with insight retained. 
3 = Occasional to frequent hallucinations or delusions; without insight; could interfere 
with daily activities. 
4 = Persistent hallucinations, delusions, or florid psychosis. Not able to care for self. 
 
3. Depression: 
0 = None. 
1 = Periods of sadness or guilt greater than normal, never sustained for days or weeks. 
2 = Sustained depression (1 week or more). 
3 = Sustained depression with vegetative symptoms (insomnia, anorexia, weight loss, loss 
of interest). 
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4 = Sustained depression with vegetative symptoms and suicidal thoughts or intent. 
 
4. Motivation/Initiative: 
0 = Normal. 
1 = Less assertive than usual; more passive. 
2 = Loss of initiative or disinterest in elective (nonroutine) activities. 
3 = Loss of initiative or disinterest in day to day (routine) activities. 
4 = Withdrawn, complete loss of motivation. 
 
 
 
II. ACTIVITIES OF DAILY LIVING (DETERMINE FOR "ON/OFF") 
 
5. Speech: 
0 = Normal. 
1 = Mildly affected. No difficulty being understood. 
2 = Moderately affected. Sometimes asked to repeat statements. 
3 = Severely affected. Frequently asked to repeat statements. 
4 = Unintelligible most of the time. 
 
6. Salivation: 
0 = Normal. 
1 = Slight but definite excess of saliva in mouth; may have nighttime drooling. 
2 = Moderately excessive saliva; may have minimal drooling. 
3 = Marked excess of saliva with some drooling. 
4 = Marked drooling, requires constant tissue or handkerchief. 
 
7. Swallowing: 
0 = Normal. 
1 = Rare choking. 
2 = Occasional choking. 
3 = Requires soft food. 
4 = Requires NG tube or gastrotomy feeding. 
 
8. Handwriting: 
0 = Normal. 
1 = Slightly slow or small. 
2 = Moderately slow or small; all words are legible. 
3 = Severely affected; not all words are legible. 
4 = The majority of words are not legible. 
 
9. Cutting food and handling utensils: 
0 = Normal. 
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1 = Somewhat slow and clumsy, but no help needed. 
2 = Can cut most foods, although clumsy and slow; some help needed. 
3 = Food must be cut by someone, but can still feed slowly. 
4 = Needs to be fed. 
 
10. Dressing: 
0 = Normal. 
1 = Somewhat slow, but no help needed. 
2 = Occasional assistance with buttoning, getting arms in sleeves. 
3 = Considerable help required, but can do some things alone. 
4 = Helpless. 
 
11. Hygiene: 
0 = Normal. 
1 = Somewhat slow, but no help needed. 
2 = Needs help to shower or bathe; or very slow in hygienic care. 
3 = Requires assistance for washing, brushing teeth, combing hair, going to bathroom. 
4 = Foley catheter or other mechanical aids. 
 
12. Turning in bed and adjusting bed clothes: 
0 = Normal. 
1 = Somewhat slow and clumsy, but no help needed. 
2 = Can turn alone or adjust sheets, but with great difficulty. 
3 = Can initiate, but not turn or adjust sheets alone. 
4 = Helpless. 
 
13. Falling- (unrelated to freezing): 
0 = None. 
1 = Rare falling. 
2 = Occasionally falls, less than once per day. 
3 = Falls an average of once daily. 
4 = Falls more than once daily. 
 
14. Freezing when walking: 
0 = None. 
1 = Rare freezing when walking; may have start hesitation. 
2 = Occasional freezing when walking. 
3 = Frequent freezing. Occasionally falls from freezing. 
4 = Frequent falls from freezing. 
 
15. Walking: 
0 = Normal. 
1 = Mild difficulty. May not swing arms or may tend to drag leg. 
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2 = Moderate difficulty, but requires little or no assistance. 
3 = Severe disturbance of walking, requiring assistance. 
4 = Cannot walk at all, even with assistance. 
 
16. Tremor: 
0 = Absent. 
1 = Slight and infrequently present. 
2 = Moderate; bothersome to patient. 
3 = Severe; interferes with many activities. 
4 = Marked; interferes with most activities. 
 
17. Sensory complaints related to parkinsonism: 
0 = None. 
1 = Occasionally has numbness, tingling, or mild aching. 
2 = Frequently has numbness, tingling, or aching; not distressing. 
3 = Frequent painful sensations. 
4 = Excruciating pain. 
 
 
III. MOTOR EXAMINATION 
 
18. Speech: 
0 = Normal. 
1 = Slight loss of expression, diction and/or volume. 
2 = Monotone, slurred but understandable; moderately impaired. 
3 = Marked impairment, difficult to understand. 
4 = Unintelligible. 
 
19. Facial Expression: 
0 = Normal. 
1 = Minimal hypomimia, could be normal "Poker Face". 
2 = Slight but definitely abnormal diminution of facial expression. 
3 = Moderate hypomimia; lips parted some of the time. 
4 = Masked or fixed facies with severe or complete loss of facial expression; lips parted 
1/4 inch or more. 
 
20. Tremor at rest: 
0 = Absent. 
1 = Slight and infrequently present. 
2 = Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently 
present. 
3 = Moderate in amplitude and present most of the time. 
4 = Marked in amplitude and present most of the time. 
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21. Action or Postural Tremor of hands: 
0 = Absent. 
1 = Slight; present with action. 
2 = Moderate in amplitude, present with action. 
3 = Moderate in amplitude with posture holding as well as action. 
4 = Marked in amplitude; interferes with feeding. 
 
22. Rigidity: (Judged on passive movement of major joints with patient relaxed in sitting 
position. Cogwheeling to be ignored.) 
0 = Absent. 
1 = Slight or detectable only when activated by mirror or other movements. 
2 = Mild to moderate. 
3 = Marked, but full range of motion easily achieved. 
4 = Severe, range of motion achieved with difficulty. 
 
23. Finger Taps: (Patient taps thumb with index finger in rapid succession with widest 
amplitude possible, each hand separately.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in 
movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement. 
4 = Can barely perform the task. 
 
24. Hand Movements: (Patient opens and closes hands in rapid succession with widest 
amplitude possible, each hand separately.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in 
movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement. 
4 = Can barely perform the task. 
 
25. Rapid Alternating Movements of Hands: (Pronation-supination movements of hands, 
vertically and horizontally, with as large an amplitude as possible, both hands 
simultaneously.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in 
movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement. 
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4 = Can barely perform the task. 
 
26. Leg Agility: (Patient taps heel on the ground in rapid succession picking up entire leg. 
Amplitude should be at least 3 inches.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in 
movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement. 
4 = Can barely perform the task. 
 
27. Arising from Chair: (Patient attempts to arise from a straight-back wood or metal 
chair with arms folder across chest.) 
(Patient attempts to rise from a straightbacked chair, with arms folded across chest.) 
0 = Normal. 
1 = Slow; or may need more than one attempt. 
2 = Pushes self up from arms of seat. 
3 = Tends to fall back and may have to try more than one time, but can get up without 
help. 
4 = Unable to arise without help. 
 
28. Posture: 
0 = Normal erect. 
1 = Not quite erect, slightly stooped posture; could be normal for older person. 
2 = Moderately stooped posture, definitely abnormal; can be slightly leaning to one side. 
3 = Severely stooped posture with kyphosis; can be moderately leaning to one side. 
4 = Marked flexion with extreme abnormality of posture. 
 
29. Gait: 
0 = Normal. 
1 = Walks slowly, may shuffle with short steps, but no festination (hastening steps) or 
propulsion. 
2 = Walks with difficulty, but requires little or no assistance; may have some festination, 
short steps, or propulsion. 
3 = Severe disturbance of gait, requiring assistance. 
4 = Cannot walk at all, even with assistance. 
 
30. Postural Stability: (Response to sudden, strong posterior displacement produced by 
pull on shoulders while patient erect with eyes open and feet slightly apart. Patient is 
prepared.) 
0 = Normal. 
1 = Retropulsion, but recovers unaided. 
2 = Absence of postural response; would fall if not caught by examiner. 
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3 = Very unstable, tends to lose balance spontaneously. 
4 = Unable to stand without assistance. 
 
31. Body Bradykinesia and Hypokinesia: (Combining slowness, hesitancy, decreased 
armswing, small amplitude, and poverty of movement in general.) 
0 = None. 
1 = Minimal slowness, giving movement a deliberate character; could be normal for some 
persons. Possibly reduced amplitude. 
2 = Mild degree of slowness and poverty of movement which is definitely abnormal. 
Alternatively, some reduced amplitude. 
3 = Moderate slowness, poverty or small amplitude of movement. 
4 = Marked slowness, poverty or small amplitude of movement. 
 
 
IV. COMPLICATIONS OF THERAPY (In the past week) 
 
A. Dyskinesias 
 
32. Duration: What proportion of the waking day are dyskinesias present? (Historical 
information.) 
0 = None 
1 = 1-25% of day. 
2 = 26-50% of day. 
3 = 51-75% of day. 
4 = 76-100% of day. 
 
33. Disability: How disabling are the dyskinesias? (Historical information; may be 
modified by office examination.) 
0 = Not disabling. 
1 = Mildly disabling. 
2 = Moderately disabling. 
3 = Severely disabling. 
4 = Completely disabled. 
 
34. Painful Dyskinesias: How painful are the dyskinesias? 
0 = No painful dyskinesias. 
1 = Slight. 
2 = Moderate. 
3 = Severe. 
4 = Marked. 
 
35. Presence of Early Morning Dystonia: (Historical information) 
0 = No 
1 = Yes 
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B. Clinical Fluctuations 
 
36. Are "off" periods predictable as to timing after a dose of medication? 
0 = No 
1 = Yes 
 
37. Are "off" periods unpredictable as to timing after a dose of medication? 
0 = No 
1 = Yes 
 
38. Do "off" periods come on suddenly, e.g., over a few seconds? 
0 = No 
1 = Yes 
 
39. What proportion of the waking day is the patient "off" on average? 
0 = None 
1 = 1-25% of day. 
2 = 26-50% of day. 
3 = 51-75% of day. 
4 = 76-100% of day. 
 
 
C. Other Complications 
 
40. Does the patient have anorexia, nausea, or vomiting? 
0 = No 
1 = Yes 
 
41. Any sleep disturbances, e.g., insomnia or hypersomnolence? 
0 = No 
1 = Yes 
 
42. Does the patient have symptomatic orthostasis? 
0 = No 
1 = Yes 
 
V. MODIFIED HOEHN AND YAHR STAGING 
 
STAGE 0    = No signs of disease. 
STAGE 1    = Unilateral disease. 
STAGE 1.5 = Unilateral plus axial involvement. 
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STAGE 2    = Bilateral disease, without impairment of balance. 
STAGE 2.5 = Mild bilateral disease, with recovery on pull test. 
STAGE 3    = Mild to moderate bilateral disease; some postural instability; physically 
independent. 
STAGE 4    = Severe disability; still able to walk or stand unassisted. 
STAGE 5    = Wheelchair bound or bedridden unless aided. 
 
VI. SCHWAB AND ENGLAND ACTIVITIES OF DAILY LIVING SCALE 
 
100% = Completely independent. Able to do all chores without slowness, difficulty or 
impairment. Essentially normal. Unaware of any difficulty. 
90%  =  Completely independent. Able to do all chores with some degree of slowness, 
difficulty  and impairment. Might take twice as long. Beginning to be aware of 
difficulty. 
80%  =  Completely independent in most chores. Takes twice as long. Conscious of 
difficulty and slowness. 
70%  =  Not completely independent. More difficulty with some chores. Three to four 
times as long in some. Must spend a large part of the day with chores. 
60%  =  Some dependency. Can do most chores, but exceedingly slowly and with much 
effort. Errors; some impossible. 
50%  =  More dependent. Help with half, slower, etc. Difficulty with everything. 
40%  =  Very dependent. Can assist with all chores, but few alone. 
30%  =  With effort, now and then does a few chores alone or begins alone. Much help 
needed. 
20%  =  Nothing alone. Can be a slight help with some chores. Severe invalid. 
10%  =  Totally dependent, helpless. Complete invalid. 
0%    =  Vegetative functions such as swallowing, bladder and bowel functions are not 
functioning. Bedridden. 
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20.5.4 FIM 
 
TIRCON: Deferiprone PKAN Study Protocol             VERSION: Amendment 6 Final 
STUDY CODE: TIRCON2012V1                                 DATE: 31 JUL 2013 
Page 116 of 150 
 
 
TIRCON: Deferiprone PKAN Study Protocol             VERSION: Amendment 6 Final 
STUDY CODE: TIRCON2012V1                                 DATE: 31 JUL 2013 
Page 117 of 150 
 
 
TIRCON: Deferiprone PKAN Study Protocol             VERSION: Amendment 6 Final 
STUDY CODE: TIRCON2012V1                                 DATE: 31 JUL 2013 
Page 118 of 150 
 
20.5.5 WeeFIM 
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20.5.6 PedsQL 
PedsQL 4.0 Parents (ages 2-4)     Copyright © 1998 JW Varni, Ph.D. All rights reserved                                                                       
01/00                                  
PedsQL-4.0-Core – US/English 
PedsQL-4.0-Core-YC_eng-USori.doc 
 
 
 
 
 
PedsQL ™ 
Pediatric Quality of Life  
Inventory  
 
                                                       Version 4.0 
 
 
PARENT REPORT for TODDLERS (ages 2-4) 
 
 
 
 
DIRECTIONS 
 
     On the following page is a list of things that might be a problem for your child. 
     Please tell us how much of a problem each one has been for your child 
     during the past  ONE  month by circling: 
 
0 if it is never a problem  
1 if it is almost never a problem  
2 if it is sometimes a problem 
3 if it is often a problem 
4 if it is almost always a problem 
 
     There are no right or wrong answers.   
     If you do not understand a question, please ask for help. 
 
 
 
 
 
ID# 
__________________________ 
 
Date:________________________
_ 
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In the past ONE month, how much of a problem has your child had with … 
 
PHYSICAL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Walking  0 1 2 3 4 
2.  Running 0 1 2 3 4 
3.  Participating in active play or exercise  0 1 2 3 4 
4.  Lifting something heavy 0 1 2 3 4 
5.  Bathing  0 1 2 3 4 
6.  Helping to pick up his or her toys  0 1 2 3 4 
7.  Having hurts or aches 0 1 2 3 4 
8.  Low energy level 0 1 2 3 4 
 
EMOTIONAL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Feeling afraid or scared 0 1 2 3 4 
2.  Feeling sad or blue 0 1 2 3 4 
3.  Feeling angry 0 1 2 3 4 
4.  Trouble sleeping 0 1 2 3 4 
5.  Worrying  0 1 2 3 4 
 
SOCIAL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Playing with other children 0 1 2 3 4 
2.  Other kids not wanting to play with him or her 0 1 2 3 4 
3.  Getting teased by other children 0 1 2 3 4 
4.  Not able to do things that other children his or her 
     age can do 0 1 2 3 4 
5.  Keeping up when playing with other children 0 1 2 3 4 
 
*Please complete this section if your child attends school or daycare 
SCHOOL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Doing the same school activities as peers 0 1 2 3 4 
2.  Missing school/daycare because of not feeling well 0 1 2 3 4 
3.  Missing school/daycare to go to the doctor or 
     Hospital 
0 1 2 3 4 
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PedsQL™ 
Pediatric Quality of Life 
Inventory 
 
Version 4.0 
 
YOUNG CHILD REPORT (ages 5-7) 
 
Instructions for interviewer: 
 
I am going to ask you some questions about things that might be a problem for some 
children.  I want to know how much of a problem any of these things might be for you. 
  
Show the child the template and point to the responses as you read. 
 
If it is not at all a problem for you, point to the smiling face  
 
If it is sometimes a problem for you, point to the middle face  
 
If it is a problem for you a lot, point to the frowning face 
 
I will read each question. Point to the pictures to show me how much of a problem it is 
for you. Let’s try a practice one first. 
 
 Not at all Sometimes  A lot  
1 Is it hard for you to snap your fingers    
         
Ask the child to demonstrate snapping his or her fingers to determine whether or not the 
question was answered correctly.  Repeat the question if the child demonstrates a response 
that is different from his or her action.    
ID# 
__________________________ 
 
Date:________________________
_ 
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Think about how you have been doing for the last few weeks.  Please listen carefully to 
each sentence and tell me how much of a problem this is for you. 
 
After reading the item, gesture to the template.  If the child hesitates or does not seem to understand 
how to answer, read the response options while pointing at the faces. 
 
PHYSICAL FUNCTIONING (problems with…) Not  
at all 
Some-
times  
A lot 
1.  Is it hard for you to walk  0 2 4 
2.  Is it hard for you to run 0 2 4 
3.  Is it hard for you to play sports or exercise 0 2 4 
4.  Is it hard for you to pick up big things  0 2 4 
5.  Is it hard for you to take a bath or shower  0 2 4 
6.  Is it hard for you to do chores (like pick up your toys)  0 2 4 
7.  Do you have hurts or aches (Where?___________ ) 0 2 4 
8.  Do you ever feel too tired to play  0 2 4 
 
Remember, tell me how much of a problem this has been for you for the last few weeks. 
EMOTIONAL FUNCTIONING (problems with…) Not  
at all 
Some-
times  
A lot 
1.  Do you feel scared 0 2 4 
2.  Do you feel sad 0 2 4 
3.  Do you feel mad 0 2 4 
4.  Do you have trouble sleeping 0 2 4 
5.  Do you worry about what will happen to you 0 2 4 
 
SOCIAL FUNCTIONING (problems with…) Not  
at all 
Some-
times  
A lot 
1.  Is it hard for you to get along with other kids 0 2 4 
2.  Do other kids say they do not want to play with you 0 2 4 
3.  Do other kids tease you  0 2 4 
4.  Can other kids do things that you cannot do 0 2 4 
5.  Is it hard for you to keep up when you play with other 
     Kids 0 2 4 
 
SCHOOL FUNCTIONING (problems with…) Not  
at all 
Some-
times  
A lot 
1.  Is it hard for you to pay attention in school  0 2 4 
2.  Do you forget things  0 2 4 
3.  Is it hard to keep up with schoolwork  0 2 4 
4.  Do you miss school because of not feeling good  0 2 4 
5.  Do you miss school because you have to go to the 
     doctor’s or hospital 0 2 4 
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How much of a problem is this for 
you? 
 
 
 
 
         Not at all       Sometimes       A lot 
 
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PedsQL ™  
Pediatric Quality of Life  
Inventory  
 
Version 4.0 
 
 
PARENT REPORT for YOUNG CHILDREN (ages 5-7) 
 
 
 
 
DIRECTIONS 
 
     On the following page is a list of things that might be a problem for your child. 
     Please tell us how much of a problem each one has been for your child 
     during the past  ONE  month by circling: 
 
0 if it is never a problem  
1 if it is almost never a problem  
2 if it is sometimes a problem 
3 if it is often a problem 
4 if it is almost always a problem 
 
     There are no right or wrong answers.   
     If you do not understand a question, please ask for help. 
 
 
 
 
 
 
ID# 
__________________________ 
 
Date:________________________
_ 
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In the past ONE month, how much of a problem has your child had with 
… 
PHYSICAL FUNCTIONING (problems with…) Never Almost 
Never
Some-
times 
Often Almost 
Always
1.  Walking more than one block 0 1 2 3 4 
2.  Running 0 1 2 3 4 
3.  Participating in sports activity or exercise  0 1 2 3 4 
4.  Lifting something heavy 0 1 2 3 4 
5.  Taking a bath or shower by him or herself  0 1 2 3 4 
6.  Doing chores, like picking up his or her toys  0 1 2 3 4 
7.  Having hurts or aches 0 1 2 3 4 
8.  Low energy level 0 1 2 3 4 
 
EMOTIONAL FUNCTIONING (problems with…) Never Almost 
Never
Some-
times 
Often Almost 
Always
1.  Feeling afraid or scared 0 1 2 3 4 
2.  Feeling sad or blue 0 1 2 3 4 
3.  Feeling angry 0 1 2 3 4 
4.  Trouble sleeping 0 1 2 3 4 
5.  Worrying about what will happen to him or her 0 1 2 3 4 
 
SOCIAL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Getting along with other children 0 1 2 3 4 
2.  Other kids not wanting to be his or her friend 0 1 2 3 4 
3.  Getting teased by other children 0 1 2 3 4 
4.  Not able to do things that other children his or 
     her age can do  
0 1 2 3 4 
5.  Keeping up when playing with other children 0 1 2 3 4 
 
SCHOOL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Paying attention in class 0 1 2 3 4 
2.  Forgetting things 0 1 2 3 4 
3.  Keeping up with school activities 0 1 2 3 4 
4.  Missing school because of not feeling well  0 1 2 3 4 
5.  Missing school to go to the doctor or hospital 0 1 2 3 4 
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PedsQL ™  
Pediatric Quality of Life  
Inventory 
 
Version 4.0 
 
 
CHILD  REPORT (ages 8-12) 
 
 
 
 
DIRECTIONS 
 
     On the following page is a list of things that might be a problem for you. 
     Please tell us how much of a problem each one has been for you 
     during the past  ONE  month by circling: 
 
0 if it is never a problem  
1 if it is almost never a problem  
2 if it is sometimes a problem 
3 if it is often a problem 
4 if it is almost always a problem 
 
     There are no right or wrong answers.   
     If you do not understand a question, please ask for help. 
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Date:________________________
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In the past ONE month, how much of a problem has this been for you … 
     
ABOUT MY HEALTH AND ACTIVITIES (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  It is hard for me to walk more than one block 0 1 2 3 4 
2.  It is hard for me to run 0 1 2 3 4 
3.  It is hard for me to do sports activity or exercise 0 1 2 3 4 
4.  It is hard for me to lift something heavy 0 1 2 3 4 
5.  It is hard for me to take a bath or shower by myself  0 1 2 3 4 
6.  It is hard for me to do chores around the house  0 1 2 3 4 
7.  I hurt or ache  0 1 2 3 4 
8.  I have low energy 0 1 2 3 4 
   
ABOUT MY FEELINGS (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.   I feel afraid or scared 0 1 2 3 4 
2.   I feel sad or blue 0 1 2 3 4 
3.   I feel angry 0 1 2 3 4 
4.   I have trouble sleeping 0 1 2 3 4 
5.   I worry about what will happen to me 0 1 2 3 4 
 
HOW I GET ALONG WITH OTHERS (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  I have trouble getting along with other kids 0 1 2 3 4 
2.  Other kids do not want to be my friend  0 1 2 3 4 
3.  Other kids tease me  0 1 2 3 4 
4.  I cannot do things that other kids my age can do 0 1 2 3 4 
5.  It is hard to keep up when I play with other kids 0 1 2 3 4 
  
ABOUT SCHOOL (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.   It is hard to pay attention in class 0 1 2 3 4 
2.   I forget things 0 1 2 3 4 
3.   I have trouble keeping up with my schoolwork 0 1 2 3 4 
4.   I miss school because of not feeling well  0 1 2 3 4 
5.   I miss school to go to the doctor or hospital 0 1 2 3 4 
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PedsQL ™  
Pediatric Quality of Life  
Inventory  
 
Version 4.0 
 
 
PARENT REPORT for CHILDREN (ages 8-12) 
 
 
 
 
DIRECTIONS 
 
     On the following page is a list of things that might be a problem for your child. 
     Please tell us how much of a problem each one has been for your child 
     during the past  ONE  month by circling: 
 
0 if it is never a problem  
1 if it is almost never a problem  
2 if it is sometimes a problem 
3 if it is often a problem 
4 if it is almost always a problem 
 
     There are no right or wrong answers.   
     If you do not understand a question, please ask for help. 
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Date:________________________
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In the past ONE month, how much of a problem has your child had with… 
 
PHYSICAL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Walking more than one block 0 1 2 3 4 
2.  Running 0 1 2 3 4 
3.  Participating in sports activity or exercise  0 1 2 3 4 
4.  Lifting something heavy 0 1 2 3 4 
5.  Taking a bath or shower by him or herself  0 1 2 3 4 
6.  Doing chores around the house  0 1 2 3 4 
7.  Having hurts or aches 0 1 2 3 4 
8.  Low energy level 0 1 2 3 4 
 
EMOTIONAL FUNCTIONING (problems with…) Never Almost 
Never
Some-
times 
Often Almost 
Always
1.  Feeling afraid or scared 0 1 2 3 4 
2.  Feeling sad or blue 0 1 2 3 4 
3.  Feeling angry 0 1 2 3 4 
4.  Trouble sleeping 0 1 2 3 4 
5.  Worrying about what will happen to him or her 0 1 2 3 4 
 
SOCIAL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Getting along with other children 0 1 2 3 4 
2.  Other kids not wanting to be his or her friend 0 1 2 3 4 
3.  Getting teased by other children 0 1 2 3 4 
4.  Not able to do things that other children his or her 
     age can do  
0 1 2 3 4 
5.  Keeping up when playing with other children 0 1 2 3 4 
 
SCHOOL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Paying attention in class 0 1 2 3 4 
2.  Forgetting things 0 1 2 3 4 
3.  Keeping up with schoolwork 0 1 2 3 4 
4.  Missing school because of not feeling well  0 1 2 3 4 
5.  Missing school to go to the doctor or hospital 0 1 2 3 4 
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PedsQL ™  
Pediatric Quality of Life  
Inventory 
 
Version 4.0 
 
 
TEEN REPORT (ages 13-18) 
 
 
 
 
DIRECTIONS 
 
     On the following page is a list of things that might be a problem for you. 
     Please tell us how much of a problem each one has been for you 
     during the past  ONE  month by circling: 
 
0 if it is never a problem  
1 if it is almost never a problem  
2 if it is sometimes a problem 
3 if it is often a problem 
4 if it is almost always a problem 
 
     There are no right or wrong answers.   
     If you do not understand a question, please ask for help. 
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Date:________________________
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In the past ONE month, how much of a problem has this been for you … 
 
ABOUT MY HEALTH AND ACTIVITIES (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  It is hard for me to walk more than one block 0 1 2 3 4 
2.  It is hard for me to run 0 1 2 3 4 
3.  It is hard for me to do sports activity or exercise  0 1 2 3 4 
4.  It is hard for me to lift something heavy 0 1 2 3 4 
5.  It is hard for me to take a bath or shower by myself  0 1 2 3 4 
6.  It is hard for me to do chores around the house  0 1 2 3 4 
7.  I hurt or ache  0 1 2 3 4 
8.  I have low energy 0 1 2 3 4 
 
ABOUT MY FEELINGS (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.   I feel afraid or scared 0 1 2 3 4 
2.   I feel sad or blue 0 1 2 3 4 
3.   I feel angry 0 1 2 3 4 
4.   I have trouble sleeping 0 1 2 3 4 
5.   I worry about what will happen to me 0 1 2 3 4 
 
HOW I GET ALONG WITH OTHERS (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  I have trouble getting along with other teens 0 1 2 3 4 
2.  Other teens do not want to be my friend  0 1 2 3 4 
3.  Other teens tease me  0 1 2 3 4 
4.  I cannot do things that other teens my age can do 0 1 2 3 4 
5.  It is hard to keep up with my peers 0 1 2 3 4 
    
ABOUT SCHOOL (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.   It is hard to pay attention in class 0 1 2 3 4 
2.   I forget things 0 1 2 3 4 
3.   I have trouble keeping up with my schoolwork 0 1 2 3 4 
4.   I miss school because of not feeling well  0 1 2 3 4 
5.   I miss school to go to the doctor or hospital 0 1 2 3 4 
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PedsQL ™  
Pediatric Quality of Life  
Inventory  
 
Version 4.0 
 
PARENT REPORT for TEENS (ages 13-18) 
 
 
 
 
DIRECTIONS 
 
     On the following page is a list of things that might be a problem for your teen. 
     Please tell us how much of a problem each one has been for your teen 
     during the past  ONE  month by circling: 
 
0 if it is never a problem  
1 if it is almost never a problem  
2 if it is sometimes a problem 
3 if it is often a problem 
4 if it is almost always a problem 
 
     There are no right or wrong answers.   
     If you do not understand a question, please ask for help. 
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Date:________________________ 
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In the past ONE month, how much of a problem has your teen had with … 
 
PHYSICAL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Walking more than one block 0 1 2 3 4 
2.  Running 0 1 2 3 4 
3.  Participating in sports activity or exercise  0 1 2 3 4 
4.  Lifting something heavy 0 1 2 3 4 
5.  Taking a bath or shower by him or herself  0 1 2 3 4 
6.  Doing chores around the house  0 1 2 3 4 
7.  Having hurts or aches 0 1 2 3 4 
8.  Low energy level 0 1 2 3 4 
 
EMOTIONAL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Feeling afraid or scared 0 1 2 3 4 
2.  Feeling sad or blue 0 1 2 3 4 
3.  Feeling angry 0 1 2 3 4 
4.  Trouble sleeping 0 1 2 3 4 
5.  Worrying about what will happen to him or her 0 1 2 3 4 
 
SOCIAL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1.  Getting along with other teens 0 1 2 3 4 
2.  Other teens not wanting to be his or her friend 0 1 2 3 4 
3.  Getting teased by other teens 0 1 2 3 4 
4.  Not able to do things that other teens his or her age can 
do  
0 1 2 3 4 
5.  Keeping up with other teens 0 1 2 3 4 
 
SCHOOL FUNCTIONING (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1.  Paying attention in class 0 1 2 3 4 
2.  Forgetting things 0 1 2 3 4 
3.  Keeping up with schoolwork 0 1 2 3 4 
4.  Missing school because of not feeling well  0 1 2 3 4 
5.  Missing school to go to the doctor or hospital 0 1 2 3 4 
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Young Adult Quality of Life 
Inventory 
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YOUNG ADULT REPORT (ages 18-25) 
 
 
 
DIRECTIONS 
 
     On the following page is a list of things that might be a problem for you. 
     Please tell us how much of a problem each one has been for you 
     during the past  ONE  month by circling: 
 
0 if it is never a problem  
1 if it is almost never a problem  
2 if it is sometimes a problem 
3 if it is often a problem 
4 if it is almost always a problem 
 
     There are no right or wrong answers.   
     If you do not understand a question, please ask for help. 
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Date:________________________
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In the past ONE month, how much of a problem has this been for you … 
ABOUT MY HEALTH AND ACTIVITIES (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1. It is hard for me to walk more than one block  0 1 2 3 4 
2. It is hard for me to run 0 1 2 3 4 
3. It is hard for me to do sports activity or exercise 0 1 2 3 4 
4. It is hard for me to lift something heavy 0 1 2 3 4 
5. It is hard for me to take a bath or shower by myself 0 1 2 3 4 
6. It is hard for me to do chores around the house  0 1 2 3 4 
7. I hurt or feel pain 0 1 2 3 4 
8. I have low energy 0 1 2 3 4 
 
ABOUT MY FEELINGS (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1. I feel afraid or scared 0 1 2 3 4 
2. I feel sad or blue 0 1 2 3 4 
3. I feel angry 0 1 2 3 4 
4. I have trouble sleeping 0 1 2 3 4 
5. I worry about what will happen to me 0 1 2 3 4 
 
HOW I GET ALONG WITH OTHERS (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1. I have trouble getting along with other young adults 0 1 2 3 4 
2. Other young adults do not want to be my friend 0 1 2 3 4 
3. Other young adults tease me 0 1 2 3 4 
4. I cannot do things that others my age can do 0 1 2 3 4 
5. It is hard to keep up with my peers  0 1 2 3 4 
    
ABOUT MY WORK/STUDIES  (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1. It is hard to pay attention at work or school 0 1 2 3 4 
2. I forget things 0 1 2 3 4 
3. I have trouble keeping up with my work or studies 0 1 2 3 4 
4. I miss work or school because of not feeling well 0 1 2 3 4 
5. I miss work or school to go to the doctor or hospital 0 1 2 3 4 
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PedsQL ™  
Pediatric Quality of Life  
Inventory  
 
Version 4.0 
 
 
 
PARENT REPORT for YOUNG ADULTS (ages 18-25) 
 
 
 
 
 
DIRECTIONS 
 
     On the following page is a list of things that might be a problem for your child. 
     Please tell us how much of a problem each one has been for your child 
     during the past  ONE  month by circling: 
 
0 if it is never a problem  
1 if it is almost never a problem  
2 if it is sometimes a problem 
3 if it is often a problem 
4 if it is almost always a problem 
 
     There are no right or wrong answers.   
     If you do not understand a question, please ask for help. 
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Date:________________________ 
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In the past ONE month, how much of a problem has your child had with … 
PHYSICAL FUNCTIONING (PROBLEMS WITH…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Walking more than one block 0 1 2 3 4 
2.  Running 0 1 2 3 4 
3.  Participating in sports activity or exercise  0 1 2 3 4 
4.  Lifting something heavy 0 1 2 3 4 
5.  Taking a bath or shower by him or herself  0 1 2 3 4 
6.  Doing chores around the house  0 1 2 3 4 
7.  Having hurts or aches 0 1 2 3 4 
8.  Low energy level 0 1 2 3 4 
 
EMOTIONAL FUNCTIONING (PROBLEMS WITH…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1.  Feeling afraid or scared 0 1 2 3 4 
2.  Feeling sad or blue 0 1 2 3 4 
3.  Feeling angry 0 1 2 3 4 
4.  Trouble sleeping 0 1 2 3 4 
5.  Worrying about what will happen to him or her 0 1 2 3 4 
 
SOCIAL FUNCTIONING (PROBLEMS WITH…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1.  Getting along with other young adults 0 1 2 3 4 
2.  Other young adults not wanting to be his or her friend 0 1 2 3 4 
3.  Getting teased by other young adults 0 1 2 3 4 
4.  Not able to do things that others his or her age can do  0 1 2 3 4 
5.  Keeping up with other young adults 0 1 2 3 4 
 
SCHOOL FUNCTIONING (PROBLEMS WITH…) Never Almost 
Never 
Some-
times 
Often Almost 
Always 
1.  Paying attention at work or school 0 1 2 3 4 
2.  Forgetting things 0 1 2 3 4 
3.  Keeping up with work or studies 0 1 2 3 4 
4.  Missing work or school because of not feeling well  0 1 2 3 4 
5.  Missing work or school to go to the doctor or hospital 0 1 2 3 4 
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PedsQL™  
Adult Quality of Life 
Inventory 
 
Version 4.0 
 
 
ADULT REPORT 
 
 
 
 
DIRECTIONS 
 
     On the following page is a list of things that might be a problem for you. 
     Please tell us how much of a problem each one has been for you 
     during the past  ONE  month by circling: 
 
0 if it is never a problem  
1 if it is almost never a problem  
2 if it is sometimes a problem 
3 if it is often a problem 
4 if it is almost always a problem 
 
     There are no right or wrong answers.   
     If you do not understand a question, please ask for help. 
 
ID# 
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Date:________________________
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In the past ONE month, how much of a problem has this been for you … 
 
ABOUT MY HEALTH AND ACTIVITIES (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1. It is hard for me to walk more than one block  0 1 2 3 4 
2. It is hard for me to run 0 1 2 3 4 
3. It is hard for me to do sports activity or exercise 0 1 2 3 4 
4. It is hard for me to lift something heavy 0 1 2 3 4 
5. It is hard for me to take a bath or shower by myself 0 1 2 3 4 
6. It is hard for me to do chores around the house  0 1 2 3 4 
7. I hurt or ache 0 1 2 3 4 
8. I have low energy 0 1 2 3 4 
 
ABOUT MY FEELINGS (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1. I feel afraid or scared 0 1 2 3 4 
2. I feel sad or blue 0 1 2 3 4 
3. I feel angry 0 1 2 3 4 
4. I have trouble sleeping 0 1 2 3 4 
5. I worry about what will happen to me 0 1 2 3 4 
 
HOW I GET ALONG WITH OTHERS (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1. I have trouble getting along with other adults 0 1 2 3 4 
2. Other adults do not want to be my friend 0 1 2 3 4 
3. Other adults tease me 0 1 2 3 4 
4. I cannot do things that others my age can do 0 1 2 3 4 
5. It is hard to keep up with my peers  0 1 2 3 4 
    
ABOUT MY WORK/STUDIES  (problems with…) Never Almost 
Never 
Some-
times 
Often Almost 
Always
1. It is hard to pay attention at work or school 0 1 2 3 4 
2. I forget things 0 1 2 3 4 
3. I have trouble keeping up with my work or studies 0 1 2 3 4 
4. I miss work or school because of not feeling well 0 1 2 3 4 
5. I miss work or school to go to the doctor or hospital 0 1 2 3 4 
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 20.5.7 PSQI 
 
PITTSBURGH SLEEP QUALITY INDEX 
 
INSTRUCTIONS: 
 
The following questions relate to your usual sleep habits during the past month only. Your 
answers should indicate the most accurate reply for the majority of days and nights in the past 
month. 
 
Please answer all questions. 
 
1. During the past month, what time have you usually gone to bed at night? 
 
                           BED TIME ___________ 
 
2. During the past month, how long (in minutes) has it usually taken you to fall asleep each 
night? 
                           NUMBER OF MINUTES ___________ 
 
3. During the past month, what time have you usually gotten up in the morning? 
 
                          GETTING UP TIME ___________ 
 
4. During the past month, how many hours of actual sleep did you get at night? (This may be 
    different than the number of hours you spent in bed.) 
 
                          HOURS OF SLEEP PER NIGHT ___________  
 
 
For each of the remaining questions, check the one best response. Please answer all 
questions. 
5. During the past month, how often have you had trouble sleeping because you . . . 
 
a) Cannot get to sleep within 30 minutes 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
b) Wake up in the middle of the night or early morning 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
c) Have to get up to use the bathroom 
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Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
d) Cannot breathe comfortably 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
e) Cough or snore loudly 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
f) Feel too cold 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
g) Feel too hot 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
h) Had bad dreams 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
i) Have pain 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
j) Other reason(s), please describe__________________________________________ 
__________________________________________________________________________ 
 
How often during the past month have you had trouble sleeping because of this? 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
6. During the past month, how would you rate your sleep quality overall? 
 
Very good   ___________ 
Fairly good ___________ 
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Fairly bad   ___________ 
Very bad     ___________ 
 
7. During the past month, how often have you taken medicine to help you sleep (prescribed or 
    "over the counter")? 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
8. During the past month, how often have you had trouble staying awake while driving, eating 
    meals, or engaging in social activity? 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
9. During the past month, how much of a problem has it been for you to keep up enough 
    enthusiasm to get things done? 
 
No problem at all                                    __________ 
Only a very slight problem                     __________ 
Somewhat of a problem                          __________ 
A very big problem                                 __________ 
 
10. Do you have a bed partner or room mate? 
 
No bed partner or room mate                  __________ 
Partner/room mate in other room            __________ 
Partner in same room, but not same bed __________ 
Partner in same bed                                 __________ 
 
If you have a room mate or bed partner, ask him/her how often in the past month you 
have had . . . 
 
a) Loud snoring 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
b) Long pauses between breaths while asleep 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
c) Legs twitching or jerking while you sleep 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
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d) Episodes of disorientation or confusion during sleep 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
 
e) Other restlessness while you sleep; please describe__________________________________ 
___________________________________________________________________________ 
 
Not during the         Less than                  Once or twice     Three or more 
past month_____    once a week_____    a week_____       times a week_____ 
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20.5.8 Likert Scale 
 
The Likert scale is a psychometric scale used in this study to rate the patient’s state with 
regards to its PKAN symptoms on a specific day. Patients will be asked at Baseline, 
Month 6, 12 and 18 (or early termination visit) study visits how they would rate their day 
with regards to their PKAN symptoms on that day. A 5 point rating scale will be used as:  
 
1, very good;  
2, good;  
3, neutral;  
4, bad;  
5, very bad.  
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20.6 Declaration of Helsinki 
 
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI 
 
Ethical Principles for Medical Research Involving Human Subjects 
Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and 
amended by the: 
29th WMA General Assembly, Tokyo, Japan, October 1975 
35th WMA General Assembly, Venice, Italy, October 1983 
41st WMA General Assembly, Hong Kong, September 1989 
48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996 
52nd WMA General Assembly, Edinburgh, Scotland, October 2000 
53th WMA General Assembly, Washington 2002 (Note of Clarification on paragraph 29 
added) 
55th WMA General Assembly, Tokyo 2004 (Note of Clarification on Paragraph 30 
added) 
59th WMA General Assembly, Seoul, October 2008 
 
A. INTRODUCTION 
 
1. The World Medical Association (WMA) has developed the Declaration of Helsinki as 
a statement of ethical principles for medical research involving human subjects, including 
research on identifiable human material and data. 
The Declaration is intended to be read as a whole and each of its constituent paragraphs 
should not be applied without consideration of all other relevant paragraphs. 
 
2. Although the Declaration is addressed primarily to physicians, the WMA encourages 
other participants in medical research involving human subjects to adopt these principles. 
 
3. It is the duty of the physician to promote and safeguard the health of patients, 
including those who are involved in medical research. The physician's knowledge and 
conscience are dedicated to the fulfilment of this duty. 
 
4. The Declaration of Geneva of the WMA binds the physician with the words, “The 
health of my patient will be my first consideration,” and the International Code of 
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Medical Ethics declares that, “A physician shall act in the patient's best interest when 
providing medical care.” 
 
5. Medical progress is based on research that ultimately must include studies involving 
human subjects. Populations that are underrepresented in medical research should be 
provided appropriate access to participation in research. 
 
6. In medical research involving human subjects, the well-being of the individual 
research subject must take precedence over all other interests. 
 
7. The primary purpose of medical research involving human subjects is to understand 
the causes, development and effects of diseases and improve preventive, diagnostic and 
therapeutic interventions (methods, procedures and treatments). Even the best current 
interventions must be evaluated continually through research for their safety, 
effectiveness, efficiency, accessibility and quality. 
 
8. In medical practice and in medical research, most interventions involve risks and 
burdens. 
 
9. Medical research is subject to ethical standards that promote respect for all human 
subjects and protect their health and rights. Some research populations are particularly 
vulnerable and need special protection. These include those who cannot give or refuse 
consent for themselves and those who may be vulnerable to coercion or undue influence. 
10. Physicians should consider the ethical, legal and regulatory norms and standards for 
research involving human subjects in their own countries as well as applicable 
international norms and standards. No national or international ethical, legal or regulatory 
requirement should reduce or eliminate any of the protections for research subjects set 
forth in this Declaration. 
 
B. PRINCIPLES FOR ALL MEDICAL RESEARCH 
 
11. It is the duty of physicians who participate in medical research to protect the life, 
health, dignity, integrity, right to self-determination, privacy, and confidentiality of 
personal information of research subjects. 
 
12. Medical research involving human subjects must conform to generally accepted 
scientific principles, be based on a thorough knowledge of the scientific literature, other 
relevant sources of information, and adequate laboratory and, as appropriate, animal 
experimentation. The welfare of animals used for research must be respected. 
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13. Appropriate caution must be exercised in the conduct of medical research that may 
harm the environment. 
 
14. The design and performance of each research study involving human subjects must be 
clearly described in a research protocol. The protocol should contain a statement of the 
ethical considerations involved and should indicate how the principles in this Declaration 
have been addressed. The protocol should include information regarding funding, 
sponsors, institutional affiliations, other potential conflicts of interest, incentives for 
subjects and provisions for treating and/or compensating subjects who are harmed as a 
consequence of participation in the research study. The protocol should describe 
arrangements for post-study access by study subjects to interventions identified as 
beneficial in the study or access to other appropriate care or benefits. 
 
15. The research protocol must be submitted for consideration, comment, guidance and 
approval to a research ethics committee before the study begins. This committee must be 
independent of the researcher, the sponsor and any other undue influence. It must take 
into consideration the laws and regulations of the country or countries in which the 
research is to be performed as well as applicable international norms and standards but 
these must not be allowed to reduce or eliminate any of the protections for research 
subjects set forth in this Declaration. The committee must have the right to monitor 
ongoing studies. The researcher must provide monitoring information to the committee, 
especially information about any serious adverse events. No change to the protocol may 
be made without consideration and approval by the committee. 
 
16. Medical research involving human subjects must be conducted only by individuals 
with the appropriate scientific training and qualifications. Research on patients or healthy 
volunteers requires the supervision of a competent and appropriately qualified physician 
or other health care professional. The responsibility for the protection of research 
subjects must always rest with the physician or other health care professional and never 
the research subjects, even though they have given consent. 
 
17. Medical research involving a disadvantaged or vulnerable population or community 
is only justified if the research is responsive to the health needs and priorities of this 
population or community and if there is a reasonable likelihood that this population or 
community stands to benefit from the results of the research. 
 
18. Every medical research study involving human subjects must be preceded by careful 
assessment of predictable risks and burdens to the individuals and communities involved 
in the research in comparison with foreseeable benefits to them and to other individuals 
or communities affected by the condition under investigation. 
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19. Every clinical trial must be registered in a publicly accessible database before 
recruitment of the first subject. 
 
20. Physicians may not participate in a research study involving human subjects unless 
they are confident that the risks involved have been adequately assessed and can be 
satisfactorily managed. Physicians must immediately stop a study when the risks are 
found to outweigh the potential benefits or when there is conclusive proof of positive and 
beneficial results. 
 
21. Medical research involving human subjects may only be conducted if the importance 
of the objective outweighs the inherent risks and burdens to the research subjects. 
 
22. Participation by competent individuals as subjects in medical research must be 
voluntary. Although it may be appropriate to consult family members or community 
leaders, no competent individual may be enrolled in a research study unless he or she 
freely agrees. 
 
23. Every precaution must be taken to protect the privacy of research subjects and the 
confidentiality of their personal information and to minimize the impact of the study on 
their physical, mental and social integrity. 
 
24. In medical research involving competent human subjects, each potential subject must 
be adequately informed of the aims, methods, sources of funding, any possible conflicts 
of interest, institutional affiliations of the researcher, the anticipated benefits and 
potential risks of the study and the discomfort it may entail, and any other relevant 
aspects of the study. The potential subject must be informed of the right to refuse to 
participate in the study or to withdraw consent to participate at any time without reprisal. 
Special attention should be given to the specific information needs of individual potential 
subjects as well as to the methods used to deliver the information. After ensuring that the 
potential subject has understood the information, the physician or another appropriately 
qualified individual must then seek the potential subject’s freely-given informed consent, 
preferably in writing. If the consent cannot be expressed in writing, the non-written 
consent must be formally documented and witnessed. 
 
25. For medical research using identifiable human material or data, physicians must 
normally seek consent for the collection, analysis, storage and/or reuse. There may be 
situations where consent would be impossible or impractical to obtain for such research 
or would pose a threat to the validity of the research. In such situations the research may 
be done only after consideration and approval of a research ethics committee. 
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26. When seeking informed consent for participation in a research study the physician 
should be particularly cautious if the potential subject is in a dependent relationship with 
the physician or may consent under duress. In such situations the informed consent 
should be sought by an appropriately qualified individual who is completely independent 
of this relationship. 
 
27. For a potential research subject who is incompetent, the physician must seek 
informed consent from the legally authorized representative. These individuals must not 
be included in a research study that has no likelihood of benefit for them unless it is 
intended to promote the health of the population represented by the potential subject, the 
research cannot instead be performed with competent persons, and the research entails 
only minimal risk and minimal burden. 
 
28. When a potential research subject who is deemed incompetent is able to give assent 
to decisions about participation in research, the physician must seek that assent in 
addition to the consent of the legally authorized representative. The potential subject’s 
dissent should be respected. 
 
29. Research involving subjects who are physically or mentally incapable of giving 
consent, for example, unconscious patients, may be done only if the physical or mental 
condition that prevents giving informed consent is a necessary characteristic of the 
research population. In such circumstances the physician should seek informed consent 
from the legally authorized representative. If no such representative is available and if the 
research cannot be delayed, the study may proceed without informed consent provided 
that the specific reasons for involving subjects with a condition that renders them unable 
to give informed consent have been stated in the research protocol and the study has been 
approved by a research ethics committee. Consent to remain in the research should be 
obtained as soon as possible from the subject or a legally authorized representative. 
 
30. Authors, editors and publishers all have ethical obligations with regard to the 
publication of the results of research. Authors have a duty to make publicly available the 
results of their research on human subjects and are accountable for the completeness and 
accuracy of their reports. They should adhere to accepted guidelines for ethical reporting. 
Negative and inconclusive as well as positive results should be published or otherwise 
made publicly available. Sources of funding, institutional affiliations and conflicts of 
interest should be declared in the publication. Reports of research not in accordance with 
the principles of this Declaration should not be accepted for publication. 
 
C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH 
MEDICAL CARE 
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31. The physician may combine medical research with medical care only to the extent 
that the research is justified by its potential preventive, diagnostic or therapeutic value 
and if the physician has good reason to believe that participation in the research study 
will not adversely affect the health of the patients who serve as research subjects. 
 
32. The benefits, risks, burdens and effectiveness of a new intervention must be tested 
against those of the best current proven intervention, except in the following 
circumstances: 
• The use of placebo, or no treatment, is acceptable in studies where no current proven 
intervention exists; or 
• Where for compelling and scientifically sound methodological reasons the use of 
placebo is necessary to determine the efficacy or safety of an intervention and the 
patients who receive placebo or no treatment will not be subject to any risk of serious or 
irreversible harm. Extreme care must be taken to avoid abuse of this option. 
 
33. At the conclusion of the study, patients entered into the study are entitled to be 
informed about the outcome of the study and to share any benefits that result from it, for 
example, access to interventions identified as beneficial in the study or to other 
appropriate care or benefits. 
34. The physician must fully inform the patient which aspects of the care are related to 
the research. The refusal of a patient to participate in a study or the patient’s decision to 
withdraw from the study must never interfere with the patient-physician relationship. 
 
35. In the treatment of a patient, where proven interventions do not exist or have been 
ineffective, the physician, after seeking expert advice, with informed consent from the 
patient or a legally authorized representative, may use an unproven intervention if in the 
physician's judgement it offers hope of saving life, re-establishing health or alleviating 
suffering. Where possible, this intervention should be made the object of research, 
designed to evaluate its safety and efficacy. In all cases, new information should be 
recorded and, where appropriate, made publicly available. 
